DOWNLOAD THE OFFICIAL WCN APP

- See full scientific program
- See full list of speakers
- Customize your personal schedule

Search for 'WCN 2019'

WWW.2019.WCN-NEUROLOGY.COM
ACCELERATING THE PACE OF CHANGE

WCN 2019
XXIV WORLD CONGRESS OF NEUROLOGY
DUBAI, UNITED ARAB EMIRATES, OCTOBER 27-31 2019

PROGRAM BOOK
ABOUT THE WFN

MISSION: THE WFN’S MISSION IS TO FOSTER QUALITY NEUROLOGY AND BRAIN HEALTH WORLDWIDE

The World Federation of Neurology was formed in Brussels in 1957, as an association of national neurological societies. Today WFN represents 117 professional national societies in all regions of the world, and each society registers its own individual member neurologists with us. The delegates, one from each national society, elect the trustees and officers.

The mission of the WFN, as a UK registered charity, is to foster quality neurology and brain health worldwide, a goal we seek to achieve by promoting global neurological education and training, with the emphasis placed firmly on under-resourced parts of the world. The WFN holds biennial world congresses, which rotate throughout the regions (Africa, Americas, Asia, Europe) of the world. The congress consists of scientific sessions, teaching courses as well as structural and business meetings. The next congress following Kyoto (2017) will be in Dubai in 2019.

Education, improvement of neurologic sciences and knowledge are the main aims of the WFN. For this reason several programs such as Junior travelling grants, departmental visits, international courses, WFN -teaching centers, grants to fund local projects, and a joint CME program with the American Academy of Neurology are currently provided.

The joint AAN WFN CME Program (Continuum) is offered to many countries where there is a need for neurological educational material especially in those with limited resources. To date there are 45 countries participating in the program. Through this training, neurological teams globally have enhanced their skills as well as being made aware of new techniques, best practices to guide patient care.

The WFN encourages the empowerment of local and regional activities through cooperation with the six regional Neurological associations: the American Academy of Neurology (AAN), the European Academy of Neurology (EAN), the Asian Oceanian Association of Neurology (AOAN), the Pan American Federation of Neurological Societies (PAFNS), the Pan Arab Union of Neurological Societies (PAUNS) and the newly founded African Academy of Neurology (AFAN).

Brain health is the main goal of all the WFN activities and in order to achieve this, the WFN coordinates the World Brain Alliance (WBA) which includes the World Psychiatric Association (WPA), the World Federation of Neurosurgical Societies (WFNS), the World Federation of NeuroRehabilitation (WFNR), the International Child Neurology Association (ICNA), the International Brain Research Organization (IBRO) and the WHO. Working together is crucial to achieve our intertwined goals.

The development of neurology has created several specialist societies, such as the World Stroke Organization, the International Parkinson and Movement Disorder Society, the International League Against Epilepsy, Multiple Sclerosis International, Alzheimer’s Disease International, the International Headache Society, and the Peripheral Nerve Society among others. The WFN is committed and delighted in cooperating with them all.

The WFN has led in the development of the new WHO ICD 11, and is actively contributing to the second edition of the WHO Neurology Atlas. The WFN is an active partner in the campaign to control and manage the neurological aspects of NCD through close collaboration with the WHO.

The WFN has several committees which are dedicated to assisting the WFN with specific tasks such as education, research groups, membership, publications, and finance and congress organization. These committees are created from members from all parts of the world and they provide crucial help to the WFN in order to serve its needs and activities.

The WFN has a website (www.wfneurology.org), social media (Facebook, Twitter) an electronic magazine WN (available on the website), and two scientific journals; the Journal of the Neurological Sciences and eNeurological Sci. The WFN is eager to promote neurology worldwide, and to improve prevention and diagnosis management for patients. Please look out for WFN activities on the website and in the social media.
# TABLE OF CONTENTS

## CONGRESS INFORMATION
- About the WFN .................................................. 2
- Welcoming Words .................................................. 4
- Committees .......................................................... 5
- General Information ............................................. 6
- Timetable .............................................................. 8
- WFN Business Meetings ....................................... 18
- Venue Maps .......................................................... 20
- CME/CPD Accreditation ....................................... 22
- Optional Networking Events Program .................. 24

## PROGRAM HIGHLIGHTS
- Plenary Lectures .................................................. 25
- The Tournament of the Minds ................................ 27
- Information for Presenters .................................... 28

## SCIENTIFIC PROGRAM
- Sunday, October 27 ............................................. 33
- Monday, October 28 ............................................ 61
- Tuesday, October 29 ............................................ 83
- Wednesday, October 30 ..................................... 103
- Thursday, October 31 .......................................... 121

## INDEX OF AUTHORS
................................................................. 137

## RECOGNITION, ACKNOWLEDGEMENTS AND INDUSTRY SUPPORT
- Acknowledgements ............................................. 149
- Exhibitors ........................................................... 150
- Industry Symposia .............................................. 151
- Exhibition Map .................................................. 156
- List of Exhibitors ............................................... 157
- Exhibitor and Sponsor Profiles ............................ 158
Dear Friends, Colleagues, Delegates and Attendees,

On behalf of the World Federation of Neurology it is my very great pleasure to welcome you to the XXIV World Congress of Neurology in Dubai.

The World Federation of Neurology has been most fortunate that this World Congress is being co-hosted by the Emirates Neurological Society. Together we are certain that you will help make this an outstanding World Congress of Neurology. The Congress will comprise four and a half days of high quality plenary, main topic and scientific session topic lectures, teaching courses, workshops, free papers, sponsored symposia and the Tournament of the Minds. A faculty in excess of 265 and many more selected for the free paper sessions and poster sessions will deliver this wide ranging choice of educational opportunity to you. Complementing this exciting daily selection will be the Welcome Reception and the Networking Event, set with Dubai City as the striking backdrop for opportunities to develop new professional relationships and renew existing acquaintances. With the flavour of the region firmly part of this event this World Congress of Neurology will be both unique and memorable and will justify your efforts to attend.

I wish you and your colleagues a most valuable and enjoyable experience.

William Carroll
President, World Federation of Neurology

---

Dear Friends and Colleagues,

We are pleased to welcome you to the 24th World Congress of Neurology 2019 in Dubai, UAE. We welcome all of you from every part of the world. It is an honour for the Emirates Neurological Society (EMINS) to host the WCN in 2019. The EMINS in the largest neurology organisation in the UAE and regularly hosts regional and international conferences. This year we have had the privilege to organise the WCN.

It will be held in the World Trade Centre, Dubai. We wish to make the congress a huge success with the cooperation of all of you. It will be an historic meeting which will serve as a springboard to strongly advance the Initiative of the WFN in Asia for the advancement of neurology both scientifically and clinically thus “Accelerating the Pace of Change”.

You will be able to participate in very active discussions and hear cutting-edge lectures by the world’s top scientists and neurologists in all fields of neurology.

Dubai, as you will know, is a relatively new city incorporating the ancient Arab culture and civilization into modern architecture.

The Local Organising Committee is at your service in case you need any assistance and in close collaboration with the World Federation of Neurology welcomes you to Dubai, UAE for WCN 2019.

Dr Suhail Abdulla Mohammed Al Rukn
Congress President - XXIV World Congress of Neurology (WCN2019)
President, EMINS, UAE
COMMITTEES

CONGRESS ORGANIZING COMMITTEE
William Carroll, Australia | WFN President
Ryuji Kaji, Japan | First Vice President and WFN Congress Committee Chair
Suhail Abdulla Al Rukn, United Arab Emirates | Congress President
Richard Stark, Australia | WFN Treasurer
Wolfgang Grisold, Austria | Secretary General
Chris Kennard, United Kingdom | WFN Scientific Program Committee Chair
Saeed Bohlega, Saudi Arabia | Local Scientific Program Committee Co-Chair
Steve Lewis, USA | WFN Teaching Course Committee Chair
Mustapha Elalouoi Faris, Morocco | WFN Teaching Course Committee Co-Chair
Riadh Gouider, Tunisia | WCN 2019 Local Organising Committee Chair
Jihad Inshasi, United Arab Emirates | EMINS Representative

WFN CONGRESS
SCIENTIFIC PROGRAM COMMITTEE
Chris Kennard (Chair), United Kingdom
Saeed Bohlega (Co-Chair), Saudi Arabia
Francisco Cardoso, Brazil
Terrence Cascino, USA
Marianne De Visser, Netherlands
John England, USA
Amadou Gallo Diop, Senegal
Chandrashekar Meshram, India
Hidehiro Mizusawa, Japan
Bo Norrving, Sweden
Emilio Perruca, Italy
Yoshikazu Ugawa, Japan
Lawrence Wong, Hong Kong

WFN CONGRESS EDUCATION PROGRAM
AND TEACHING COURSE COMMITTEE
Steve Lewis (Chair), USA
Mustapha Elalouoi Faris (Co-Chair), Morocco
Amal Alhashami, Oman
Wolfgang Grisold, Austria
Sarosh Katrak, India
Mona Khawaja, Saudi Arabia
Akram Mehdawi, Iraq

WCN 2019 – LOCAL COMMITTEE
Saeed Bohlega (Chair), Saudi Arabia
Jihad Inshasi (Vice Chair), United Arab Emirates
Riadh Gouider (Chair), Tunisia
Pournamy Sarathchandran (Vice Chair), United Arab Emirates
Suhail Abdulla Alrukn, United Arab Emirates
Arsalan Ahmed, Pakistan
Abdulla Al Asimi, Oman
Adel Al Jishi, Bahrain
Jassim Al Hashil, Kuwait
Abubaker Al Madani, United Arab Emirates
Mohamed Al Mekhlafi, Saudi Arabia
Nazha Birouk, Morocco
Hamidon Basri, Malaysia
Murat Emre, Turkey
Husnain Hashim, United Arab Emirates
Hassan Hosny, Egypt
Chaker Khamis, Lebanon
Maria Khan, United Arab Emirates
Walid Khoja, Saudi Arabia
Adel Misk, Palestine
Mohamed Sahaaraq, Iran
Mohammad Wasay, Pakistan
Bassem Yamout, Lebanon

TOURNAMENT COMMITTEE
Richard Stark, Australia (Chairman)
Faouzi Belahsen, Morocco
Nicholas Davies, United Kingdom
Ricardo Fadic, Chile
Takashi Kanda, Japan
Serenella Servidei, Italy
GENERAL INFORMATION

CONGRESS VENUE
Dubai World Trade Centre
Sheikh Zayed Rd
+971 4 332 1000

LANGUAGE
English is the official language of the Congress. All sessions and presentations will be given in English.

REGISTRATION DESK HOURS
Sunday, October 27 07:00 – 19:30
Monday, October 28 06:30 – 18:15
Tuesday, October 29 07:15 – 16:15
Wednesday, October 30 06:30 – 16:15
Thursday, October 31 06:30 – 14:30

EXHIBITION HOURS
Sunday, October 27 10:00 -end of Welcome Reception
Monday, October 28 10:00 -17:00
Tuesday, October 29 10:00 – 15:00
Wednesday, October 30 10:00 – 15:00

NAME BADGES
All participants and exhibitors are requested to wear their name badges throughout the Congress, and present vouchers for social events and workshops in order to be admitted to the lecture halls and scheduled activities.

WIFI
WIFI will be available at the Congress in public areas and in the Exhibition Area.

SCIENTIFIC MOBILE APP
View the Scientific Program on your personal device. The program application is designed for cross platform access via laptop, mobile devices such as Smartphones, iphones, Androids etc. Access the application via browser. Participants will have full access to the Scientific Program including the abstracts and PDF’s of those delegates who uploaded a PDF version of their Posters to the APP. The application has smart phone search possibilities within the Scientific Program by session type, name or hall.

CONGRESS ABSTRACTS
The official Congress accepted and registered abstracts are available on the Congress website and Mobile App, and have also been published in an online supplement of the Journal of the Neurological Sciences (JNS). Please visit the Congress website in order to view the abstracts, or view them via the Scientific Mobile App.

TEACHING COURSES
All Teaching Courses are included as part of the Congress registration fee, and do not have an additional cost. There is no need to register for these courses. Attendance is on a first-come first-served basis.

WORKSHOPS
Please note that the workshops require pre-registration. Tickets may be purchased at the Onsite Registration Kiosks in the Registration Area – subject to availability.
**ELSEVIER YOUNG INVESTIGATOR AWARD**
The Elsevier Young Investigator Award is awarded to two deserving abstract submitters during the Congress for the Best Clinical Paper and the Best Research Paper. The Elsevier Prize Ceremony will take place during the Congress Closing Ceremony on Thursday, October 31 at 14:00.

**ANGELA VINCENT AWARD FOR BEST YOUNG NEUROLOGIST INVESTIGATOR**
The WFN has awarded for the first time in 2019, a single award to the Best Young Neurologist Investigator from the region of the World Congress of Neurology. The award will be handed out during the Congress Closing Ceremony on Thursday, October 31 at 14:00.

**COFFEE AND LUNCH BREAKS**
Coffee, light refreshments and lunch will be served to all Congress participants in the Exhibition Area as indicated in the timetable.

**BAGGAGE AND CLOAK ROOM**
Due to local regulations, baggage and cloakrooms facilities are not permitted at the congress centre – please use the facilities in your hotel.

**RECOGNITION, ACKNOWLEDGEMENTS AND INDUSTRY SUPPORT**
In accordance with compliance regulations, Industry supporting the Congress will be acknowledged separately from the Scientific Program. Industry Information will appear at the back of the book, under the section Recognition, Acknowledgements and Industry Support.

**GUEST ATTENDANCE POLICY**
All event activities (including educational sessions, meal functions, Exhibit Hall, etc.) are exclusively reserved for registered attendees. Non-registered guests (including children, family members, colleagues, etc.) are not allowed in any of the event areas. Badges provided at registration are required for entrance into all functions and will be strictly enforced.

**PHOTOGRAPHY AND RECORDING PRIVILEGES**
No photographs, video recording or audio recording may be permitted in the scientific sessions at this Congress unless otherwise authorized by the Scientific Committee or the Congress Chairman.

**SAFETY AND SECURITY**
Please do not leave any bags or suitcases unattended at any time, whether inside or outside session halls.

**SMOKING POLICY**
WCN is a non-smoking Congress and participants are requested to refrain from smoking in the Congress Venue.

**CONGRESS ORGANIZER**
Kenes Group Organizers of Congresses S.A.
Rue François-Versonnex 7
1207 Geneva, Switzerland
wcn@kenes.com
## TIMETABLE

<table>
<thead>
<tr>
<th>Teaching Course</th>
<th>Scientific Session: MT (Main Topics)</th>
<th>Free Papers</th>
<th>Plenary Lecture</th>
<th>Regional Symposium Session</th>
</tr>
</thead>
</table>

**SUNDAY, OCTOBER 27, 2019**

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:45</td>
<td>Plenary Lecture 1: Fulton Award Lecture</td>
</tr>
<tr>
<td>08:45 - 09:15</td>
<td>Plenary Lecture 2</td>
</tr>
<tr>
<td>09:15 - 10:45</td>
<td>MT1a: Movement Disorders, MT2a: Stroke, MT3a: Epilepsy, TC 1: Neuroinfectious Disease/Tropical Neurology, TC 2: Multiple Sclerosis and Other Demyelinating Disease</td>
</tr>
<tr>
<td>10:45 - 11:15</td>
<td>Coffee Break, Poster Viewing and Exhibition Visit</td>
</tr>
<tr>
<td>11:15 - 12:45</td>
<td>MT1b: Movement Disorders, MT2b: Stroke, MT3b: Epilepsy, TC 1: Neuroinfectious Disease/Tropical Neurology continued, TC 2: Multiple Sclerosis and Other Demyelinating Disease continued</td>
</tr>
<tr>
<td>12:45 - 14:45</td>
<td>Lunch Break, Poster Viewing and Exhibition Visit</td>
</tr>
<tr>
<td>13:00 - 14:30</td>
<td></td>
</tr>
<tr>
<td>14:30 - 14:45</td>
<td>Short Break</td>
</tr>
<tr>
<td>14:45 - 16:15</td>
<td>MT1c: Movement Disorders, MT2c: Stroke, MT3c: Epilepsy, TC 3: Sleep Neurology, TC 4: Multiple Sclerosis and Other Demyelinating Diseases</td>
</tr>
<tr>
<td>16:15 - 16:45</td>
<td>Coffee Break, Poster Viewing and Exhibition Visit</td>
</tr>
<tr>
<td>16:45 - 18:15</td>
<td>MT1d: Movement Disorders, MT2d: Stroke, MT3d: Epilepsy, TC 3: Sleep Neurology continued, TC 4: Multiple Sclerosis and Other Demyelinating Diseases continued</td>
</tr>
<tr>
<td>18:15 - 18:20</td>
<td>Short Break</td>
</tr>
<tr>
<td>18:20 - 19:00</td>
<td>Opening Ceremony</td>
</tr>
<tr>
<td>19:00</td>
<td>Welcome Reception in the Exhibition</td>
</tr>
</tbody>
</table>
### Scientific Session: Topics

<table>
<thead>
<tr>
<th>Session</th>
<th>Sponsored Symposium</th>
<th>TC Workshops</th>
<th>Tournament of the Minds</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Sheikh Rashid A</th>
<th>Sheikh Rashid B</th>
<th>Abu Dhabi A</th>
<th>Abu Dhabi B</th>
<th>Dubai C</th>
<th>Dubai D</th>
</tr>
</thead>
</table>

**SUNDAY, OCTOBER 27, 2019**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:45</td>
<td>Plenary Lecture 1: Fulton Award Lecture</td>
</tr>
<tr>
<td>08:45 - 09:15</td>
<td>Plenary Lecture 2</td>
</tr>
<tr>
<td>09:15 - 10:45</td>
<td>MT1a: Movement Disorders</td>
</tr>
<tr>
<td></td>
<td>MT2a: Stroke</td>
</tr>
<tr>
<td></td>
<td>MT3a: Epilepsy</td>
</tr>
<tr>
<td></td>
<td>TC 1: Neuroinfectious Disease/Tropical Neurology</td>
</tr>
<tr>
<td></td>
<td>TC 2: Multiple Sclerosis and Other Demyelinating Disease</td>
</tr>
<tr>
<td></td>
<td>T1a: 2. Bringing MR Innovation to the Clinic</td>
</tr>
<tr>
<td></td>
<td>T2a: 3. Neuropsychiatry</td>
</tr>
<tr>
<td></td>
<td>Free Papers: Stroke 1</td>
</tr>
<tr>
<td></td>
<td>Neurosonology Workshop</td>
</tr>
<tr>
<td></td>
<td>Free Papers: Autoimmune Disorders</td>
</tr>
<tr>
<td>10:45 - 11:15</td>
<td>Coffee Break, Poster Viewing and Exhibition Visit</td>
</tr>
<tr>
<td>11:15 - 12:45</td>
<td>MT1b: Movement Disorders</td>
</tr>
<tr>
<td></td>
<td>MT2b: Stroke</td>
</tr>
<tr>
<td></td>
<td>MT3b: Epilepsy</td>
</tr>
<tr>
<td></td>
<td>TC 1: Neuroinfectious Disease/Tropical Neurology</td>
</tr>
<tr>
<td></td>
<td>TC 2: Multiple Sclerosis and Other Demyelinating Disease</td>
</tr>
<tr>
<td></td>
<td>T1b: 2. Bringing MR Innovation to the Clinic</td>
</tr>
<tr>
<td></td>
<td>T2b: 3. Neuropsychiatry</td>
</tr>
<tr>
<td></td>
<td>T3: Maximising Neuroplasticity in Neurorehabilitation</td>
</tr>
<tr>
<td></td>
<td>Neurosonology Workshop Cont.</td>
</tr>
<tr>
<td></td>
<td>Free Papers: CNS Infections</td>
</tr>
<tr>
<td>12:45 - 14:45</td>
<td>Lunch Break, Poster Viewing and Exhibition Visit</td>
</tr>
<tr>
<td></td>
<td>Sponsored Symposium -non CME/CPD credit</td>
</tr>
<tr>
<td></td>
<td>Sponsored Symposium -non CME/CPD credit</td>
</tr>
<tr>
<td>14:30 - 14:45</td>
<td>Short Break</td>
</tr>
<tr>
<td>14:45 - 16:15</td>
<td>MT1c: Movement Disorders</td>
</tr>
<tr>
<td></td>
<td>MT2c: Stroke</td>
</tr>
<tr>
<td></td>
<td>MT3c: Epilepsy</td>
</tr>
<tr>
<td></td>
<td>TC 3: Sleep Neurology</td>
</tr>
<tr>
<td></td>
<td>TC 4: Multiple Sclerosis and Other Demyelinating Disease</td>
</tr>
<tr>
<td></td>
<td>T4a: Head Injury and Critical Care Neurology</td>
</tr>
<tr>
<td></td>
<td>T5a: Mitochondrial Dysfunction in Neurological Disease</td>
</tr>
<tr>
<td></td>
<td>TC 5: Behavioral Neurology</td>
</tr>
<tr>
<td></td>
<td>Free Papers: Dementia</td>
</tr>
<tr>
<td></td>
<td>EMG Workshop</td>
</tr>
<tr>
<td></td>
<td>Pan-American Symposium Session</td>
</tr>
<tr>
<td>16:15 - 16:45</td>
<td>Coffee Break, Poster Viewing and Exhibition Visit</td>
</tr>
<tr>
<td></td>
<td>Sponsored Symposium -non CME/CPD credit</td>
</tr>
<tr>
<td></td>
<td>Sponsored Symposium -non CME/CPD credit</td>
</tr>
<tr>
<td>16:45 - 18:15</td>
<td>MT1d: Movement Disorders</td>
</tr>
<tr>
<td></td>
<td>MT2d: Stroke</td>
</tr>
<tr>
<td></td>
<td>MT3d: Epilepsy</td>
</tr>
<tr>
<td></td>
<td>TC 3: Sleep Neurology</td>
</tr>
<tr>
<td></td>
<td>TC 4: Multiple Sclerosis and Other Demyelinating Disease</td>
</tr>
<tr>
<td></td>
<td>T4b: Head Injury and Critical Care Neurology</td>
</tr>
<tr>
<td></td>
<td>T5b: Mitochondrial Dysfunction in Neurological Disease</td>
</tr>
<tr>
<td></td>
<td>TC 5: Behavioral Neurology</td>
</tr>
<tr>
<td></td>
<td>Free Papers: Epilepsy 1</td>
</tr>
<tr>
<td></td>
<td>EMG Workshop</td>
</tr>
<tr>
<td></td>
<td>North American Symposium Session: Dementia - Finding the Cure</td>
</tr>
<tr>
<td>18:15 - 18:20</td>
<td>Short Break</td>
</tr>
<tr>
<td>18:20 - 19:00</td>
<td>Opening Ceremony</td>
</tr>
<tr>
<td>19:00</td>
<td>Welcome Reception in the Exhibition</td>
</tr>
</tbody>
</table>
# MONDAY, OCTOBER 28, 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 - 08:00</td>
<td><strong>TC 6:</strong> Neuro-Ophthalmology</td>
</tr>
<tr>
<td>08:00 - 08:30</td>
<td>Plenary Lecture 3</td>
</tr>
<tr>
<td>08:30 - 09:00</td>
<td>Plenary Lecture 4</td>
</tr>
<tr>
<td>09:00 - 10:45</td>
<td>Presidential Symposium, WFN Medals Presentation &amp; Soriano Plenary Award Lecture</td>
</tr>
<tr>
<td>10:45 - 11:15</td>
<td>Coffee Break, Poster Viewing and Exhibition Visit</td>
</tr>
<tr>
<td>11:15 - 12:45</td>
<td><strong>MT4a:</strong> Dementia, <strong>T6a:</strong> Neurooncology, <strong>T6a:</strong> Sleep and Circadian Neuroscience, <strong>TC 7:</strong> Movement Disorders, <strong>TC 8:</strong> Epilepsy, <strong>TC 9:</strong> Management of Stroke on Stroke Units</td>
</tr>
<tr>
<td>12:45 - 14:45</td>
<td>Lunch Break, Poster Viewing and Exhibition Visit</td>
</tr>
<tr>
<td>13:00 - 14:30</td>
<td>Sponsored Symposium -non CME/CPD credit</td>
</tr>
<tr>
<td>14:30 - 14:45</td>
<td>Short Break</td>
</tr>
<tr>
<td>14:45 - 16:15</td>
<td><strong>MT4b:</strong> Dementia, <strong>T6b:</strong> Neurooncology, <strong>T6a:</strong> Sleep and Circadian Neuroscience, <strong>TC 7:</strong> Movement Disorders continued, <strong>TC 8:</strong> Epilepsy continued, <strong>TC 9:</strong> Management of Stroke on Stroke Units continued</td>
</tr>
<tr>
<td>16:15 - 16:45</td>
<td>Coffee Break, Poster Viewing and Exhibition Visit</td>
</tr>
<tr>
<td>16:45 - 18:15</td>
<td><strong>MT4c:</strong> Dementia, <strong>T24:</strong> Motor Neurone Disease</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>------------</td>
<td>----------------------------------</td>
</tr>
<tr>
<td>07:00 - 08:00</td>
<td>TC 6: Neuro-Ophthalmology</td>
</tr>
<tr>
<td>08:00 - 08:30</td>
<td>Plenary Lecture 3</td>
</tr>
<tr>
<td>08:30 - 09:00</td>
<td>Plenary Lecture 4</td>
</tr>
<tr>
<td>09:00 - 10:45</td>
<td>Presidential Symposium, WFN Medals Presentation &amp; Soriano Plenary Award</td>
</tr>
<tr>
<td>10:45 - 11:15</td>
<td>Coffee Break, Poster Viewing and Exhibition Visit</td>
</tr>
<tr>
<td>11:15 - 12:45</td>
<td>MT4a: Dementia</td>
</tr>
<tr>
<td>12:45 - 14:45</td>
<td>Lunch Break, Poster Viewing and Exhibition Visit</td>
</tr>
<tr>
<td>13:00 - 14:30</td>
<td>Sponsored Symposium - non CME/CPD credit</td>
</tr>
<tr>
<td>14:30 - 14:45</td>
<td>Short Break</td>
</tr>
<tr>
<td>14:45 - 16:15</td>
<td>MT4b: Dementia</td>
</tr>
<tr>
<td>16:15 - 16:45</td>
<td>Coffee Break, Poster Viewing and Exhibition Visit</td>
</tr>
<tr>
<td>16:45 - 18:15</td>
<td>MT4c: Movement Disorders</td>
</tr>
<tr>
<td>18:15 - 20:15</td>
<td>MT4d: Motor Neurone Disease</td>
</tr>
</tbody>
</table>

Free Papers:
- T7a: Neuroophthal-mology
- T8: Ethical Aspects of Neurological Practise
- Free Papers: Movement Disorders 1
- TC10: Advocacy
- Free Papers: MS & Demyelinating Diseases 1

Pan-Arab Regional Symposium
- T9: Neurological Education – Challenges and Innovations Across the Globe
- TC 10: Advocacy continued
- Pan-Arab Regional Symposium

Asian-Oceanian Regional Symposium
- TC 10: Advocacy continued
- Asian-Oceanian Regional Symposium
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:30</td>
<td>Sheikh Rashid E</td>
<td>Sheikh Maktoum A</td>
<td>Sheikh Maktoum C</td>
<td>Sheikh Maktoum D</td>
<td>Sheikh Maktoum B</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:30 - 09:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00 - 10:30</td>
<td></td>
<td></td>
<td>MT5a: MS and Demyelinating Disorders</td>
<td>MT6a: Tropical and Geographic Neurology</td>
<td>T10a: Behavioural Neurology</td>
<td>TC 11: Neuro-Ophthalmology</td>
<td>TC 12: Neuromuscular Diseases</td>
</tr>
<tr>
<td>10:30 - 11:00</td>
<td>Coffee Break, Poster Viewing and Exhibition Visit</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 - 12:30</td>
<td>MT5b: MS and Demyelinating Disorders</td>
<td>MT5b: MS and Demyelinating Disorders</td>
<td>MT6b: Tropical and Geographic Neurology</td>
<td>T10b: Behavioural Neurology</td>
<td>TC 11: Neuro-Ophthalmology</td>
<td>TC 12: Neuromuscular Diseases</td>
<td></td>
</tr>
<tr>
<td>12:30 - 14:30</td>
<td>Lunch Break, Poster Viewing and Exhibition Visit</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00 - 14:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00-14:00</td>
<td>Tournament of the Minds: Heats” Qualifying Round</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30 - 14:45</td>
<td>Short Break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:45 - 16:15</td>
<td>MT5c: MS and Demyelinating Disorders</td>
<td>MT5c: MS and Demyelinating Disorders</td>
<td>MT6c: Tropical and Geographic Neurology</td>
<td>T11: Brain-Computer Interfaces and Robotics</td>
<td>T12: Autoimmune Neurological Disorders</td>
<td>TC 12: Neuromuscular Diseases</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Networking Event</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:00 - 08:30</td>
<td>Plenary Lecture</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:30 - 09:00</td>
<td>Plenary Lecture</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00 - 10:30</td>
<td>MT5a: MS and Demyelinating Disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MT6a: Tropical and Geographic Neurology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T10a: Behavioural Neurology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TC 11: Neuro-Ophthalmology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TC 12: Neuromuscular Diseases</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TC 13: Headache</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TC 14: Palliative Care in Neurology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TC 15: Neurocritical Care</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Free Papers: Late Breaking</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Free Papers: Stroke 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 - 11:00</td>
<td>Coffee Break, Poster Viewing and Exhibition Visit</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 - 12:30</td>
<td>MT5b: MS and Demyelinating Disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MT6b: Tropical and Geographic Neurology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T10b: Behavioural Neurology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TC 11: Neuro-Ophthalmology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TC 12: Neuromuscular Diseases</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TC 13: Headache continued</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TC 14: Palliative Care in Neurology continued</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TC 15: Neurocritical Care</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Free Papers: Child Neurology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Free Papers: MS &amp; Demyelinating Diseases 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30 - 14:30</td>
<td>Lunch Break, Poster Viewing and Exhibition Visit</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00 - 14:30</td>
<td>Tournament of the Minds: Heats” Qualifying Round</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsored Symposium -non CME/CPD credit</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T13: Headache continued</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TC 14: Palliative Care in Neurology continued</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TC 15: Neurocritical Care</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Free Papers: Late Breaking</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Free Papers: Stroke 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30 - 14:45</td>
<td>Short Break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:45 - 16:15</td>
<td>MT5c: MS and Demyelinating Disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MT6c: Tropical and Geographic Neurology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T11: Brain-Computer Interfaces and Robotics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T12: Autoimmune Neurological Disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TC 12: Neuromuscular Diseases</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T13: Brain Death, the Grey Zone and Persistent Vegetative State</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T14: How Useful is Big Data in Neurology?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>European Regional Symposium: MANAGEMENT OF ACUTE STROKE IN SUB SAHARAN AFRICA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pan-African Regional Symposium: MANAGEMENT OF ACUTE STROKE IN SUB SAHARAN AFRICA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Free Papers: Motor Neuron Disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:15 - 17:00</td>
<td>Poster and Exhibition Viewing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00 - 18:00</td>
<td>Poster and Exhibition Viewing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00 - 19:00</td>
<td>Poster and Exhibition Viewing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00 - 20:00</td>
<td>Poster and Exhibition Viewing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00 - 21:00</td>
<td>Networking Event</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:00 - 22:00</td>
<td>Networking Event</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## WEDNESDAY, OCTOBER 30, 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speakers</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 - 08:00</td>
<td>TC 16: Neuroimaging</td>
<td>Sheikh Rashid E</td>
<td></td>
</tr>
<tr>
<td>08:00 - 08:30</td>
<td>Plenary Lecture 7</td>
<td>Sheikh Maktoum A</td>
<td></td>
</tr>
<tr>
<td>08:30 - 09:00</td>
<td>Plenary Lecture 8</td>
<td>Sheikh Maktoum C</td>
<td></td>
</tr>
<tr>
<td>09:00 - 10:30</td>
<td>MT7a: Headache and Pain, MT8a: Neuromuscular Diseases, T15a: Child</td>
<td>Sheikh Maktoum D</td>
<td>TC 16: Neuroimaging</td>
</tr>
<tr>
<td></td>
<td>Neurology</td>
<td>Sheikh Maktoum A</td>
<td></td>
</tr>
<tr>
<td>10:30 - 11:00</td>
<td>Coffee Break, Poster Viewing and Exhibition Visit</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 - 12:30</td>
<td>MT7b: Headache and Pain, MT8b: Neuromuscular Diseases, T15b: Child</td>
<td>Sheikh Maktoum A</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Neurology</td>
<td>Sheikh Maktoum D</td>
<td>TC 18: Neuro-Oncologycontinued</td>
</tr>
<tr>
<td>12:30 - 14:30</td>
<td>Lunch Break, Poster Viewing and Exhibition Visit</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30 - 14:30</td>
<td>13:00-14:00 Tournament of the Minds: Semi Final</td>
<td>Sheikh Maktoum B</td>
<td></td>
</tr>
<tr>
<td></td>
<td>13:00-14:00 Tournament of the Minds: Semi Final</td>
<td>Sheikh Maktoum D</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsored Symposium - non CME/CPD credit (13:00 - 14:30)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30 - 14:45</td>
<td>Short Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>-------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>07:00-08:00</td>
<td>TC 16: Neuroimaging</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:00-08:30</td>
<td>Plenary Lecture 7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:30-09:00</td>
<td>Plenary Lecture 8</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| 09:00-10:30 | MT7a: Headache and Pain  
MT8a: Neuromuscular Diseases  
T15a: Child Neurology  
TC 18: Neuro-Oncology  
TC 19: Dementia  
TC 20: Neuro-Otology  
TC 21: Neurology and Internal Medicine  
Free Papers: Headache  
Free Papers: Neurophysiology |
| 10:30-11:00 | Coffee Break, Poster Viewing and Exhibition Visit                      |
| 11:00-12:30 | MT7b: Headache and Pain  
MT8b: Neuromuscular Diseases  
T15b: Child Neurology  
TC 18: Neuro-Oncology  
TC 19: Dementia continued  
TC 20: Neuro-Otology continued  
TC 21: Neurology and Internal Medicine continued  
Free Papers: Functional Disorders and Behavioral Neurology  
Free Papers: Neuroimaging |
| 12:30-14:30 | Lunch Break, Poster Viewing and Exhibition Visit                      |
| 12:30-14:30 13:00-14:00 | Tournament of the Minds: Semi Final  
Sponsored Symposium - non CME/CPD credit (13:00 - 14:30) |
| 14:30-14:45 | Short Break                                                             |
| 14:45-16:15 | MT7c: Headache and Pain  
MT8c: Neuromuscular Diseases  
T16: Psychiatric Aspects of Neurology  
T17: Environment and Neurology  
T18: The Microbiome and Neurology  
Free Papers: Epilepsy 2  
Free Papers: Movement Disorders 2 |
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 - 08:00</td>
<td>TC 22: Headache</td>
<td>Sheikh Maktoum B</td>
</tr>
<tr>
<td>08:00 - 08:30</td>
<td>Plenary Lecture 9: Barucha Award Lecture</td>
<td>Sheikh Maktoum C</td>
</tr>
<tr>
<td>08:30 - 09:00</td>
<td>Plenary Lecture 10</td>
<td>Sheikh Maktoum A, Sheikh Maktoum B</td>
</tr>
<tr>
<td>09:00 - 10:30</td>
<td>MT8d: Neuromuscular Diseases</td>
<td>T19a: Neuro-Otology</td>
</tr>
<tr>
<td></td>
<td>T20a: Palliative Care</td>
<td>T21a: Prions and Neurodegenerative Diseases</td>
</tr>
<tr>
<td>10:30 - 11:00</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>11:00 - 12:30</td>
<td>MT7d: Headache and Pain</td>
<td>T19a: Neuro-Otology</td>
</tr>
<tr>
<td></td>
<td>T20a: Palliative Care</td>
<td>T21a: Prions and Neurodegenerative Diseases</td>
</tr>
<tr>
<td>12:30-12:45</td>
<td>Short Break</td>
<td></td>
</tr>
<tr>
<td>12:45 - 14:00</td>
<td>Tournament of the Minds: Final</td>
<td></td>
</tr>
<tr>
<td>14:00 - 14:30</td>
<td>Closing Ceremony</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>07:00 - 08:00</td>
<td>Plenary Lecture 9: Barucha Award Lecture</td>
<td></td>
</tr>
<tr>
<td>08:00 - 09:00</td>
<td>Plenary Lecture 10</td>
<td></td>
</tr>
<tr>
<td>09:00 - 10:30</td>
<td>MT8d: Neuromuscular Diseases</td>
<td></td>
</tr>
<tr>
<td></td>
<td>T19a: Neuro-Otology</td>
<td></td>
</tr>
<tr>
<td></td>
<td>T20a: Palliative Care</td>
<td></td>
</tr>
<tr>
<td></td>
<td>T21a: Prions and Neurodegenerative Diseases</td>
<td></td>
</tr>
<tr>
<td></td>
<td>T22: History of Neurology: Neurosciences in Medieval Arab Medicine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TC 24: Neuroimaging</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TC 25: Autoimmune Neurologic Disorders</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TC 26: Child Neurology</td>
<td></td>
</tr>
<tr>
<td></td>
<td>T23: Dementias Across Different Populations, Culture and Languages</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Free Papers: Miscellaneous 1</td>
<td></td>
</tr>
<tr>
<td>10:30 - 11:00</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>11:00 - 12:30</td>
<td>MT7d: Headache and Pain</td>
<td></td>
</tr>
<tr>
<td></td>
<td>T19b: Neuro-Otology</td>
<td></td>
</tr>
<tr>
<td></td>
<td>T20b: Palliative Care</td>
<td></td>
</tr>
<tr>
<td></td>
<td>T21b: Prions and Neurodegenerative Diseases</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TC 25: Autoimmune Neurologic Disorders continued</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TC 26: Child Neurology continued</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Free Papers: Neurorehabilitation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Free Papers: Miscellaneous 2</td>
<td></td>
</tr>
<tr>
<td>12:30 - 12:45</td>
<td>Short Break</td>
<td></td>
</tr>
<tr>
<td>12:45 - 14:00</td>
<td>Tournament of the Minds: Final</td>
<td></td>
</tr>
<tr>
<td>14:00 - 14:30</td>
<td>Closing Ceremony</td>
<td></td>
</tr>
</tbody>
</table>
WFN BUSINESS MEETINGS

Concurrent WFN Business Meetings will take place throughout the Congress. All meetings are by invitation only.

<table>
<thead>
<tr>
<th>NAME OF THE MEETING</th>
<th>TIME</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>SATURDAY, OCTOBER 26</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WFN Trustees Meeting</td>
<td>08:00-10:00</td>
<td>Ajman A</td>
</tr>
<tr>
<td>WFN Congress Committee</td>
<td>10:00-11:00</td>
<td>Ajman A</td>
</tr>
<tr>
<td>WFN Finance Committee Meeting</td>
<td>11:00-12:00</td>
<td>Ajman A</td>
</tr>
<tr>
<td>WFN Membership Committee Meeting</td>
<td>12:00-13:00</td>
<td>Ajman A</td>
</tr>
<tr>
<td>Council of Delegates</td>
<td>13:10-17:30</td>
<td>Abu Dhabi A</td>
</tr>
<tr>
<td>SUNDAY, OCTOBER 27</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tournament of the Minds Committee</td>
<td>08:30-10:30</td>
<td>Ajman B+C</td>
</tr>
<tr>
<td>WFN Speciality Group Committee</td>
<td>09:00-10:00</td>
<td>Ajman A</td>
</tr>
<tr>
<td>WFN Environmental Neurology SG</td>
<td>10:00-12:00</td>
<td>Ajman D</td>
</tr>
<tr>
<td>WFN Education Committee</td>
<td>11:00-12:30</td>
<td>Ajman A</td>
</tr>
<tr>
<td>WFN Publication &amp; Communications Committee</td>
<td>13:00-14:00</td>
<td>Ajman A</td>
</tr>
<tr>
<td>WFN E-Communications Committee</td>
<td>14:00-15:00</td>
<td>Ajman A</td>
</tr>
<tr>
<td>WFN Neurosonology SG</td>
<td>14:00-16:00</td>
<td>Ajman D</td>
</tr>
<tr>
<td>WFN Constitutions and Bye-laws Committee</td>
<td>15:00-16:00</td>
<td>Ajman A</td>
</tr>
<tr>
<td>NAME OF THE MEETING</td>
<td>TIME</td>
<td>ROOM</td>
</tr>
<tr>
<td>---------------------------------------------------------</td>
<td>----------------</td>
<td>---------</td>
</tr>
<tr>
<td>MONDAY, OCTOBER 28</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Global Neurology Alliance</td>
<td>12:00-13:30</td>
<td>Ajman D</td>
</tr>
<tr>
<td>WFN Public Awareness and Advocacy Committee</td>
<td>14:00-15:00</td>
<td>Ajman A</td>
</tr>
<tr>
<td>TUESDAY, OCTOBER 29</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WFN Migrant Neurology SG</td>
<td>10:00-12:00</td>
<td>Ajman D</td>
</tr>
<tr>
<td>WCN 2023 Briefing</td>
<td>11:00-12:00</td>
<td>Ajman A</td>
</tr>
<tr>
<td>WFN Trustees Meeting</td>
<td>12:00-14:00</td>
<td>Ajman A</td>
</tr>
<tr>
<td>WEDNESDAY, OCTOBER 30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WFN Neuroepidemiology SG</td>
<td>10:00-12:00</td>
<td>Ajman A</td>
</tr>
<tr>
<td>Tropical and Geographical Research Group of WFN</td>
<td>12:30-14:30</td>
<td>Dubai D</td>
</tr>
<tr>
<td>WCN 2021 Congress Committee SPC &amp; TCC Meeting</td>
<td>14:00-16:00</td>
<td>Ajman A</td>
</tr>
</tbody>
</table>
VENUE MAPS

GROUND LEVEL

CONVENTION GATE ENTRANCE

ELEVATORS TO FIRST FLOOR (MEETING ROOMS)

ELEVATORS TO FIRST FLOOR (MEETING ROOMS)

Sheikh Maktoum A SESSION HALL
Sheikh Maktoum B SESSION HALL
Sheikh Maktoum C SESSION HALL
Sheikh Maktoum D SESSION HALL
Sheikh Rashid A SESSION HALL
Sheikh Rashid B SESSION HALL
Sheikh Rashid C, D, F EXHIBITION, POSTERS
Sheikh Rashid E PLENARY

REGISTRATION

REGISTRATION

IBIS WORLD TRADE CENTER HOTEL

NOVOTEL

GROUND LEVEL

FIRST LEVEL

EXHIBITION ACCESS TO:

TO: FIRST FLOOR

ELEVATOR TO:

ELEVATOR TO:

EXHIBITION GATE ENTRANCE

TO: FIRST FLOOR

TO: FIRST FLOOR

IBIS WORLD TRADE CENTER HOTEL

NOVOTEL

GROUND LEVEL

ELEVATORS TO FIRST FLOOR (MEETING ROOMS)

ELEVATORS TO FIRST FLOOR (MEETING ROOMS)

EXHIBITION ACCESS TO:

TO: FIRST FLOOR

ELEVATOR TO:

ELEVATOR TO:

EXHIBITION GATE ENTRANCE

TO: FIRST FLOOR

TO: FIRST FLOOR

IBIS WORLD TRADE CENTER HOTEL

NOVOTEL

GROUND LEVEL
CME/CPD ACCREDITATION

COMMITMENT TO THE HIGHEST STANDARDS IN CME/CPD
Kenes is committed to being a valuable and knowledgeable partner in the design and delivery of educationally strong, independent, transparent, and effective CME/CPD programmes. Kenes is a proud member of the Good CME Practice Group (gCMEp), a member organisation contributing to improving health outcomes by:

• Championing best practice in CME/CPD
• Maintaining and improving standards
• Mentoring and educating
• Working in collaboration with critical stakeholders

Membership in the Good CME Practice Group illustrates the Kenes commitment to high standards and knowledgeable partnership with its clients in the design and delivery of educationally strong, independent, transparent, effective, and financially viable medical events.

ACCREDITATION STATEMENT AND CREDIT DESIGNATION
EUROPEAN ACCREDITATION COUNCIL FOR CONTINUING MEDICAL EDUCATION (UEMS/EACCME)
The 24th World Congress of Neurology is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS): www.uems.net.

The 24th World Congress of Neurology is designated for a maximum of, or up to, 31 European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

AMERICAN MEDICAL ASSOCIATION (AMA)
Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at https://www.ama-assn.org/education/cme/uemseaccme-cme-credit-recognition.

ROYAL COLLEGE OF PHYSICIANS AND SURGEONS OF CANADA
Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada. For more information, visit: www.royalcollege.ca/rcsite/cpd/providers/international-accreditation-agreements-e

EDUCATIONAL OBJECTIVES
After attending this event, participants should be able to:

• Address individual needs in compliance with their Continuous Professional Development (CPD) plan.
• Summarize major developments in the field of neurology.
• Describe innovative approaches to neurorehabilitation and its clinical application.
• Examine new trends, techniques, therapies, and diagnostic procedures in neurology.
• Evaluate the disorders of the autonomic nervous system.
• Review current basic clinical practice and technology in the field of neurology.
• Enhance a collaboration with the world's scientific experts to advance scientific knowledge about neurology.
TARGET AUDIENCE

WCN 2019 bring together leading scientists, public health experts, policy-makers to translate recent scientific advances into action. Because of the diverse, clinically focused educational offering, participants are able to tailor the curriculum to meet the needs of international clinicians of all levels of experience.

CREDIT BREAKDOWN

Each participant should claim only those hours of credit that he/she actually spent in the educational activity.

<table>
<thead>
<tr>
<th>Day</th>
<th>Maximum Credits</th>
</tr>
</thead>
<tbody>
<tr>
<td>October 27, 2019</td>
<td>7</td>
</tr>
<tr>
<td>October 28, 2019</td>
<td>8</td>
</tr>
<tr>
<td>October 29, 2019</td>
<td>5</td>
</tr>
<tr>
<td>October 30, 2019</td>
<td>6</td>
</tr>
<tr>
<td>October 31, 2019</td>
<td>5</td>
</tr>
<tr>
<td>Total Credits:</td>
<td>31</td>
</tr>
</tbody>
</table>

TO RECEIVE YOUR CME/CPD CERTIFICATE

The CME/CPD certificate will be available after completing the online evaluation and credit claiming procedure. The process takes about 5 minutes. We thank you for your feedback as it is an important part of CME/CPD accreditation and helps improve future educational offerings.

BEFORE NOVEMBER 28, 2019:

1. Access the online system via any of the following
   - Visit the following link https://www.surveymonkey.com/r/WCN2019Evaluation
   - Please note that web browsers Mozilla Firefox 2.X or higher, or Google Chrome are recommended
   - Visit the CME/CPD Accreditation page on the event website
   - Follow the link in the email sent at the end of the event
2. Complete the anonymous online evaluation
3. Complete the credit claim form and submit
4. The CME/CPD certificate will be available for download and/or print for your personal records

Kindly note that the WCN 2019 online evaluation will be active on the last day of the meeting. You will then be able to access it and claim your CME/CPD certificate.
OPTIONAL NETWORKING EVENTS PROGRAM

OPENING CEREMONY & WELCOME RECEPTION
SUNDAY, OCTOBER 27 | 18:20 | SHEIKH RASHID E

All registered participants are invited to attend the Opening Ceremony and Welcome Reception. The opening ceremony will be held in the Congress Center in the Main Plenary Hall -Sheikh Rashid E.

The Opening Ceremony will be immediately followed by the Welcome Reception in the Exhibition. Please join us for the official XXIV World Congress of Neurology opening.

CULTURAL NETWORKING EVENT
TUESDAY, OCTOBER 29 | 17:00 | BAB AL SHAMS, AL HADHEERAH RESTAURANT

Transportation to this event is only by the busses departing from the congress venue.

Like a scene out of a fairytale, Al Hadheerah at Bab Al Shams Desert Resort & Spa is the place to experience Arabia in all its glory. From authentic Middle Eastern cuisine prepared using ancient recipes, to lively dance and music performances, to mesmerising camel and equestrian shows, this must-visit venue in Dubai leaves no stone unturned in creating an Arabian experience - right down to the last detail.

Evening includes:
- Transportation
- Buffet
- Assorted soft drinks, and Arabic coffee
- Camel and Horse Riding
- Horse show on the dunes
- Camel Caravan on the dunes
- Falcon Display
- Dabka Folkloric Dance
- Belly Dancer
- Oriental Band

Buses will depart from the Congress Center from 17:00 and will return to the Congress Center after dinner. Tickets are available for purchasing via the Onsite Registration Kiosks in the Registration Area – subject to availability.

Ticket Cost: USD 60 (per person)
PLENARY LECTURES

Plenary Lecture 1:
Sunday, October 27 | 08:00-08:45 | Sheikh Rashid E
Fulton Award Lecture: THE BATTLE TO BEAT PARKINSON'S DISEASE
Patrick Brundin, USA

Plenary Lecture 2:
Sunday, October 27 | 08:45-09:15 | Sheikh Rashid E
NEUROGENETICS
Fowzan Alkuraya, Saudi Arabia

Plenary Lecture 3:
Monday, October 28 | 08:00-08:30 | Sheikh Rashid E
READING IN THE BRAIN: MAPPING THE MASSIVE IMPACT OF LITERACY ON BRAIN CIRCUITS
Stansilas Dehaene, France

Plenary Lecture 4:
Monday, October 28 | 08:30 0 09:00 | Sheikh Rashid E
THE GRAY ZONE AND BRAIN DEATH
Adrian Owen, Canada

PRESIDENTIAL SYMPOSIUM, WFN MEDALS PRESENTATION & SORIANO AWARD PLENARY LECTURE
Monday, October 28 | 09:00 -10:45 | Sheikh Rashid E

09:00-09:20
WFN Medals Presentation

09:20-09:50
Soriano Award Lecture: LIGHT, CIRCADIAN RHYTHMS AND SLEEP: MECHANISMS TO NEW THERAPEUTICS
Russell Foster, United Kingdom

09:50
THE WHO AND NEUROLOGY: RECENT COLLABORATIVE OUTCOMES
VIDEO MESSAGE FROM DR ADHANOM GHEBREYESUS TEDROS
DIRECTOR-GENERAL, WHO

ICD-11: HOW WILL IT IMPROVE NEUROLOGY
Raad Shakir (United Kingdom)

THE IMPLICATIONS OF THE RECLASSIFICATION OF STROKE AS A NEUROLOGICAL DISEASE
Bo Norrving (Sweden)

10:20-10:45
A GLOBAL ROLE FOR THE WORLD FEDERATION OF NEUROLOGY
WFN President: W.M. Carroll, Australia
Plenary Lecture 5:
Tuesday, October 29 | 08:00-08:30 | Sheikh Rashid E
Yahr Award Lecture: TREATING HUNTINGTON’S DISEASE
Sarah Tabrizi, United Kingdom

Plenary Lecture 6:
Tuesday, October 29 | 08:30-09:00 | Sheikh Rashid E
IMAGING PAIN
Irene Tracey, United Kingdom

Plenary Lecture 7:
Wednesday, October 30 | 08:00-08:30 | Sheikh Rashid E
WHAT IS GENOMICS TEACHING US ABOUT NEURDEGENERATION AND WHAT SHOULD WE DO ABOUT IT?
John Hardy, United Kingdom

Plenary Lecture 8:
Wednesday, October 30 | 08:30-09:00 | Sheikh Rashid E
MULTIPLE SCLEROSIS
Mar Tintore, Spain

Plenary Lecture 9:
Thursday, October 31 | 08:00-08:30 | Sheikh Rashid E
Barucha Award Lecture: BRAIN-MACHINE INTERFACES: FROM BASIC SCIENCES TO NEUROREHABILITATION
Miguel Nicolelis, Brazil

Plenary Lecture 10:
Thursday, October 31 | 08:30-09:00 | Sheikh Rashid E
THE PROMISE OF THE BRAIN INITIATIVE© FOR THOSE WITH NEURO/MENTAL/SUBSTANCE ABUSE DISORDERS
Walter Koroshetz, USA
THE TOURNAMENT OF THE MINDS

This article was originally published in World Neurology.

The Tournament of the Minds is a unique opportunity for WCN 2019 participants to interact with colleagues, test intellectual tenacity, and demonstrate national pride, all while competing in country teams. As such, the aim of the Tournament of the Minds is to provide an experience that is both educational and entertaining for participants, integrating various aspects of neurology. This is the seventh time the Tournament has been organized by the World Federation of Neurology at a World Neurology Congress.

Based on previous Tournaments, we know that this dynamic and enjoyable activity enriches the Congress for all participants – both professionally and socially.

WFN member societies are invited to enter a team of 4 neurologists in the Tournament. Teams will compete in a knockout competition, to answer questions on a range of neurological topics based on clinical cases from around the world; the questions will focus on visual material, videos and stills, with a minimum of text. Tournament judges will award the winning team an attractive prize.

All teams will first take part in a Qualifying Round. The 8 teams that achieve the highest scores will progress to a Semi-Final Round and compete in two groups of 4 teams, with the winners of each group advancing to the Final.

There will be one team per country but, where there are a limited number of neurologists, a team may consist of nationals from more than one country. Congress organizers hope that the Tournament will attract many competitors from all participating countries.

To participate, please contact the president of the relevant local Member Society who is responsible for coordinating national teams. For more details on Member Societies, please visit: http://www.wfneurology.org/member-societies; or approach the Congress Secretariat at the Faculty Desk, stating the full names and email addresses of all members of your team, as well as the country you will be representing at the Tournament. Please indicate who the team leader will be.

The Tournament sessions will take place as follows:

**TUESDAY, OCTOBER 29 | SHEIKH MAKTOUM C**
13:00 – 14:00 - Tournament of the Minds: “Heats” Qualifying Round

**WEDNESDAY, OCTOBER 30 | SHEIKH MAKTOUM A & SHEIKH MAKTOUM C**
13:00 – 14:00 - Tournament of the Minds: Semi Final

**THURSDAY, OCTOBER 31 | SHEIKH MAKTOUM A**
13:00 – 14:00 - Tournament of the Minds: Final
INFORMATION FOR SPEAKERS
AND FREE PAPER PRESENTERS

A Speakers' Ready Room will be available every day throughout the Congress for Speakers.

Please find below the Speakers' Ready Room opening hours:

Sunday, October 27   07:00 – 19:30
Monday, October 28   06:30 – 18:15
Tuesday, October 29  07:15 – 16:15
Wednesday, October 30 06:30 – 16:15
Thursday, October 31 06:30 – 14:30

PLEASE NOTE: IN COMPLIANCE WITH EACCME REQUIREMENTS ALL ORAL PRESENTERS ARE REQUESTED TO INCLUDE
A SLIDE DISCLOSING CONFLICTS OF INTEREST AT THE BEGINNING OF THEIR PRESENTATION.

Please visit the Speakers' Ready Room to download a template of the disclosure slide.

GUIDELINES

If using a PowerPoint presentation (or PDF), please note you need to bring it on USB Memory stick and load it
on one of the congress computers in the Speakers' Ready Room at least 1 hour before the start of the session.

Please note that the congress computers in the session halls are being supplied with Windows 10 Pro + MS

If combining video films with PowerPoint, please make sure to check it in the session hall where your lecture
is taking place during a coffee or lunch break prior to your session, at least 40 minutes before the start of the
session - even after checking it in the Speakers’ Ready Room.

Alternatively you may supply your own laptop computer. In such a case please confirm that it has a HDMI port
for external signal and come to check it first in the Speakers’ Ready Room as soon as you arrive and later on
in the session hall where your lecture is taking place during the coffee or lunch break prior to your session, at
least 40 minutes before the start of the session.

PRESENTATION DURATION

The duration of your presentation is indicated in the interactive scientific program as well as on the congress
mobile APP. Please note that your presentation time includes time for questions and answers. Therefore, you
are asked to plan your presentation accordingly.

IMPORTANT NOTE FOR MACINTOSH USERS

In order to use MAC presentations on a PC compatible computer please note that you need to prepare it
according to the instructions below, before bringing it to the uploading station in the session Hall:

1. Use a common font, such as Arial, Times New Roman, Verdana etc. (special fonts might be changed to a
default font on a PowerPoint based PC).

2. Insert pictures as JPG files (and not TIF, PNG or PICT - these images will not be visible on a PowerPoint
based PC).

Alternatively you may use your own Macintosh laptop computer. In such a case please confirm you provide it
with a HDMI adaptor for external signal and come to test it as soon as you arrive in the session Hall where your
Presentation is taking place during the coffee or lunch break prior to your session.
It is important that poster presenters adhere to the poster shift schedule below. The Organizing Committee will not be responsible for posters that are not removed by the end of the poster slot.

**PAPER POSTER SHIFT SCHEDULE**

Posters will be mounted in 4 shifts:

**Poster Session 1:**
**CHANNELopathies /NEuroEthics /NEuroOncology /PAIN - PART I /SLEEP Disorders - PART I /STEM Cells and GENE therapy - PART I /STROKE /Training in Neurology - PART I AND TRAUMATIC BRAIN INJURY**

Sunday, October 27, 2019 (Mounting from 08:00 and dismounting by 16:00)

**Poster Session 2:**
**AUTOimmune Disorders - PART I /CNS Infections - PART I /Dementia - PART I /Epilepsy - PART I /HeaLTh EcOnomics and Outcomes /NeuroEPIDemiology aNd Environmental and Other**

Monday, October 28, 2019 (Mounting from 08:00 and dismounting by 16:00)

**Poster Session 3:**
**AuToNomic NeurOus System Disorders /HistOry of NeurOlogy /MoToR NeurOn Disease /MoverMent Disorders /MS & DemyelinatIng DiseAses /NeurOmuscular Disorders /VestiBuLar Disorders and NutriTiOnal Disorders or IntoxICations**

Tuesday, October 29, 2019 (Mounting from 08:00 and dismounting by 16:00)

**Poster Session 4:**
**Ataxia and CerEBellar Disorders /AUTOimmune Disorders - PART II /CNS Infections - PART II /Dementia - PART II /Epilepsy - PART II /Functional Disorders and BBehavioral Neurology /HeaDache /Metabolic and Mitochondrial Diseases /Neuro-critical Care /NeuroGenetics /NeuroOphtHALMoLOGY /NeuroPhysiology /NeuroRehabilitation /PAIN - PART II /Sleep Disorders - PART II /STEM Cells and GENE therapy - PART II /Training in Neurology - PART II /CHiLD Neurology aNdNeuroImaging**

Wednesday October 30, 2019 (Mounting from 08:00 and dismounting by 16:00)

Posters should be mounted from 08:00 on the day of your shift and removed by 16:00 on the same day.

The organizers cannot be responsible for posters not removed by the above stated time.

- Poster Boards will be located in the Exhibition.
- Please stand at your Poster during coffee and lunch breaks
- There will be a Poster Helpdesk onsite to assist you.
## OVERVIEW OF POSTERS

<table>
<thead>
<tr>
<th>Topic</th>
<th>Pres. Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>POSTER SHIFT 01</td>
<td></td>
</tr>
<tr>
<td>Channelopathies</td>
<td>001-004</td>
</tr>
<tr>
<td>Neuroethics</td>
<td>005-007</td>
</tr>
<tr>
<td>Neurooncology</td>
<td>008-030</td>
</tr>
<tr>
<td>Pain</td>
<td>031-047</td>
</tr>
<tr>
<td>Sleep Disorders</td>
<td>048-058</td>
</tr>
<tr>
<td>Stem Cells and Gene Therapy</td>
<td>059-060</td>
</tr>
<tr>
<td>Stroke</td>
<td>061-344</td>
</tr>
<tr>
<td>Training in Neurology</td>
<td>345-349</td>
</tr>
<tr>
<td>Traumatic Brain Injury</td>
<td>350-360</td>
</tr>
<tr>
<td>POSTER SHIFT 02</td>
<td></td>
</tr>
<tr>
<td>Autoimmune Disorders</td>
<td>001-067</td>
</tr>
<tr>
<td>CNS Infections</td>
<td>068-119</td>
</tr>
<tr>
<td>Dementia</td>
<td>120-175</td>
</tr>
<tr>
<td>Epilepsy</td>
<td>176-276</td>
</tr>
<tr>
<td>Health Economics &amp; Outcomes</td>
<td>277-281</td>
</tr>
<tr>
<td>Neuroepidemiology and Environmental</td>
<td>282-290</td>
</tr>
<tr>
<td>Other</td>
<td>291-356</td>
</tr>
<tr>
<td>POSTER SHIFT 03</td>
<td></td>
</tr>
<tr>
<td>Motor Neuron Disease</td>
<td>001-022</td>
</tr>
<tr>
<td>Autonomic Nervous System Disorders</td>
<td>023-038</td>
</tr>
<tr>
<td>History of Neurology</td>
<td>039-041</td>
</tr>
<tr>
<td>Movement Disorders</td>
<td>042-167</td>
</tr>
<tr>
<td>MS &amp; Demyelinating Diseases</td>
<td>168-263</td>
</tr>
<tr>
<td>Neuromuscular Disorders</td>
<td>264-340</td>
</tr>
<tr>
<td>Neurootology - Vestibular disorders</td>
<td>341-351</td>
</tr>
<tr>
<td>Nutritional Disorders or Intoxications</td>
<td>352-360</td>
</tr>
<tr>
<td>POSTER SHIFT 04</td>
<td></td>
</tr>
<tr>
<td>Ataxia and Cerebellar Disorders</td>
<td>001-014</td>
</tr>
<tr>
<td>Autoimmune Disorders</td>
<td>015-025</td>
</tr>
<tr>
<td>CNS Infections</td>
<td>026-031</td>
</tr>
<tr>
<td>Dementia</td>
<td>032-046</td>
</tr>
<tr>
<td>Epilepsy</td>
<td>047-066</td>
</tr>
<tr>
<td>Functional Disorders and Behavioral Neurology</td>
<td>067-089</td>
</tr>
<tr>
<td>Headache</td>
<td>090-139</td>
</tr>
<tr>
<td>Metabolic and Mitochondrial Diseases</td>
<td>140-156</td>
</tr>
<tr>
<td>Neuro-critical Care</td>
<td>157-173</td>
</tr>
<tr>
<td>Neurogenetics</td>
<td>174-197</td>
</tr>
<tr>
<td>Neuroophthalmology</td>
<td>198-207</td>
</tr>
<tr>
<td>Neurophysiology</td>
<td>208-248</td>
</tr>
<tr>
<td>Neurorehabilitation</td>
<td>249-273</td>
</tr>
<tr>
<td>Pain</td>
<td>274-278</td>
</tr>
<tr>
<td>Sleep Disorders</td>
<td>279-280</td>
</tr>
<tr>
<td>Stem Cells and Gene Therapy</td>
<td>281-282</td>
</tr>
<tr>
<td>Training in Neurology</td>
<td>283-284</td>
</tr>
<tr>
<td>Child Neurology</td>
<td>285-327</td>
</tr>
<tr>
<td>Neuroimaging</td>
<td>328-362</td>
</tr>
</tbody>
</table>
SUNDAY, OCTOBER 27, 2019

08:00 - 08:45  SHEIKH RASHID E

PLENARY LECTURE 1: FULTON AWARD LECTURE

Chairs: W.M. Carroll (Australia)
G. Deuschl (Germany)

08:00  FULTON SYMPOSIUM LECTURE: THE BATTLE TO BEAT PARKINSON'S DISEASE
P. Brundin (USA)

08:45 - 09:15  SHEIKH RASHID E

PLENARY LECTURE 2: NEUROGENETICS

Chairs: R. Gouider (Tunisia)
M. El Alaoui Faris (Morocco)

08:45  NEUROGENETICS
F. Alkuraya (Saudi Arabia)

09:15 - 10:45  SHEIKH RASHID E

SCIENTIFIC SESSION: MT (MAIN TOPICS): MT1A: MOVEMENT DISORDERS

Chairs: E.M. Valente (Italy)
R. Takahashi (Japan)

ADVANCES IN PARKINSON'S DISEASE

09:15  UPDATE ON PATHOGENESIS AND GENETICS
E.M. Valente (Italy)

09:45  DIAGNOSIS AND BIOMARKERS
A. Aldakheel (Saudi Arabia)

10:15  CURRENT STRATEGIES AND NEW MEDICATIONS TO TREAT ADVANCED PD
R. Takahashi (Japan)
09:15 - 10:45  SHEIKH MAKTOUM A

SCIENTIFIC SESSION: MT (MAIN TOPICS): MT2A: JOINT SESSION WFN/WSO: STROKE

Chairs: M. Brainin (Austria)
C. Chen (Singapore)

WSO/WFN SESSION: CHALLENGES FROM NON-MOTOR CONSEQUENCES OF STROKE

09:15  DEPRESSION
C. Chen (Singapore)

09:45  COGNITION
M. Brainin (Austria)

10:15  RECOVERY GUIDANCE WITH THE POST-STROKE CHECK LIST
K.S. Sunnerhagen (Sweden)

09:15 - 10:45  SHEIKH MAKTOUM C

SCIENTIFIC SESSION: MT (MAIN TOPICS): MT3A: EPILEPSY

Chairs: S. Wiebe (Canada)
E. Perucca (Italy)

EPILEPSY: WHAT EVERY NEUROLOGIST SHOULD KNOW

09:15  KEEP IT SIMPLE: NEW CONCEPTS AND DEFINITIONS IN EPILEPSY
S. Wiebe (Canada)

09:45  USE AND MISUSE OF NEW ANTIEPILEPTIC DRUGS
E. Perucca (Italy)

10:15  EPILEPSY SURGERY – WHAT DO I NEED TO KNOW?
Y. Comair (Lebanon)
09:15 - 10:45  SHEIKH MAKTOUM D

TEACHING COURSE: TC 1: NEUROINFECTIONOUS DISEASE/TROPICAL NEUROLOGY PART I

Chairs: M. Medina (Honduras)
       C. Meshram (India)

09:15  CSF EVALUATION IN NEURO-INFECTIONS
       R. Shakir (United Kingdom)

09:45  CEREBRAL VENOUS THROMBOSIS IN TROPICAL AREAS
       C. Meshram (India)

10:15  NEUROLOGICAL CONSEQUENCES OF ARBOVIRUS INFECTIONS
       M. Medina (Honduras)

09:15 - 10:45  SHEIKH MAKTOUM B

TEACHING COURSE: TC 2: MULTIPLE SCLEROSIS AND OTHER DEMYELINATING DISEASE: KEY MANAGEMENT FACTORS IN MS IN 2019

Chairs: S. Khoury (Lebanon)
       X. Montalban (Canada)

09:15  EARLY TREATMENT
       S. Daoudi (Algeria)

09:45  EARLY IDENTIFICATION OF NON-RESPONDERS
       X. Montalban (Canada)

10:15  FIGHT AGAINST TREATMENT INERTIA
       X. Montalban (Canada)

09:15 - 10:45  SHEIKH RASHID A

SCIENTIFIC SESSION: TOPICS: T1A: 2. BRINGING MR INNOVATION TO THE CLINIC

Chairs: J. Masdeu (USA)
       O. Del Brutto (Ecuador)

09:15  ADVANCES IN MULTIPLE SCLEROSIS MRI
       R. Alroughani (Kuwait)

09:45  NEUROIMAGING OF NEUROCYSTICERCOSIS
       O. Del Brutto (Ecuador)

10:15  IMAGING OF OTHER ENCEPHALITIS AND OF NONCOMPRESSIVE ACUTE TRANSVERSE MYELOPATHIES
       R. Garg (India)
09:15 - 10:45 SHEIKH RASHID B

SCIENTIFIC SESSION: TOPICS: T2A: 3. NEUROPSYCHIATRY

Chairs: E. Krishnamoorthy (India)
D. Arciniegas (USA)

CLINICAL NEUROPSYCHIATRY

09:15 WHAT DETERMINES A GOOD OUTCOME FROM TRAUMATIC BRAIN INJURY
D. Arciniegas (USA)

09:45 THE NEW NEUROLOGY OF SCHIZOPHRENIA
L. Tebartz Van Elst (Germany)

10:15 THE BORDERLANDS BETWEEN EPILEPSY AND BEHAVIOUR REVISITED
E. Krishnamoorthy (India)
FREE PAPERS 01 - STROKE 1

Chairs: D. Hanley (USA)
D.A. De Silva (Singapore)

09:15 A STUDY OF DECOMPRESSIVE CRANIECTOMY IN ACUTE STROKE - A RETROSPECTIVE STUDY FROM A TERTIARY CARE CENTRE FROM INDIA
N.S. Madduru (India)

09:25 THE EFFECT OF TRANSCRANIAL DIRECT STIMULATION(TDCS) AND EXERCISE ON COGNITION AND MOTOR ASPECT IN PATIENTS WITH CHRONIC STROKE
S. Kaura, M.V.P. Srivastava, S.S. Kumaran (India)

09:35 COMPARISON OF ONE-SESSION ANODAL TDCS EFFECTS ON FINE MOTOR CONTROL IN SUBACUTE AND CHRONIC STROKE PATIENTS.
E. Pavlova, R.V. Semenov, A.B. Guekht (Sweden)

09:45 ASSOCIATION BETWEEN ADMISSION BLOOD FIBRINOGEN-ALBUMIN RATIO AND CLINICAL OUTCOMES AFTER ACUTE LACUNAR INFARCTION

09:55 INTRACRANIAL Atherosclerotic Disease Among Saudis; Prevalence, Characteristics and Predictors of Outcome
M. Alabbas, A. Al Khathaami, A. El Metwally, M. Badri1, M. Alskaini (Saudi Arabia)

10:05 WOMEN VS MEN. SEX DIFFERENCE OUTCOMES AFTER MECHANICAL THROMBECTOMY IN ACUTE ISCHEMIC STROKE

10:15 CLINICAL INTERVENTIONS TO MANAGE SLEEP APNEA IN PATIENTS WITH STROKE: SYSTEMATIC REVIEW AND META-ANALYSIS OF THE ONGOING CLINICAL TRIALS
S. Redkar, V. Redkar, S. Redkar, M. Inamdar, A. Inamdar, M. Jagtap, D. Khanolkar, R. Shradhha, S. Kulkarni, S. Deshpande (India)

10:25 HYPODENSITIES WITHIN HEMATOMA IS TIME DEPENDENT AND PREDICTS OUTCOME AFTER SPONTANEOUS INTRACEREBRAL HEMORRHAGE

10:35 A PATIENT-ASSESSOR BLINDED, RANDOMIZED CONTROLLED TRIAL OF COMPREHENSIVE ACUPUNCTURE THERAPY FOR NEOUROPSYCHIATRIC SEQUELAE OF STROKE
Z.J. Zhang (Hong Kong S.A.R.)
09:15 - 10:45

TC WORKSHOPS: NEUROSONOLOGY WORKSHOP PART I

Chairs: M. Del Sette (Italy)
        K. Niederkorn (Austria)

09:15  EVIDENCE BASED NEUROSONOLOGY
       M. Del Sette (Italy)

09:35  CAROTID DOPPLER ULTRASOUND: CLINICAL APPLICATIONS
       E. Bartels (Germany)

09:55  NEUROVASCULAR ULTRASOUND AGAINST OTHER MODALITIES: IS IT THE WINNER? CASE SCENARIOS
       F. Abd-Allah (Egypt)

10:15  MICROEMBOLIC SIGNALS AS A MARKER FOR STROKE RISK
       M. Kaps (Germany)
09:15 - 10:45  DUBAI D

FREE PAPERS 02 - AUTOIMMUNE DISORDERS

Chairs: P. Chinnery (United Kingdom)
E. Shosha (Bahrain)

09:15  EPIDEMIOLOGY OF PARANEOPLASTIC NEUROLOGIC DISORDERS AND AUTOIMMUNE ENCEPHALITIDES IN FRANCE
J. Hebert, B. Riche, M. Rabilloud, J. Honnorat (France)

09:25  CARDIOVASCULAR COMPLICATIONS AND ITS RELATIONSHIP WITH FUNCTIONAL OUTCOME IN GUILLAIN–BARRE SYNDROME (GBS)
R. Verma, S. Gupta, R.K. Garg, H.S. Malhotra, P. Sharma (India)

09:35  CLINICAL FEATURES OF THE SEIZURES IN THE NEURONAL SURFACE ANTIBODY-ASSOCIATED AUTOIMMUNE ENCEPHALITIS - REPORT OF 18 CASES
Y. Wang, Y. Wang, F. Song (China)

09:45  NEUROMYELITIS OPTICA SPECTRUM DISORDERS IN ARABIAN GULF (NMOAG); FIRST CLINICAL AND RADIOLOGICAL DELINEATION COHORT

09:55  ANTI GAD AUTOIMMUNOPATHY: A SYNDROME OR A SPECTRUM? AN INSIGHT FROM THE OMANI COHORT STUDY
A. Alobaidy, M. Alkindi, M. Alsulaimi, A. Alajmi, J. Alshekaili (Oman)

10:05  TYPICAL AND ATYPICAL NEUROMYELITIS OPTICA SPECTRUM DISORDER - ITS IMPLICATIONS, AN INDIAN STUDY
V.K.C. Koduri, V.S. Nagarjunakonda, V. Uppala, R. Gajula (India)

10:15  NASAL ADMINISTRATION OF FASUDIL-MODIFIED MONONUCLEAR CELLS SHOWED MULTITARGET THERAPEUTIC EFFECT ON EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS

10:25  CLINICAL ANALYSIS OF 9 CASES OF LEUCINE-RICH GLIOMA INACTIVATED 1 PROTEIN ASSOCIATED ENCEPHALITIS
Y. Wang, Y. Li, F. Song (China)

10:35  EFFICACY OF SATRALIZUMAB IN SUBGROUPS OF PATIENTS IN SAKURASKY: A PHASE III DOUBLE-BLIND, PLACEBO-CONTROLLED, ADD-ON STUDY IN PATIENTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD)
T. Yamamura, I. Kleiter, K. Fujihara, J. Palace, J. Greenberg, B. Zakrzewska-Pniewska, F. Patti, C.P. Tsai, A. Saiz, M. Haramura, Y. Terada, Y. Kawata, J. De Seze (Japan)
10:45 - 11:15
EXHIBITION AREA

COFFEE, POSTER VIEWING AND EXHIBITION VISIT

11:15 - 12:45
SHEIKH RASHID E

SCIENTIFIC SESSION: MT (MAIN TOPICS): MT1B: MOVEMENT DISORDERS

Chairs: M. Stamelou (Greece)
H. Ling (United Kingdom)

ATYPICAL PARKINSONISM (MSA, PSP, CBS)

11:15 DIFFERENTIAL DIAGNOSIS AND PHENOTYPIC SPECTRUM
M. Stamelou (Greece)

11:45 BIOMARKERS
G. Hoeglinger (Germany)

12:15 MANAGEMENT OF MSA, PSP AND CBS
H. Ling (United Kingdom)

11:15 - 12:45
SHEIKH MAKTOUM A

SCIENTIFIC SESSION: MT (MAIN TOPICS): MT2B: JOINT SESSION WFN/WSO: STROKE

Chairs: S. Al-Rukn (United Arab Emirates)
D. Werring (United Kingdom)

WSO/WFN SESSION: INTENSIVE CARE IN STROKE

11:15 STROKE – UPDATES ON SURGICAL OPTIONS IN SUBARACHNOID HEMORRHAGES
F. Roser (United Arab Emirates)

11:45 CENTRAL BREATHING DISTURBANCES
E. Schmutzhard (Austria)

12:15 IS THERE STILL A PLACE FOR HYPOTHERMIA?
B. Van der Worp (The Netherlands)
11:15 - 12:45  SHEIKH MAKTOM C

SCIENTIFIC SESSION: MT (MAIN TOPICS): MT3B: EPILEPSY

Chairs: R. Nabbout (France)  
E. Wirrell (USA)

CHALLENGES IN PEDIATRIC EPILEPSY

11:15  THE BRAVE NEW WORLD OF GENETICS IN EPILEPSY  
R. Nabbout (France)

11:45  PROGRESSIVE MYOCLONIC EPILEPSY  
A. Gargouri-Berrechid (Tunisia)

12:15  EMERGING IMMUNE THERAPIES IN PEDIATRIC EPILEPSY  
E. Wirrell (USA)

11:15 - 12:45  SHEIKH MAKTOM D

TEACHING COURSE: TC 1: NEUROINFECTIOUS DISEASE/TROPICAL NEUROLOGY PART II

Chairs: A.G. Diop (Senegal)  
R. Gouider (Tunisia)

11:15  APPROACH TO NEUROTUBERCULOSIS, THE GREAT CHAMELEON  
M. Thakre (United Arab Emirates)

11:45  DIAGNOSIS AND MANAGEMENT OF NEUROBRUCELLOSIS  
R. Gouider (Tunisia)

12:15  FROM THE INFECTED BRAIN CELLS TO SEIZURES  
A.G. Diop (Senegal)
11:15 - 12:45 SHEIKH MAKTOUM B

TEACHING COURSE: TC 2: MULTIPLE SCLEROSIS AND OTHER DEMYELINATING DISEASE: PERSONALIZED MEDICINE IN MS

Chairs: S. Khoury (Lebanon)
X. Montalban (Canada)

11:15 IDENTIFYING PROGNOSTIC FACTORS
R. Milo (Israel)

11:45 HIGHLY EFFICACIOUS DRUGS
X. Montalban (Canada)

12:15 BIOLOGICAL BIOMARKERS FOR DIAGNOSIS /PROGNOSIS AND TREATMENT RESPONSES
S. Khoury (Lebanon)

11:15 - 12:45 SHEIKH RASHID A

SCIENTIFIC SESSION: TOPICS: T1B: 2. BRINGING MR INNOVATION TO THE CLINIC

Chairs: O. Del Brutto (Ecuador)
J. Masdeu (USA)

11:15 ADVANCES OF MRI IN STROKE
S. Warach (USA)

11:45 7T MRI: MEASURING WHITE MATTER CHANGES IN MS AND IRON CONTENT IN BRAIN
S. Hametner (Austria)

12:15 UNRAVELING THE NEUROBIOLOGY OF NEURODEGENERATION WITH MRI AND GENETICS
J. Masdeu (USA)
11:15 - 12:45 SHEIKH RASHID B

SCIENTIFIC SESSION: TOPICS: T2B: 3. NEUROPSYCHIATRY

Chairs: E. Krishnamoorthy (India)
P. Sachdev (Australia)

NEURODEGENERATIVE DISORDERS

11:15 THE NEW NEUROBIOLOGY OF DEMENTIA
M. Thambisetty (USA)

11:45 CEREBROVASCULAR DISEASE, DEMENTIA AND DEPRESSION- WHERE IS THE NEXUS?
P. Sachdev (Australia)

12:15 THE BRAIN AND BEHAVIOUR IN PARKINSON’S DISEASE AND RELATED DISORDERS- FROM BENCH TO BEDSIDE
E. Joyce (United Kingdom)

11:15 - 12:45 ABU DHABI B

SCIENTIFIC SESSION: TOPICS: T3: MAXIMISING NEUROPLASTICITY IN NEUROREHABILITATION

Chairs: C. Pistarini (Italy)
N. Paik (Republic of Korea)

11:15 BASIC MECHANISMS UNDERLYING THE PLASTICITY AND ITS INDUCTION METHODS
Y. Ugawa (Japan)

11:45 VIRTUAL REALITY AND MOTOR REHABILITATION OF THE UPPER LIMB AFTER CNS DAMAGE
C. Pistarini (Italy)

12:15 NEW DRIVERS OF NEUROPLASTICITY ADOPTING RECENT TECHNOLOGIES
N.J. Paik (Republic of Korea)
11:15 - 12:45

TC WORKSHOPS: NEUROSONOLOGY WORKSHOP PART II

Chairs: M. Kaps (Germany)
A. Razumovsky (USA)

11:15  NEUROSONOLOGY ROLE FOR PATIENTS WITH CVD AND ACUTE STROKE
A. Razumovsky (USA)

11:45  ULTRASOUND AS A TOOL TO IDENTIFY HIGH-RISK PATIENTS (ACAS, PFO AND ESUS)
N. Bornstein (Israel)

12:15  ULTRASOUND FOR PERIPHERAL NERVE AND MUSCLES
S. Meng (Austria)
11:15 - 12:45  DUBAI D

FREE PAPERS 03 - CNS INFECTIONS

Chairs: M. El-Tamawy (Egypt)
R. Shakir (United Kingdom)

11:15  SAFETY AND EFFICACY OF INTRATHECAL INTERFERON-β THERAPY IN SUBACUTE SCLEROSING PANENCEPHALITIS - AN INTERIM ANALYSIS
H. Malhotra, N. Kumar, S. Pandey, A.K. Singh, R.K. Garg (India)

11:25  PLATELET DYSFUNCTION & COAGULATION ASSESSMENT IN PATIENTS WITH TUBERCULOUS MENINGITIS
R. Verma, S. Mahapatro, R.K. Garg, H.S. Malhotra, P. Sharma (India)

11:35  DETECTION OF MENINGO-ENCEPHALITIS TRENDS USING THE SYNDROME EVALUATION SYSTEM - A PAN-INDIA MULTIPLEX PCR STUDY
S. Bhattacharjee, R. B.v, B. Maramattom, Varkey, B. Natarajan, Subrahmanyam, B. N (India)

11:45  CLINICAL AND RADIOLOGICAL PROFILE OF TUBERCULOUS MENINGITIS IN A TERTIARY CARE CENTRE - A RETROSPECTIVE STUDY
R. Vemuri, N.V. Sundarachari (India)

11:55  CLINICAL FEATURES, OUTCOMES AND PROGNOSTIC FACTORS OF TUBERCULOUS MENINGITIS IN ADULTS WORLDWIDE: SYSTEMATIC REVIEW AND META-ANALYSIS
K. Li, L. Wen (China)

12:05  ELECTRON MICROSCOPY & DIFFERENTIAL GENE EXPRESSION OF VARIOUS NEUROTRANSMITTERS & CYTOSKELETON RELATED PROTEINS UNDER RABIES VIRUS INFECTION
W. Ahmad, F. Shahid Hussain, A. Ali, Q. Akram (Pakistan)

12:15  AN OBSERVATIONAL STUDY TO ESTABLISH THE ACCEPTANCE RATES OF LUMBAR PUNCTURE AMONG PATIENTS WITH NON-STROKE NEUROLOGICAL DISEASES AT UNIVERSITY TEACHING HOSPITALS-ADULT HOSPITAL IN LUSAKA, ZAMBIA
M. Chomba, A. Nutakki, L. Chishimba, S. Zimba, D. Saylor (Zambia)

12:25  CRYPTOCOCCAL MENINGITIS IN HIV AND NON-HIV PATIENTS - A COMPARATIVE STUDY OF CLINICAL AND CSF PARAMETERS
M.K. Acharya, B. Das, N. Begam, Nahar (India)

12:35  ETIOLOGY AND SHORT TERM OUTCOME OF ACUTE FEBRILE ENCEPHALOPATHY AMONG CHILDREN IN A TERTIARY CARE CENTRE IN SOUTH INDIA
P.A.M. Kunju, M. Iype, M. Sreedhaean, B. Thankappan (India)

12:45 - 14:45  EXHIBITION AREA

LUNCH BREAK, POSTER VIEWING AND EXHIBITION VISIT
13:00 - 14:30

**SPONSORED SYMPOSIUM - NON CME/CPD CREDIT**

FOR FULL PROGRAM, PLEASE SEE PAGE 151

13:00 - 14:30

**SPONSORED SYMPOSIUM - NON CME/CPD CREDIT**

FOR FULL PROGRAM, PLEASE SEE PAGE 152

14:30 - 14:45

**SHORT BREAK**

14:45 - 16:15

**SCIENTIFIC SESSION: MT (MAIN TOPICS): MT1C: MOVEMENT DISORDERS**

Chairs: K. Bhatia (United Kingdom)
M. de Koning-Tijssen (The Netherlands)

**HYPERKINETIC MOVEMENT DISORDERS (DYSTONIA, MYOCLONUS, CHOREA AND TIC)**

14:45 **ONE GENE MANY PHENOTYPES, ONE PHENOTYPE MANY GENES**
M. De Koning-Tijssen (The Netherlands)

15:15 **UPDATES IN TREMOR**
Z. Aldaajani (Saudi Arabia)

15:45 **TREATMENT OF HYPERKINETIC MOVEMENT DISORDERS**
K. Bhatia (United Kingdom)
14:45 - 16:15

SHEIKH MAKTOUM A

SCIENTIFIC SESSION: MT (MAIN TOPICS): MT2C: JOINT SESSION WFN/WSO: STROKE

Chairs: D. Hanley (USA)
B. Van der Worp (The Netherlands)

WSO/WFN SESSION: INTRACRANIAL HEMORRHAGES: NEW DATA, NEW DECISIONS

14:45 SURGICAL INTERVENTIONS IN ICH
D. Hanley (USA)

15:15 CSF AND OTHER INTERVENTIONS
D. Staykov (Austria)

15:45 RECURRENT HEMORRHAGES, NEW DATA, NEW DECISIONS
D. Werring (United Kingdom)

14:45 - 16:15

SHEIKH MAKTOUM C

SCIENTIFIC SESSION: MT (MAIN TOPICS): MT3C: EPILEPSY

Chairs: A. Beydoun (Lebanon)
T. Tomson (Sweden)

EPILEPSY IN SPECIAL SITUATIONS

14:45 PRACTICAL MANAGEMENT OF EPILEPSY AND PREGNANCY
T. Tomson (Sweden)

15:15 DIAGNOSIS OF EPILEPSY IN PATIENTS WITH NEW ONSET PAROXYSMAL SPELLS: HOW OFTEN ARE WE WRONG?
A. Beydoun (Lebanon)

15:45 PARASOMNIA VS FRONTAL LOBE EPILEPSY: SIMILAR BUT DIFFERENT
N. Haddad (Qatar)
14:45 - 16:15  
**SHEIKH MAHTOUM D**

**TEACHING COURSE: TC 3: SLEEP NEUROLOGY PART I**

- Chairs: A. Videnovic (USA)  
  C. Schenck (USA)

- **14:45** MANAGEMENT OF SLEEP DISORDERS IN PARKINSONIAN SYNDROMES  
  A. Videnovic (USA)

- **15:30** MANAGEMENT AND TREATMENT OF REM SLEEP BEHAVIOR DISORDER (RBD) AND OTHER DISORDERS WITH DREAM-ENACTMENT  
  C. Schenck (USA)

---

14:45 - 16:15  
**SHEIKH MAHTOUM B**

**TEACHING COURSE: TC 4: MULTIPLE SCLEROSIS AND OTHER DEMYELINATING DISEASES: NEW WAYS OF MANAGING MS**

- Chairs: S. Khoury (Lebanon)  
  X. Montalban (Canada)

- **14:45** MS CO-MORBIDITIES AND ENVIRONMENTAL EXPOSURES  
  H. Tremlett (Canada)

- **15:15** DIAGNOSTIC CRITERIA FOR MS AND NMO  
  A. Thompson (United Kingdom)

- **15:45** MANAGEMENT OF MS IN PREGNANCY  
  K. Hellwig (Germany)
14:45 - 16:15 SHEIKH RASHID A

**SCIENTIFIC SESSION: TOPICS: T4A: HEAD INJURY AND CRITICAL CARE NEUROLOGY**

Chairs: I. Ahmad (United Arab Emirates)
D. Sharp (United Kingdom)

**SURGICAL**

14:45 **ACUTE MANAGEMENT OF TBI**
I. Ahmad (United Arab Emirates)

15:15 **NEUROIMAGING OF TBI, MOVING TOWARDS ‘BIG DATA’ AND PRECISION MANAGEMENT**
V. Newcombe (United Kingdom)

15:45 **SURGICAL MANAGEMENT OF TBI**
I. Ahmad (United Arab Emirates)

---

14:45 - 16:15 SHEIKH RASHID B

**SCIENTIFIC SESSION: TOPICS: T5A: MITOCHONDRIAL DYSFUNCTION IN NEUROLOGICAL DISEASE**

Chairs: P. Chinnery (United Kingdom)
N.G. Larsson (Sweden)

14:45 **MITOCHONDRIAL DNA AND NEURODEGENERATION**
P. Chinnery (United Kingdom)

15:15 **MITOCHONDRIAL MECHANISMS IN NEURODEGENERATION – LESSONS LEARNT FROM ANIMAL MODELS OF MITOCHONDRIAL DISEASES**
N.G. Larsson (Sweden)

15:45 **MITOCHONDRIA AND OPTIC NEURODEGENERATION**
V. Carelli (Italy)
14:45 - 16:15 ABU DHABI A

TEACHING COURSE: TC 5: BEHAVIORAL NEUROLOGY PART I

Chairs: M. Freedman (Canada)  
S. Cappa (Italy)

14:45 CLINICAL APPROACH TO PREFRONTAL LOBE FUNCTIONS  
M. Freedman (Canada)

15:15 BEHAVIORAL AND MOOD CHANGES IN PREFRONTAL LOBE VERSUS PSYCHIATRIC DISORDERS  
E. Krishnamoorthy (India)

15:45 SOCIAL COGNITION AND THEORY OF MIND: THE CONTRIBUTION OF FRONTAL LOBE  
S. Cappa (Italy)
**FREE PAPERS 04 - DEMENTIA**

Chairs: T. Iwatsubo (Japan)  
N. Qadi (Saudi Arabia)

14:45 **LEWY BODY DEMENTIA AND POSTERIOR CORTICAL VARIANT ALZHEIMER’S DISEASE: SIMILARITIES AND DIFFERENCES ON FDG PET AND TRODAT SCAN**  
R. Verma, R. Ranjan (India)

14:55 **XINGNAOJING INJECTION IMPROVES Aβ1-42-INDUCED MEMORY DEFICIT IN MICE BY ALTERING OF EXCITATORY AMINO ACID TOXICITY AND SYNAPTIC PLASTICITY**  
Y. Liu, X. Cao, Y. Xu (China)

15:05 **ANTI-CYCCLIC CITRULLINATED PEPTIDE ANTIBODY IN ASSOCIATION WITH VASCULAR CELL ADHESION MOLECULE 1 (VCAM-1): FROM PRECLINICAL TO CLINICAL APPROACH TO PARKINSON’S DISEASE WITH DEMENTIA**  
H. Ebrahimi, A.D. Korczyn (Israel)

15:15 **URBANIZATION LEVELS AND THE PREVALENCE OF DEMENTIA IN TAIWAN – A DOOR-TO-DOOR NATIONWIDE POPULATION-BASED STUDY**  
Y. Sun, C.C. Liu, C.J. Lu (Taiwan R.O.C.)

15:25 **NEUROPROTECTIVE POTENTIAL OF SOLANESOL & EPIGALLOCATECHIN GALLATE ON ICV-STZ INDUCED COGNITIVE DYSFUNCTION IN RATS**  
P. Jaswal, R. Riya, G. Singh (India)

15:35 **CAN BEHAVIORAL SYMPTOMS DIFFERENTIATE CORTICAL FROM SUBCORTICAL DEMENTIA - A COMPARATIVE STUDY OF BEHAVIORAL PROFILE OF PARKINSON’S DISEASE DEMENTIA AND THE BEHAVIORAL VARIANT OF FRONTOTEMPORAL DEMENTIA**  
A. Biswas, D. Saini, A. Roy, A. Mukherjee, G. Gangopadhyay (India)

15:45 **IMPACT OF GENETIC VARIANT OF APOE E4 AND BDNF MET ON BDNF LEVELS, COGNITION AND BRAIN MORPHOMETRY IN MILD COGNITIVE IMPAIRMENT**  

15:55 **MILD COGNITIVE IMPAIRMENT ASSOCIATED WITH EVENTUAL LEWY BODY DISEASE PATHOLOGY: CLINICAL CHARACTERIZATION OF 75 PATIENTS**  

16:05 **CLINICAL AND NEUROIMAGING HETEROGENEITY OF DEMENTIA WITH LEWY BODIES**  
A. Chimagomedova, O. Levin, E. Vassenina (Russia)
14:45 - 16:15 DUBAI C

TC WORKSHOPS: EMG HANDS-ON WORKSHOP: NERVE CONDUCTION STUDIES

Chairs: N. Birouk (Morocco)
       J. Kimura (USA)

14:45  INTRODUCTIONS
       J. Kimura (USA)

14:55  SENSORY AND MOTOR NERVE CONDUCTION WITH LATE RESPONSES
       J. Kimura (USA)

15:35  ENMG FOR BRACHIAL PLEXOPATHY
       N. Birouk (Morocco)

14:45 - 16:15 DUBAI D

REGIONAL SYMPOSIUM SESSION: PAN-AMERICAN SYMPOSIUM SESSION

Chairs: M. Medina (Honduras)

14:45  NEW APPROACH OF SLEEP DISORDERS
       G.F. Do Prado (Brazil)

15:15  ANTI EPILEPTIC DRUG TREATMENT IN REFRACTORY EPILEPSIES
       S. Castillo (Chile)

15:45  ENDOTHELIAL DYSFUNCTION ON CEREBRAL SMALL VESSEL DISEASE
       M. Medina (Honduras)

16:15 - 16:45  EXHIBITION AREA

COFFEE, POSTER VIEWING AND EXHIBITION VISIT
16:45 - 18:15
SHEIKH RASHID E

SCIENTIFIC SESSION: MT (MAIN TOPICS): MT1D: MOVEMENT DISORDERS

Chairs: O. Seidi (Sudan)
A. Aggarwal (India)

TREATABLE MOVEMENT DISORDERS NOT TO BE MISSED

16:45 TREATABLE INHERITED MOVEMENT DISORDERS
H. Jinnah (USA)

17:15 DRUG-INDUCED AND OTHER SECONDARY MOVEMENT DISORDERS
A. Aggarwal (India)

17:45 AUTOIMMUNE MOVEMENT DISORDERS
O. Seidi (Sudan)

16:45 - 18:15
SHEIKH MAHTOUM A

SCIENTIFIC SESSION: MT (MAIN TOPICS): MT2D: JOINT SESSION WFN/WSO: STROKE

Chairs: D.A. De Silva (Singapore)
B. Campbell (Australia)

WSO/WFN SESSION: ACUTE ISCHEMIC STROKE MANAGEMENT

16:45 BASICS OF STROKE UNITS
D.A. De Silva (Singapore)

17:15 MOBILE STROKE UNITS AND URGENT DECISION MAKING
B. Campbell (Australia)

17:45 REPERFUSION THERAPIES
F. Al-Ajlan (Saudi Arabia)
16:45 - 18:15  SHEIKH MAKTOUM C

**SCIENTIFIC SESSION: MT (MAIN TOPICS): MT3D: EPILEPSY**

Chairs: H. Hosny (Egypt)  
E. Trinka (Austria)

**MANAGING EMERGENCIES IN EPILEPSY**

16:45  **STATUS EPILEPTICUS: MANAGEMENT AND PROGNOSIS**  
E. Trinka (Austria)

17:15  **ACUTE SYMPTOMATIC SEIZURES: WHO DEVELOPS THEM AND HOW DO WE TREAT THEM?**  
B.I. Lee (Republic of Korea)

17:45  **EPILEPSY AFTER STROKE AND TRAUMA: RISK FACTORS AND MANAGEMENT**  
H. Hosny (Egypt)

---

16:45 - 18:15  SHEIKH MAKTOUM D

**TEACHING COURSE: TC 3: SLEEP NEUROLOGY PART II**

Chairs: A. Videnovic (USA)  
C. Schenck (USA)

16:45  **DIAGNOSIS AND MANAGEMENT OF SLEEP APNOEA IN STROKE PATIENTS**  
C. Bassetti (Switzerland)

17:30  **THE SPECTRUM OF PARASOMNIAS OTHER THAN RBD - CLASSIFICATION AND VIDEO**  
C. Schenck (USA)

---

16:45 - 18:15  SHEIKH MAKTOUM B

**TEACHING COURSE: TC 4: MULTIPLE SCLEROSIS AND OTHER DEMYELINATING DISEASES: HOT TOPICS**

Chairs: S. Khoury (Lebanon)  
X. Montalban (Canada)

16:45  **RADIOLOGICALLY ISOLATED SYNDROMES**  
A. Siva (Turkey)

17:15  **WHEN TO STOP TREATMENT**  
A. Thompson (United Kingdom)

17:45  **PROGRESSIVE MS FROM PATHOGENESIS TO TREATMENT**  
S. Khoury (Lebanon)
16:45 - 18:15  SHEIKH RASHID A

SCIENTIFIC SESSION: TOPICS: T4B: HEAD INJURY AND CRITICAL CARE NEUROLOGY

Chairs: K. El Shunnar (United Arab Emirates)
I. Ahmad (United Arab Emirates)

CHRONIC TRAUMATIC ENCEPHALOPATHY

16:45  HOW CAN WE IDENTIFY AND MANAGE PROGRESSIVE PATHOLOGY AFTER TBI?
D. Sharp (United Kingdom)

17:15  CONCUSSION, TRAUMATIC BRAIN INJURY, AND CHRONIC TRAUMATIC ENCEPHALOPATHY: LESSONS FROM THE BATTLEFIELD, BALL FIELD, AND LAB BENCH
K. El Shunnar (United Arab Emirates)

17:45  DEVELOPMENT AND SPREAD OF TAU PATHOLOGY AFTER TBI
E. Zanier (Italy)
16:45 - 18:15  SHEIKH RASHID B

SCIENTIFIC SESSION: TOPICS: T5B: MITOCHONDRIAL DYSFUNCTION IN NEUROLOGICAL DISEASE

Chairs: P. Chinnery (United Kingdom)
        G. Manfredi (USA)

16:45  MITOCHONDRIA AND ALS
        G. Manfredi (USA)

17:15  MITOCHONDRIA IN PARKINSON’S DISEASE
        R. Youle (USA)

17:45  MITOCHONDRIA IN ALZHEIMER’S DISEASE
        E. Area-Gomez (USA)

16:45 - 18:15  ABU DHABI A

TEACHING COURSE: TC 5: BEHAVIORAL NEUROLOGY PART II

Chairs: M. Benabdeljlil (Morocco)
        D. Sharp (United Kingdom)

16:45  DIAGNOSIS OF FRONTO-TEMPORAL LOBAR DEGENERATIONS
        M. Benabdeljlil (Morocco)

17:15  PREFRONTAL DISORDERS IN BASAL GANGLIA DISEASES
        E. Joyce (United Kingdom)

17:45  FRONTAL COGNITIVE DYSFUNCTION FOLLOWING TRAUMATIC BRAIN INJURY
        D. Sharp (United Kingdom)
16:45 - 18:15

FREE PAPERS 05 - EPILEPSY 1

Chairs: E. Perucca (Italy)
        N. Haddad (Qatar)

16:45  CLINICAL PROFILE OF ELECTROGRAPHICALLY CONFIRMED NON-CONVULSIVE STATUS EPILEPTICUS IN A TERTIARY HOSPITAL IN THE PHILIPPINES
        V.M. Andal, M.A. Geronimo, A. Espiritu, M.L. Fernandez (Phillipines)

16:55  A POPULATION BASED STUDY OF EPILEPSY-ASSOCIATED COMORBIDITIES IN PEOPLE WITH EPILEPSY IN MOSCOW
        F. Rider, W.A. Hauser, Y. Solomatin, R. Akzhigitov, A. Yakovlev, A. Guekht (Russia)

17:05  THE IMPACT OF CONSANGUINITY ON PATIENTS WITH MESIAL TEMPORAL LOBE EPILEPSY DUE TO HIPPOCAMPAL SCLEROSIS: CASE-CONTROL STUDY IN A SAUDI POPULATION
        K. Al Qadi, F. Babtain, S. Rammal, M. Alem, A. Al Shahrani, H. Kayyali, S. Baesa, Y. Al Said (Saudi Arabia)

17:15  EPILEPSY SURGERY AT OR NEAR ELOQUENT CORTEX: CHALLENGES, APPROACHES AND OUTCOMES
        S. Kumar, D. Nayak, R.M. Rao, L. K, S. Kumar, A. Kanagarajan, V. P. v (India)

17:25  SPECIFIC CHANGES OF NEUROMAGNETIC OSCILLATIONS IN THE DIFFERENT PERIODS DURING ABSENCE SEIZURES: A MULTI-FREQUENCY MEG STUDY
        J. Sun, X. Wang (China)

17:35  TO STUDY GENETIC DETERMINANTS OF VARIOUS EPILEPSY TYPES IN EMIRATI POPULATION
        N. Rais, Y. Malik, A. Alhawai, H. Alzarooni, S. Yaqoob, S. Khan, S. Zulfiqar, S. Alrukn, A. Almadani (United Arab Emirates)

17:45  FIRST UNPROVOKED SEIZURE LIMITATION AND APPLICABILITY IN DEVELOPING COUNTRIES
        T. Obeid (Sudan)

17:55  IDENTIFICATION AND CHARACTERIZATION OF NOVEL COMPOUNDS IN BROAD BEANS (VICIA FABA) WHICH PROTECT AGAINST EXPERIMENTALLY INDUCED CONVULSIONS IN MICE
        M. Salih, A. Mustafa, M. Khalil (Saudi Arabia)

18:05  VALUE OF TRANSCRANIAL DIRECT CURRENT POLARISATION IN PEOPLE WITH FOCAL DRUG RESISTANT EPILEPSY
        N. Adel Kishk, H. Nafea, A. Nawito, A.A. Tawfeek, A.A. Abdelkader (Egypt)
16:45 - 18:15 DUBAI C

TC WORKSHOPS: EMG HANDS ON WORKSHOP: EMG

Chairs: N. Birouk (Morocco)
A. Al Madani (United Arab Emirates)

16:45 INTRODUCTIONS
N. Birouk (Morocco)

16:55 ELECTROPHYSIOLOGY OF MYOPATHY
A. Shaibani (USA)

17:35 AXONAL VS. DEMYELINATING ELECTROPHYSIOLOGY
A. Al Madani (United Arab Emirates)

16:45 - 18:15 DUBAI D

REGIONAL SYMPOSIUM SESSION: NORTH AMERICAN SYMPOSIUM SESSION:
DEMEN TIA - FINDING THE CURE

Chairs: J. Stevens (USA)
J. Morris (USA)

16:45 INTERNATIONAL RESEARCH INITIATIVES IN ALZHEIMER’S DISEASE
J. Morris (USA)

17:15 THE STATUS OF BIOMARKERS IN ALZHEIMER’S DISEASE
J. Stevens (USA)

17:45 MILD COGNITIVE IMPAIRMENT 2019- WHAT WE KNOW
R. Petersen (USA)

18:15 - 18:20
SHORT BREAK

18:20 - 19:00 SHEIKH RASHID E
OPENING CEREMONY

19:00 EXHIBITION AREA

WELCOME RECEPTION IN THE EXHIBITION
MONDAY
OCTOBER 28, 2019

WCN 2019
XXIV WORLD CONGRESS OF NEUROLOGY
DUBAI, UNITED ARAB EMIRATES, OCTOBER 27-31 2019
MONDAY, OCTOBER 28, 2019

07:00 - 08:00
SHEIKH MAKTOUN B

TEACHING COURSE: TC 6: NEURO-OPHTHALMOLOGY
G. Plant (United Kingdom)

08:00 - 08:30
SHEIKH RASHID E

PLENARY LECTURE 3: READING IN THE BRAIN
Chairs: W. Grisold (Austria)
S. Cappa (Italy)

08:00 READING IN THE BRAIN: MAPPING THE MASSIVE IMPACT OF LITERACY ON BRAIN CIRCUITS
S. Dehaene (France)

08:30 - 09:00
SHEIKH RASHID E

PLENARY LECTURE 4: THE GRAY ZONE AND BRAIN DEATH
Chairs: C. Kennard (United Kingdom)
R. Stark (Australia)

08:30 INTO THE GREY ZONE: DETECTING COVERT CONSCIOUS AWARENESS IN BEHAVIOURALLY NON-RESPONSIVE INDIVIDUALS.
A. Owen (Canada)
09:00 - 10:45  
**SCIENTIFIC PROGRAM: SHEIKH RASHID E**

**PRESIDENTIAL SYMPOSIUM, WFN MEDALS PRESENTATION & SORIANO AWARD PLENARY LECTURE**

Chairs: W.M. Carroll (Australia)  
J. Stevens (USA)

**09:00 WFN MEDALS PRESENTATION**

**09:20 SORIANO AWARD LECTURE: LIGHT, CIRCADIAN RHYTHMS AND SLEEP: MECHANISMS TO NEW THERAPEUTICS**

R. Foster (United Kingdom)

**09:50 THE WHO AND NEUROLOGY: RECENT COLLABORATIVE OUTCOMES**

VIDEO MESSAGE FROM DR ADHANOM GHEBREYESUS TEDROS DIRECTOR-GENERAL, WHO

**ICD-11: HOW WILL IT IMPROVE NEUROLOGY**

R. Shakir (United Kingdom)

**THE IMPLICATIONS OF THE RECLASSIFICATION OF STROKE AS A NEUROLOGICAL DISEASE**

B. Norrving (Sweden)

**10:25 A GLOBAL ROLE FOR THE WORLD FEDERATION OF NEUROLOGY**

W.M. Carroll (Australia)

10:45 - 11:15  
**EXHIBITION AREA**

**COFFEE, POSTER VIEWING AND EXHIBITION VISIT**

11:15 - 12:45  
**SCIENTIFIC SESSION: MT (MAIN TOPICS): MT4A: DEMENTIA**

Chairs: N. Fox (United Kingdom)  
J. Hardy (United Kingdom)

**11:15 IMAGING IN DEMENTIA**

N. Fox (United Kingdom)

**11:45 BIOMARKERS IN DEMENTIA**

A. Heslegrave (United Kingdom)

**12:15 GENETICS OF DEMENTIAS**

J. Hardy (United Kingdom)
11:15 - 12:45 SHEIKH MAKTouM A

SCIENTIFIC SESSION: TOPICS: T6A: NEUROONCOLOGY

Chairs: P. Wen (USA)
M. Van den Bent (The Netherlands)

PRIMARY BRAIN TUMORS

11:15 ADVANCES IN THERAPIES FOR GLIOBLASTOMAS
P. Wen (USA)

11:45 STANDARD AND NOVEL THERAPIES FOR LOWER GRADE GLIOMAS
M. Van den Bent (The Netherlands)

12:15 ADVANCES IN CNS LYMPHOMA
L. Nayak (USA)

11:15 - 12:45 SHEIKH MAKTouM C

SCIENTIFIC SESSION: TOPICS: T6A: SLEEP AND CIRCADIAN NEUROSCIENCE

Chairs: P. Zee (USA)
C. Trenkwalder (Germany)

SLEEP AND THE CIRCADIAN CLOCK

11:15 NEUROBIOLOGY AND GENETICS OF CIRCADIAN RHYTHMS
P. Zee (USA)

11:45 CIRCADIAN RHYTHM IN NEURODEGENERATIVE DISEASES
A. Videnovic (USA)

12:15 BRAIN IMAGING IN REM SLEEP BEHAVIOR DISORDER
D. Arnaldi (Italy)
11:15 - 12:45  SHEIKH MAKTOM D

TEACHING COURSE: TC 7: MOVEMENT DISORDERS: THE BASICS OF PARKINSON’S DISEASE

Chairs: R. Takahashi (Japan)
R. Mounia (Morocco)

11:15  CLINICAL EXAMINATION OF PD PATIENTS
A. Aldakheel (Saudi Arabia)

11:37  HOW TO START THERAPY IN EARLY PD
R. Takahashi (Japan)

11:59  USE OF IMAGING IN PD
G. Respondek (Germany)

12:21  THERAPIES IN ADVANCED PD
R. Mounia (Morocco)

11:15 - 12:45  SHEIKH MAKTOM B

TEACHING COURSE: TC 8: EPILEPSY: THE SEMIOLOGY OF EPILEPSY

Chairs: S. Wiebe (Canada)
A. Beydoun (Lebanon)

11:15  SEMIOLOGY OF TEMPORAL LOBE EPILEPSY
H. Hosny (Egypt)

11:45  SEMIOLOGY OF EXTRATEMPORAL LOBE EPILEPSY
N. Haddad (Qatar)

12:15  SEMIOLOGY OF ELECTROCLINICAL SYNDROMES OF CHILDHOOD AND ADOLESCENCE
A. Beydoun (Lebanon)
11:15 - 12:45 SHEIKH RASHID A

TEACHING COURSE: TC 9: MANAGEMENT OF STROKE ON STROKE UNITS

Chairs: S. Kesraoui (Algeria)
B. Van der Worp (The Netherlands)

11:15 DIAGNOSTIC AND THERAPY OF INCREASED INTRACRANIAL PRESSURE IN ISCHEMIC STROKE
E. Schmutzhard (Austria)

11:37 MANAGEMENT OF HYPERPYREXIA, HYPERGLYCAEMIA, AND HYPERTENSION IN ACUTE ISCHEMIC STROKE
B. Van der Worp (The Netherlands)

11:59 MANAGEMENT OF INTRACRANIAL HEMORRHAGES
D. Hanley (USA)

12:21 ICH RELATED TO DIRECT ORAL ANTICOAGULANTS
S. Kesraoui (Algeria)

11:15 - 12:45 DUBAI E+F

TC WORKSHOPS: WORKSHOP: BOTULINUM TOXIN INJECTIONS PART I

Chairs: D. Truong (USA)
R. Kaji (Japan)

11:15 CERVICAL DYSTONIA
D. Truong (USA)

12:00 USE OF ULTRASOUND WITH BOTULINUM TOXIN WITH CORRELATION ON CADAVER
S. Meng (Austria)

11:15 - 12:45 SHEIKH RASHID B

SCIENTIFIC SESSION: TOPICS: T7A: NEUROOPHTHALMOLOGY

Chairs: G. Plant (United Kingdom)
V. Lal (India)

11:15 OPTIC NEURITIS: DIFFERENTIAL DIAGNOSIS AND MANAGEMENT
G. Plant (United Kingdom)

11:45 INFECTIVE OPTIC NEUROPATHIES- DENGUE AND BEYOND
D. Milea (Singapore)

12:15 MANAGEMENT OF IIH
P. Subramanian (USA)
11:15 - 12:45

ABU DHABI A

SCIENTIFIC SESSION: TOPICS: T8: ETHICAL ASPECTS OF NEUROLOGICAL PRACTICE

Chairs: J. Illes (Canada)
       J. Chandler (Canada)

CONTEMPORARY NEUROETHICS FOR NEUROLOGY PRACTICE AND RESEARCH

11:15 THE IMPERATIVE AND MULTIDIMENSIONALITY OF NEUROETHICS FOR NEUROLOGY AND THE NEUROLOGICAL SCIENCES
       J. Illes (Canada)

11:45 EMERGING LEGAL AND REGULATORY ISSUES IN NEUROLOGY AND NEUROSURGERY
       J. Chandler (Canada)

12:15 EMERGING ETHICAL ISSUES FOR PRACTICING NEUROLOGISTS
       H. Chneiweiss (France)
11:15 - 12:45

FREE PAPERS 06 - MOVEMENT DISORDERS 1

Chairs: R. Takahashi (Japan)
        M. Stamelou (Greece)

11:15  Olfactory neural connections associated with cognition in Parkinson’s disease progression

H. Chatterjee, G. Elumalai, P. Maiti, N. Osakwe, N. Sewram (Guyana)

11:25  A safety, tolerability and biomarker update from an ongoing open-label extension study of RG6042 in adults with early manifest Huntington’s disease

B. Leavitt, S. Tabrizi, P. Sanwald Ducray, E. Wild, V. Schlegel, G. Hooper, A. Nicotra, J. Chevure, A. Smith, R. Lane, F. Bennett, L. Boak, R. Doody, S. Schobel (Canada)

11:35  Agil-AADC gene therapy results in sustained improvements in motor and developmental milestones through 5 years in children with AADC deficiency


11:45  Screening of cognitive impairment in early Parkinson’s disease using Montreal cognitive assessment (MoCA)

N. Kumar, G. Gupta (India)

11:55  The therapeutic effect of bilobalide on Parkinson’s disease possibly through anti-inflammatory and neuroprotective mechanisms


12:05  Comprehensive functional evaluation of the spectrum of multi-system atrophy with 18F-FDG PET/CT and 99MTC TRODAT-1 SPECT: 5 years experience from a tertiary care centre

R. Verma, R. Ranjan, C. Agrawal, A. Batra (India)

12:15  Effect of WuZi YanZong pill on oxidative stress response in Parkinson’s disease mice


12:25  Utilization of COMT inhibitors, dopamine agonists, and MAO-B inhibitors with levodopa-carbidopa intestinal gel in advanced Parkinson’s disease patients: summary of phase 3 and real-world studies

K.R. Chaudhuri, J. Boyd, J. Acosta, L. Bergmann, P. Kukreja, A. Antonini (USA)

12:35  Interleaving stimulation mode can improve better the health-related quality of life in primary generalized or segmental dystonia than standard bilateral pallidal deep brain stimulation

N. Kovacs, MD- Ph.D- D.Sc., B. István, P. Dávid, J. Annamária, H. Márk, V. Viktor, J. József (Hungary)
11:15 - 12:45

TEACHING COURSE: TC10: WFN-AAN NEUROLOGY FORUM PART I

Chairs: M. Wasay (Pakistan)
S. Lewis (USA)

11:15  INTRODUCTION AND APPROACH TO ADVOCACY
M. Wasay (Pakistan)

11:40  ADVOCACY IN AN INSTITUTION
J. Cardenas (USA)

12:05  ADVOCACY IN INTERNATIONAL ORGANIZATIONS
W. Grisold (Austria)

12:30  PANEL DISCUSSION
11:15 - 12:45
FREE PAPERS 07 - MS & DEMYELINATING DISEASES 1

Chairs: N. Grigoriadis (Greece)
R. Alroughani (Kuwait)

11:15 IMAGING FEATURES OF 60 PATHOLOGICALLY CONFIRMED PATIENTS WITH TUMEFACTIVE DEMYELINATING LESIONS
J. Liu, X. Qi (China)

11:25 SUSTAINED REDUCTION IN CONFIRMED DISABILITY PROGRESSION AFTER 6.5 STUDY-YEARS OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
J.S. Wolinsky, B. Brochet, H.P. Hartung, R.T. Naismith, L. Airas, K. Coutant, H. Koendgen, M. Manfrini, L. Mehta, K. Prajapati, L. Kappos (USA)

11:35 EVOKED POTENTIALS ARE IMPORTANT PREDICTORS OF FUTURE DISABILITY IN PEOPLE WITH CLINICALLY ISOLATED SYNDROME
M. Habek, L. Crnosija, T. Gabelic, B. Barun, I. Adamec, M. Krbot Skoric (Croatia)

11:45 CLINICAL SPECTRUM OF MYELIN OLIGODENDROCYTE GLYCOPROTEIN (MOG) ANTIBODY ASSOCIATED CNS DEMYELINATION
V. Aglave, P. Ojha, K. Jagiasi, G. Soni, R. Singh, P. Barvalia, R. Ansari (India)

11:55 THE ASSOCIATIONS BETWEEN REGIONAL CORTICAL ATROPHIES AND INFORMATION PROCESSING SPEED IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS
J. Komendziński, A. Wyszomirski, M. Chylińska, A. Sabisz, H. Wójcik-Dr czkowska, M. Hałas, B. Karaszewski (Poland)

12:05 PREVALENCE AND PATTERN OF MULTIPLE SCLEROSIS IN BENGHAZI LIBYA
H.A. El-Zawawi, S. Zoubi (Libya)

12:15 COMPARISON OF SERUM OXIDATIVE STRESS, ANTIOXIDANT PARAMETERS AND VITAMIN D LEVELS OF SRI LANKAN PATIENTS WITH MULTIPLE SCLEROSIS AND NEUROMYELITIS OPTICA : A PILOT STUDY
D. Wijesundara, G. Nayanajeehwi, C. Jayasinghe, B. Senanayake (Sri Lanka)

12:25 MOLECULAR CHARACTERISTICS OF THE GUT MICROBIOME IN A SAMPLE OF EGYPTIAN REMITTING RELAPSING MULTIPLE SCLEROSIS (MS) PATIENTS
J. Mekky, S. Ahmed, S. Said, R. Wani (Egypt)

12:35 NATURAL COURSE OF BENIGN MULTIPLE SCLEROSIS:RESULTS FROM 5-YEARS PROSPECTIVE STUDY
O. Shulga, O. Zheshko, T. Mamchych (Ukraine)

12:45 - 14:45
EXHIBITION AREA

LUNCH BREAK, POSTER VIEWING AND EXHIBITION VISIT
13:00 - 14:30  SHEIKH RASHID A

SPONSORED SYMPOSIUM - NON CME/CPD CREDIT

FOR FULL PROGRAM, PLEASE SEE PAGE 153

14:30 - 14:45

SHORT BREAK

14:45 - 16:15  SHEIKH RASHID E

SCIENTIFIC SESSION: MT (MAIN TOPICS): MT4B: DEMENTIA

Chairs: T. Iwatsubo (Japan)
N. Fox (United Kingdom)

14:45  MOLECULAR PATHOLOGY TO DISEASE MODIFICATION OF ALZHEIMER’S DISEASE
T. Iwatsubo (Japan)

15:15  THE MOLECULAR ORIGINS OF ALZHEIMER’S DISEASE: WHEN DOES IT START AND WHAT STRATEGIES FOR PRIMARY PREVENTION?
C. Masters (Australia)

15:45  PREVENTION OF DEMENTIA: CLINICAL TRIALS - CHALLENGES AND OPPORTUNITIES
N. Fox (United Kingdom)
14:45 - 16:15 SHEIKH MAKTUM A

SCIENTIFIC SESSION: TOPICS: T6B: NEUROONCOLOGY

Chairs: P. Wen (USA)
        M. Van den Bent (The Netherlands)

NEUROLOGIC COMPLICATIONS OF CANCER

14:45 PARANEOPLASTIC NEUROLOGIC SYNDROMES
        J. Degroot (USA)

15:15 NEUROLOGIC COMPLICATIONS OF CANCER IMMUNOTHERAPIES
        M. Weller (Switzerland)

15:45 STANDARD AND NOVEL THERAPIES FOR BRAIN AND LEPTOMENINGEAL METASTASES
        E. Le Rhun (France)

14:45 - 16:15 SHEIKH MAKTUM C

SCIENTIFIC SESSION: TOPICS: T6B: SLEEP AND CIRCADIAN NEUROSCIENCE

Chairs: C. Schenck (USA)
        B. Jeon (Republic of Korea)

REM SLEEP AND PARASOMNIAS: THE DOOR TO NEUROLOGICAL DISEASES

14:45 REM SLEEP BEHAVIOR DISORDER (RBD): CURRENT ANIMAL MODELS, PATHOPHYSIOLOGY AND THE STRONG LINK WITH THE ALPHA-SYNUCLEINOPATHIES
        C. Schenck (USA)

15:15 PRODROMAL PARKINSON’S AND RBD: CLINICAL SIGNS AND POLYSOMNOGRAPHICAL CHANGES
        C. Trenkwalder (Germany)

15:45 IMAGING OF RBD: NEW MRI AND SPECT DATA
        B. Jeon (Republic of Korea)
14:45 - 16:15 SHEIKH MAKTOUM D

TEACHING COURSE: TC 7: MOVEMENT DISORDERS: APPROACHES TO HYPERKINETIC DISORDERS

Chairs: M. Obaid (Saudi Arabia)
        H. Jinnah (USA)

14:45 APPROACH TO DYSTONIA
   H. Jinnah (USA)

15:07 APPROACH TO TREMOR/MYOCLonus
   M. Stamelou (Greece)

15:29 APPROACH TO CHOREA
   M. Obaid (Saudi Arabia)

15:51 APPROACH TO TICS
   M. Abu Al-Melh (Kuwait)

14:45 - 16:15 SHEIKH MAKTOUM B

TEACHING COURSE: TC 8: EPILEPSY: STATUS EPILEPTICUS

Chairs: S. Wiebe (Canada)
        A. Beydoun (Lebanon)

14:45 STATUS EPILEPTICUS: DIAGNOSIS AND PREHOSPITAL TREATMENT
   S. Wiebe (Canada)

15:15 TREATMENT OF ESTABLISHED, REFRACTORY AND SUPER-REFRACTORY STATUS EPILEPTICUS
   E. Trinka (Austria)

15:45 STATUS EPILEPTICUS: TREATING THE SEIZURES VS THE ETIOLOGY
   B.I. Lee (Republic of Korea)
14:45 - 16:15  
SHEIKH RASHID A

TEACHING COURSE: TC 9: MANAGEMENT OF STROKE ON STROKE UNITS CONTINUED

Chairs: M. Brainin (Austria)
        F. Belahsen (Morocco)

14:45  OVERVIEW OF STROKE UNIT CARE  
M. Brainin (Austria)

15:07  INTRAVENOUS THROMBOLYSIS  
F. Belahsen (Morocco)

15:29  THROMBECTOMY  
B. Campbell (Australia)

15:51  DIFFICULT DECISIONS IN ACUTE STROKE  
S. Kesraoui (Algeria)

14:45 - 16:15  
DUBAI E+F

TC WORKSHOPS: WORKSHOP: BOTULINUM TOXIN INJECTIONS PART II

Chairs: D. Truong (USA)
        R. Kaji (Japan)

14:45  SPASTICITY  
R. Kaji (Japan)

15:30  MIGRAINE AND OTHER USES  
J. Al-Hashel (Kuwait)

14:45 - 16:15  
SHEIKH RASHID B

SCIENTIFIC SESSION: TOPICS: T7B: NEUROOPHTHALMOLOGY

Chairs: G. Plant (United Kingdom)
        V. Lal (India)

14:45  OF PLACES AND FACES- CORTICAL VISUAL DISORDERS  
J. Barton (Canada)

15:15  PAINFUL OPHTHALMOPLEGIA- DIAGNOSTIC PEARLS  
V. Lal (India)

15:45  OCULAR MOTILITY DISORDERS WITH SPECIAL EMPHASIS ON MULTIPLE SCLEROSIS  
C. Tilikete (France)
14:45 - 16:15

SCIENTIFIC SESSION: TOPICS: T9: NEUROLOGICAL EDUCATION – CHALLENGES AND INNOVATIONS ACROSS THE GLOBE

Chairs: S. Lewis (USA)
        S. Katrak (India)

14:45 THE PERSPECTIVES OF THE WFN: THE MISSION TO TEACH OR EMPOWERING TEACHING
W. Grisold (Austria)

15:15 CHALLENGES FACED IN NEUROLOGICAL EDUCATION IN INDIA AND INNOVATIONS FOR THE FUTURE
S. Katrak (India)

15:45 GLOBAL NEUROLOGICAL CURRICULA, MILESTONES, AND THE CHALLENGE OF ASSESSMENT OF NEUROLOGIC COMPETENCE
S. Lewis (USA)
14:45 - 16:15

FREE PAPERS 08 - NEUROMUSCULAR DISORDERS

Chairs: E. Cupler (Saudi Arabia)
M. Reilly (United Kingdom)

14:45 **Antibodies to Zika Virus, Campylobacter Jejuni, Gangliosides in Guillain Barre Syndrome. A Prospective Single Centre Study from Southern India.**
D. Baskar, D. Amalnath, J. Mandal (India)

14:55 **GNE Myopathy: Disease Progression in a Large Cohort of Genetically Confirmed Cases from a Single Centre in India**

15:05 **Video Head Impulse Test Findings in Patients with Charcot-Marie-Tooth Disease 1A**
Z. Calic, V. Rakocevic-Stojanovic, S. Peric, M. Vujnic, B. Bjelica, I. Bozovic, M. Welgampola (Australia)

15:15 **Myopathies Presenting with Head Drop: Clinical Spectrum and Treatment Outcomes**
E. Naddaf, R. Alhammad (USA)

15:25 **Muscle Pathology of Anti-Mi-2 Dermatomyositis is Characterized by Perifascicular Necrosis and Perimysial Change**
J. Tanboon, M. Inoue, I. Nishino (Japan)

15:35 **Correlation Between Motor Unit Number Index (MUNIX) and Muscle Ultrasound Measurements and Clinical Outcome in ALS Patients: As Novel Biomarkers**
S. Rajabkhah Ziaratgah, S. Naffissi, D. Fathi, F. Fatehi (Iran)

15:45 **Study of Clinical Profile, Genetics and Therapeutics of Congenital Myasthenic Syndrome in an Indian Population**
G. Panandikar, S. Ravat (India)

15:55 **Immunohistochemistry Versus Genetic Studies in Muscular Dystrophies – A Cost-Effectiveness Analysis**
K. Malhotra, P. Srivastava, H. Malhotra, D. Kulshreshtha, N. Husain (India)

16:05 **Delineating the Phenotypes of Early Onset Myopathy Due to Novel Titin Gene Mutations**
M. Salih, M. Hamad, M. Savarese, I. Alorainy, H. Alkhalidi, A. Alotaibi, M. Alsagob, D. Colak, B. Udd, N. Kaya, A. Al Jarallah (Saudi Arabia)
14:45 - 16:15

**TEACHING COURSE: TC10: WFN-AAN NEUROLOGY FORUM PART II**

Chairs: W. Grisold (Austria)
T. Wijeratne (Australia)

14:45 **ADVOCACY FOR PATIENTS**  
J. Miyasaki (Canada)

15:10 **ADVOCACY PROJECT AND PRESENTATION**  
W. Struhal (Austria)

15:35 **THE QUALITIES OF HUMAN RELATIONS: RESILIENCE**  
T. Wijeratne (Australia)

16:00 **PANEL DISCUSSION**

---

14:45 - 16:15

**REGIONAL SYMPOSIUM SESSION: PAN-ARAB REGIONAL SYMPOSIUM**

Chairs: M. Abdel-Naseer (Egypt)  
M. Chokri (Tunisia)

14:45 **EPIDEMIOLOGY OF DEMENTIA IN DEVELOPING COUNTRIES**  
M. Abdel-Naseer (Egypt)

15:07 **EARLY ONSET DEMENTIA**  
S. Belarbi (Algeria)

15:29 **THE VALUE OF FUNCTIONAL IMAGING AND CSF BIOMARKERS FOR THE DIAGNOSIS OF DEGENERATIVE DEMENTIA**  
M. Damak (Tunisia)

15:51 **PHARMACOLOGICAL AND NON PHARMACOLOGICAL TREATMENT OF ALZHEIMER’S DISEASE**  
A. Awada (Lebanon)

16:13 **DISCUSSION**

---

16:15 - 16:45

**EXHIBITION AREA**

**COFFEE, POSTER VIEWING AND EXHIBITION VISIT**
16:45 - 18:15

TEACHING COURSE: TC10: WFN-AAN NEUROLOGY FORUM PART III

Chairs: J. Miyasaki (Canada)
       W. Struhal (Austria)

16:45  ADVOCACY CONTENT AND PRESENTATION
       J. Cardenas (USA)

17:10  ADVOCACY PROJECTS AND ACTION PLANNING ROUNDTABLE
       W. Struhal (Austria)
       T. Wijeratne (Australia)
       J. Cardenas (USA)
       W. Grisold (Austria)
       M. Wasay (Pakistan)
       J. Miyasaki (Canada)
       S. Lewis (USA)

17:40  PRESENTATION OF EACH CANDIDATE’S PROJECT

18:10  CLOSING REMARKS
       W. Grisold (Austria)
16:45 - 18:15  SHEIKH RASHID E

**SCIENTIFIC SESSION: MT (MAIN TOPICS): MT4C: DEMENTIA**

Chairs: F. Mangialasche (Sweden)  
C. Chen (Singapore)

16:45 **VASCULAR CONTRIBUTIONS TO DEMENTIA**
N. Qadi (Saudi Arabia)

17:15 **WORLD-WIDE FINGERS NETWORK: A GLOBAL APPROACH TO RISK REDUCTION AND PREVENTION OF DEMENTIA**
F. Mangialasche (Sweden)

17:45 **RETINAL IMAGING FOR DEMENTIA**
C. Chen (Singapore)

16:45 - 18:15  SHEIKH MAKTOUM A

**SCIENTIFIC SESSION: TOPICS: T24: MOTOR NEURON DISEASE**

Chairs: M. Kiernan (Australia)  
M. de Visser (The Netherlands)

16:45 **DIAGNOSTIC CRITERIA AND DISEASE BIOMARKERS FOR ALS**
R. Kaji (Japan)

17:15 **DOES COGNITIVE AND BEHAVIOURAL IMPAIRMENT IN AMYOTROPHIC LATERAL SCLEROSIS RESEMBLE THAT OF FRONTOTEMPORAL DEMENTIA?**
M. De Visser (The Netherlands)

17:45 **ALS TREATMENT STRATEGIES**
M. Kiernan (Australia)
16:45 - 18:15 DUBAI D

REGIONAL SYMPOSIUM SESSION: ASIAN-OCEANIAN REGIONAL SYMPOSIUM: HISTORY, PRACTICE AND SCIENCE OF TRADITIONAL MEDICINE IN ASIA

Chairs: B. Jeon (Republic of Korea)

16:45 MIDDLE EAST
S. Boholega (Saudi Arabia)

17:07 INDIA
B. Menon (India)

17:29 FAR EAST
B. Jeon (Republic of Korea)

17:51 IRAN
S. Nafissi (Iran)
TUESDAY
OCTOBER 29, 2019

WCN 2019
XXIV WORLD CONGRESS OF NEUROLOGY
DUBAI, UNITED ARAB EMIRATES, OCTOBER 27-31 2019
TUESDAY, OCTOBER 29, 2019

08:00 - 08:30

PLENARY LECTURE 5: YAHR AWARD LECTURE: TREATING HUNTINGTON'S DISEASE

Chairs: S. Lewis (USA)
       D. Truong (USA)

08:00 TREATING HUNTINGTON’S DISEASE
       S. Tabrizi (United Kingdom)

08:30 - 09:00

PLENARY LECTURE 6: IMAGING PAIN

Chairs: J. Leger (France)
       M. Hallett (USA)

08:30 IMAGING PAIN
       I. Tracey (United Kingdom)

09:00 - 10:30

SCIENTIFIC SESSION: MT (MAIN TOPICS): MT5A: MS AND DEMYELINATING DISORDERS

Chairs: A. Thompson (United Kingdom)
       W.M. Carroll (Australia)

DIAGNOSIS AND TREATMENT

09:00 EVOLVING DIAGNOSTIC CRITERIA
       A. Thompson (United Kingdom)

09:30 TREATMENT GUIDELINES – IS AN INTERNATIONAL CONSENSUS POSSIBLE
       K. Fujihara (Japan)

10:00 PROGRESS IN PROGRESSIVE MS
       W.M. Carroll (Australia)
09:00 - 10:30  SHEIKH MAHTOU A

SCIENTIFIC SESSION: MT (MAIN TOPICS): MT6A: TROPICAL AND GEOGRAPHIC NEUROLOGY

Chairs: P. Preux (France)
M. Medina (Honduras)

ARBOVIRUSES

09:00  GUILLAIN-BARRE SYNDROME AND THE ZIKA EPIDEMIC IN LATIN AMERICA: LESSONS LEARN AND THE CURRENT SITUATION
C.A. Pardo-Villamizar (USA)

09:30  NEUROLOGIC CONSEQUENCES OF ARBOVIRUS INFECTIONS: NEW CHALLENGES
M. Medina (Honduras)

10:00  DISCUSSION

09:00 - 10:30  SHEIKH MAHTOU C

SCIENTIFIC SESSION: TOPICS: T10A: BEHAVIOURAL NEUROLOGY

Chairs: S. Cappa (Italy)
M. Husain (United Kingdom)

NEW VISTAS ON LANGUAGE AND THE BRAIN

09:00  STROKE
M. Lambon Ralph (United Kingdom)

09:30  NEURODEGENERATION
S. Cappa (Italy)

10:00  SURGICAL MAPPING
H. Duffau (France)
09:00 - 10:30  SHEIKH MAKTOUM D

TEACHING COURSE: TC 11: NEURO-OPHTHALMOLOGY PART I

Chairs: G. Plant (United Kingdom)
        V. Lal (India)

09:00  ACUTE VISUAL LOSS
G. Plant (United Kingdom)

09:30  AN APPROACH TO PAPILLEDEMA
P. Subramanian (USA)

10:00  AN APPROACH TO DIFFERENT OCULAR MOTILITY DISORDERS
C. Tilikete (France)

09:00 - 10:30  SHEIKH MAKTOUM B

TEACHING COURSE: TC 12: NEUROMUSCULAR DISEASES: DIAGNOSIS AND TREATMENT OF HEREDITARY NEUROPATHIES AND MOTOR NEURON DISEASE

Chairs: M. Reilly (United Kingdom)
        M. Kiernan (Australia)

09:00  GENETIC AND CLINICAL APPROACH TO INHERITED NEUROPATHIES
M. Reilly (United Kingdom)

09:30  EARLY RECOGNITION OF AMYLOID NEUROPATHY
V. Planté-Bordeneuve (France)

10:00  UPDATE ON THERAPEUTIC OPTIONS IN ALS
M. Kiernan (Australia)

09:00 - 10:30  SHEIKH RASHID A

TEACHING COURSE: TC 13: HEADACHE PART I

Chairs: D.M. Kayed (United Arab Emirates)
        R. Stark (Australia)

09:00  ICHD 3 - WHAT'S NEW?
D.M. Kayed (United Arab Emirates)

09:30  MIGRAINE: ACUTE AND EMERGENCY DEPARTMENT TREATMENTS
A. Ducros (France)

10:00  MIGRAINE: PREVENTATIVE THERAPY
R. Stark (Australia)
09:00 - 10:30 SHEIKH RASHID B

TEACHING COURSE: TC 14: PALLIATIVE CARE IN NEUROLOGY PART I

Chairs: I. Baker (United Kingdom)
       S. Payne (United Kingdom)

09:00 ETHICAL ASPECTS OF CARE IN NEUROLOGY – HOW DO WE DISCUSS AND MANGE DIFFICULT SITUATIONS
I. Baker (United Kingdom)

09:30 CULTURAL ASPECTS OF CARE – COPING WITH DIVERSITY
O. Shamieh (Jordan)

10:00 ADVANCE CARE PLANNING – HOW DO WE FACILITATE PATIENT DECISION MAKING
S. Payne (United Kingdom)

09:00 - 10:30 ABU DHABI A

TEACHING COURSE: TC 15: NEUROCRITICAL CARE PART I

Chairs: A. Rabinstein (USA)

09:00 OPTIMAL MEDICAL MANAGEMENT AFTER ENDOVASCULAR STROKE THERAPY
A. Rabinstein (USA)

09:30 TREATMENT OF INTRACEREBRAL HEMORRHAGE: THE PRESENT AND FUTURE
D. Hanley (USA)

10:00 PRACTICAL PEARLS IN THE MANAGEMENT OF SUBARACHNOID HEMORRHAGE
E. Schmutzhard (Austria)
FREE PAPERS 09 - LATE BREAKING

Chairs: S. Lewis (USA)
       C. Kennard (United Kingdom)

09:00   BURDEN OF DISEASE DUE TO EPILEPSY IN LATIN AMERICA: A SYSTEMATIC ANALYSIS OF THE
        GLOBAL BURDEN DISEASE STUDY 2017
        K. Pacheco-Barrios, A. Cardenas-Rojas, C. Alva-Diaz (Peru)

09:10   NEUROSCIENCE IN ICD11
        R. Shakir (United Kingdom)

09:20   EVALUATION OF MOTOR SYMPTOMS IN PATIENTS WITH PARKINSON'S DISEASE THROUGH MET AND
        PAL MEASURED WITH 3-AXIS ACCELEROMETER: PILOT PROSPECTIVE OBSERVATIONAL STUDY IN A
        SINGLE CENTER
        H. Ito, D. Yokoi, K. Rei, H. Okada, Y. Kajita, S. Okuda (Japan)

09:30   THE ROLE OF GENETIC FACTORS IN LEVODOPA-INDUCED DYSKINESIAS DEVELOPMENT IN RUSSIAN
        PATIENTS WITH PARKINSON'S DISEASE: A PILOT STUDY
        G. Akhmadeeva, I. Khidiyatova, I. Gilyazova, A. Baitimerov, R. Magzhanov (Russia)

09:40   EFFICACY AND SAFETY OF THE BRUTON'S TYROSINE KINASE INHIBITOR EVOBRUTINIB IN PATIENTS
        WITH RELAPSING MULTIPLE SCLEROSIS OVER 48 WEEKS: A RANDOMIZED, PLACEBO-CONTROLLED,
        PHASE 2 STUDY
        S. Syed, F. Dangond, J.S. Wolinsky (Canada)

09:50   LONG-TERM DISEASE STABILITY ASSESSED BY THE EXPANDED DISABILITY STATUS SCALE IN
        PATIENTS TREATED WITH CLADRIBINE TABLETS IN THE CLARITY EXTENSION STUDIES
        G. Giovannoni, G. Comi, K. Rammohan, P. Rieckmann, P. Vermersch, F. Dangond, B. Keller,
        D. Jack (United Kingdom)

10:00   SEASONAL POSTPARTUM HYPERNATREMIC ENCEPHALOPATHY WITH OSMOTIC DEMYELINATION
        AND RHABDOMYOLYSIS: A RARE TROPICAL DISEASE
        K.R. Naik, S. Aralikatte Onkarappa (India)

10:10   IMAGE-GUIDED FRAMELESS STEREOTAXY IN SUBTHALAMIC DEEP BRAIN STIMULATION: THREE-
        YEAR CLINICAL OUTCOME
        T. Tufo, F. Bove, D. Mulas, A. Bentivoglio, B. Cioni, C. Piano (Italy)

10:20   BURDEN OF DISEASE DUE TO STROKE IN LATIN AMERICA: A SYSTEMATIC ANALYSIS OF THE GLOBAL
        BURDEN DISEASE STUDY 2017
        K. Pacheco-Barrios, S. Giannoni-Luza., C. Alva-Diaz (Peru)
FREE PAPERS 10 - STROKE 2

09:00 A RANDOMIZED CONTROLLED TRIAL OF NEUROPROTECTIVE EFFECTS OF N-ACETYL-CYSTEINE IN PATIENTS WITH ACUTE ISCHEMIC STROKE

09:10 DISCREPANCY IN CORE INFARCT BETWEEN CT ASPECTS AND CT PERFUSION WHEN SELECTING FOR MECHANICAL THROMBECTOMY
S. John, S.I. Hussain, B. Piechowski, M.A. Dogar (United Arab Emirates)

09:20 EFFECTS OF SMOKING STATUS ON THE AGE AT ONSET OF FIRST-EVER STROKE: DATA FROM KOREAN STROKE REGISTRY

09:30 SERUM HOMOCYSTEINE LEVEL IS RELATED TO LARGE ARTERY DISEASE IN ACUTE ISCHEMIC STROKE.

09:40 NEUTROPHIL TO LYMPHOCYTE RATIO PREDICTS POOR OUTCOMES AFTER ACUTE ISCHEMIC STROKE: A COHORT STUDY AND UPDATED SYSTEMATIC REVIEW
L. Wang, Q. Song, C. Wang, S. Wu, M. Liu (China)

09:50 FASTEST DETECTION OF ISCHEMIC PENUMBRA USING COMPREHENSIVE 10 MINUTES MRI PROTOCOL INCLUDING ASAP-ASL, AND ITS UTILITY IN TREATING ACUTE STROKE.
P. Oak, Y. Sawant, M. Verma, D. Patkar (India)

10:00 YIELD OF IMPLANTABLE LOOP RECORDER IN DETECTION OF ATRIAL FIBRILLATION AFTER EMBOLIC STROKE OF UNDETERMINED SOURCE: A SINGLE CENTER EXPERIENCE
S. Lourenco, V. Neves, B. Sara, E. Tania, C. Corzo, P. Dionisio, C. Barata, L. Rebocho, J. Aguiar (Portugal)

10:10 ASPIRATION VERSUS STENTRIEVAL TECHNIQUE AS FIRST PASSAGE FOR MECHANICAL THROMBECTOMY IN ACUTE ISCHEMIC STROKE

10:20 EFFECTIVENESS OF HOME-BASED COMPREHENSIVE NEUROPSYCHOLOGICAL REHABILITATION FOR POST STROKE APHASIA IN LIMITED RESOURCE SETTINGS: AN FMRI BASED RANDOMIZED CONTROLLED TRIAL
H. Kaur, S. Kumaran, R. Bhatia, S. Chopra, A. Nehra (India)
10:30 - 11:00  EXHIBITION AREA

COFFEE, POSTER VIEWING AND EXHIBITION VISIT

11:00 - 12:30  SHEIKH RASHID E

SCIENTIFIC SESSION: MT (MAIN TOPICS): MT5B: MS AND DEMYELINATING DISORDERS

   Chairs: M. Tintore (Spain)
          R. Alroughani (Kuwait)

11:00  THE ROLE OF PREGNANCY IN LONG TERM PROGNOSIS
       M. Tintore (Spain)

11:30  PREGNANCY IN THE NEW TREATMENT ERA
       K. Hellwig (Germany)

12:00  PAEDIATRIC MULTIPLE SCLEROSIS
       R. Alroughani (Kuwait)

11:00 - 12:30  SHEIKH MAKTOUM A

SCIENTIFIC SESSION: MT (MAIN TOPICS): MT6B: TROPICAL AND GEOGRAPHIC NEUROLOGY

   Chairs: M. Medina (Honduras)
          P. Preux (France)

   TROPICAL NEGLECTED DISEASES

11:00  CHALLENGES IN MANAGEMENT OF CNS TUBERCULOSIS
       C. Meshram (India)

11:30  PARAINFECTIONAL NEUROPATHIES
       J. England (USA)

12:00  NEUROCYSTICERCOSIS AND EPILEPSY: DIAGNOSIS, TREATMENT AND PREVENTION
       M. Medina (Honduras)
11:00 - 12:30 SHEIKH MAKTOUM C

SCIENTIFIC SESSION: TOPICS: T10B: BEHAVIOURAL NEUROLOGY

Chairs: S. Cappa (Italy)
M. Husain (United Kingdom)

FRONTAL LOBE: COGNITION AND BEHAVIOUR

11:00 OVERVIEW OF EXECUTIVE FUNCTION AND THE DYSEXECUTIVE SYNDROME
M. Husain (United Kingdom)

11:30 ALTERED BEHAVIOUR AND SOCIAL COGNITION IN BRAIN DISORDERS
O. Piguet (Australia)

12:00 COGNITION AND BEHAVIOUR IN FRONTOTEMPORAL DEMENTIA
B. Dickerson (USA)

11:00 - 12:30 SHEIKH MAKTOUM D

TEACHING COURSE: TC 11: NEURO-OPHTHALMOLOGY PART II

Chairs: G. Plant (United Kingdom)
V. Lal (India)

11:00 INFECTIONS AND NEUROOPHTHALMOLOGY
D. Milea (Singapore)

11:30 AN APPROACH TO MEDICAL OPHTHALMOLEGIA
V. Lal (India)

12:00 BASICS OF CORTICAL VISUAL DISORDERS
J. Barton (Canada)
11:00 - 12:30  SHEIKH MAHTOUM B

TEACHING COURSE: TC 12: NEUROMUSCULAR DISEASES: HOW TO DIAGNOSE A HEREDITARY MUSCLE DISORDER? PATTERN RECOGNITION AND GENETICS

Chairs: M. de Visser (The Netherlands)
        E. Cupler (Saudi Arabia)

11:00  CLINICAL PHENOTYPES OF PATIENTS WITH HYPERCKEMIA
        M. de Visser (The Netherlands)

11:30  DIAGNOSTIC APPROACH TO MUSCLE CHANNELOPATHIES
        E. Cupler (Saudi Arabia)

12:00  APPROACH TO GENETIC MUSCLE DISORDERS
        R. Mohammed Abdoh (Morocco)

11:00 - 12:30  SHEIKH RASHID A

TEACHING COURSE: TC 13: HEADACHE PART II

Chairs: D.M. Kayed (United Arab Emirates)
        R. Stark (Australia)

11:00  NERVE BLOCKS & INTERVENTIONAL TECHNIQUES
        J. Al-Hashel (Kuwait)

11:30  MIGRAINE IN WOMEN: MENSTRUAL MIGRAINE + IMAGING & MEDICATIONS DURING PREGNANCY
        P. Pozo-Rosich (Spain)

12:00  CLUSTER HEADACHE & OTHER TACS
        S. Wang (Taiwan R.O.C.)
11:00 - 12:30 SHEIKH RASHID B

TEACHING COURSE: TC 14: PALLIATIVE CARE IN NEUROLOGY PART II

Chairs: J. Miyasaki (Canada)
       P. Eastman (Australia)

11:00  COLLABORATION BETWEEN NEUROLOGY AND PALLIATIVE CARE – HOW, WHEN, WHERE?
       D. Oliver (United Kingdom)

11:30  HOW DO WE PROVIDE PALLIATIVE CARE FOR PEOPLE WITH MOVEMENT DISORDERS?
       J. Miyasaki (Canada)

12:00  THE ROLE OF PALLIATIVE CARE IN THE CARE OF PEOPLE WITH STROKE
       P. Eastman (Australia)

11:00 - 12:30 ABU DHABI A

TEACHING COURSE: TC 15: NEUROCRITICAL CARE PART II

Chairs: B. Young (Canada)
       A. Rabinstein (USA)

11:00  PROGNOSIS OF TRAUMATIC BRAIN INJURY: USING CLINICAL ASSESSMENT, ELECTROPHYSIOLOGY, BIOMARKERS AND STRUCTURAL IMAGING.
       B. Young (Canada)

11:30  NOVEL THERAPEUTIC OPTIONS FOR SUPER-REFRACTORY STATUS EPILEPTICUS
       E. Trinka (Austria)

12:00  AUTONOMIC DISORDERS IN PATIENTS WITH ACUTE BRAIN INJURY
       A. Rabinstein (USA)
FREE PAPERS 11 - CHILD NEUROLOGY

11:00  CORRELATION BETWEEN RISK FACTORS FOR DIABETIC PERIPHERAL NEUROPATHY AND NERVE CONDUCTION STUDY PARAMETERS IN CHILDREN WITH TYPE 1 DIABETES MELLITUS ATTENDING SUDAN CHILDHOOD DIABETES CENTRE
A. Musa, H. Ahmed, N. Abuelwafa, M. Abdullah, A. Ahmed (Sudan)

11:10  DEVELOPMENT OF SOCIAL INTERACTION SKILLS OF AUTISTIC CHILDREN BY MUSICAL THERAPY
V. Balasubramanian, G. Bharathi, B. Vellinigri (India)

11:20  SERUM BILIRUBIN AS A NEUROINFLAMMATORY BIOMARKER IN CHILDHOOD AND ADOLESCENT MIGRAINE
M. Melake, W. El-Sheikh, H. El-shony (Egypt)

11:30  HEADACHES IN CHILDREN
A. Mahmoud (Saudi Arabia)

11:40  CLINICAL FEATURES AND TARGETED NEXT-GENERATION SEQUENCING OF IDIOPATHIC EARLY ONSET EPILEPTIC ENCEPHALOPATHY IN 68 PATIENTS
A. Arafat, PhD student in Xiang (China)

11:50  THE BURDEN OF MIGRAINE AMONG THE PEDIATRIC POPULATION
H. Upadhyaya, E. Pearlman, S. Avasti, J. Ford, H. Detke (USA)

12:00  MAGNETIC RESONANCE IMAGING (MRI) EVALUATION OF GLOBAL DEVELOPMENTAL DELAY IN PEDIATRIC PATIENTS.: A RETROSPECTIVE STUDY
H. Hafiz, A. Raidah, S. Bashir (Saudi Arabia)

12:10  PERIOPERATIVE ISCHEMIC STROKE IN CHILDREN UNDERGOING CARDIAC SURGERY FOR CONGENITAL HEART DISEASES (CHD) WITH CARDIOPULMONARY BYPASS(CPB)
O. Globa, L. Kuzenkova, V. Lastovka, R. Tepaev, A. Anikin (Russia)

12:20  ARACHNOID CYST MANAGEMENT IN CHILDREN
G. Odintsova, K. Samochernyk, N. Samochernyk, M. Nikolaenko (Russia)
11:00 - 12:30  DUBAI C

FREE PAPERS 12 - MS & DEMYELINATING

Chairs: M. Sahraian (Iran)
        H. Tremlett (Canada)

11:00  SAFETY OF OCRELIZUMAB IN MULTIPLE SCLEROSIS: UPDATED ANALYSIS IN PATIENTS WITH RELAPSING AND PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
S. Hauser, L. Kappos, X. Montalban, L. Craveiro, R. Hughes, J. McNamara, A. Pradhan, D. Wormser, H. Koendgen, J.S. Wolinsky (USA)

11:10  CLINICAL PHENOTYPES AND OUTCOMES OF MYELIN-OLIGODENDROCYTE-GLYCOPEPTIDE-IGG-ASSOCIATED DISORDERS (MOGAD) IN A CONSECUTIVE COHORT OF SRI LANKAN PATIENTS: THE LARGEST SERIES FROM ASIA TO DATE
B. Senanayake, M. Aravinthan, J. Jetprapaikulsan, J. Wijesekera, U. Ranawaka, M. Riffy, S. Pittock (Sri Lanka)

11:20  REAL-WORLD EXPERIMENT OF RITUXIMAB IN MULTIPLE SCLEROSIS
S. Esmaeili, M. Motamed, Z. Mirzaasgari, B. Zamani, M.T. Joghatayi, M. Mojtahed (Iran)

11:30  QUANTIFICATION OF PUPILLARY LIGHT REFLEX ABNORMALITIES IN PATIENTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER AND MULTIPLE SCLEROSIS USING AUTOMATED INFRARED PUPILLOMETRY
S. Samadzadeh, R. Abolfazli, S. Najafina, C. Morcinek, P. Rieckmann (Germany)

11:40  COMPARISON OF BRAIN VOLUME BETWEEN NEUROMYELITIS OPTIC AND MULTIPLE SCLEROSIS PATIENTS IN INDONESIA
R. Estiasari, S. Firdausia, R. Mulyadi, R. Eddy Yunus (Indonesia)

11:50  HYDROXYFASUDIL AMELIORATES EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS POSSIBLY THROUGH IMMUNOMODULATION AND ANTI-INFLAMMATORY EFFECTS
J. Wang, Q. Miao, R.X. Sui, L.J. Song, Z. Chai, J.Z. Yu, Y.H. Li, J.J. Huang, L. Feng, B.G. Xiao, C.G. Ma (China)

12:00  MULTIPLE SCLEROSIS AND ANTIPHOSPHOLIPID ANTIBODIES: CLINICAL FEATURES AND PROGNOSIS
D. Kasatkin (Russia)

12:10  THERAPEUTIC PLASMA EXCHANGE IN THE TREATMENT OF SEVERE MULTIPLE SCLEROSIS RELAPSE: TWELVE YEARS OF EXPERIENCE IN BELGRADE, SERBIA
S. Mesaros, T. Pekmezovic, J. Ivanovic, V. Martinovic, D. Sockic, J. Drulovic (Serbia)

12:20  QUANTIFICATION OF VIDEO-OČULOGRAPHY AS A BIOMARKER FOR REMYELINATION – AN EXAMPLE FROM FAMPRIDINE IN INTERNUCLEAR OPHTHALMOPLEGIA
S. Van Dijkman, K.M.S. Kanhai, G.J. Groeneveld (The Netherlands)

12:30 - 14:30  EXHIBITION AREA

LUNCH BREAK, POSTER VIEWING AND EXHIBITION VISIT
13:00 - 14:00 SHEIKH MAHTOUM C

TOURNAMENT OF THE MINDS: “HEATS” QUALIFYING ROUND

Chairs: R. Stark (Australia)
N. Davies (United Kingdom)
F. Belahsen (Morocco)

13:00 - 14:30 SHEIKH RASHID A

SPONSORED SYMPOSIUM -NON CME/CPD CREDIT

TO VIEW THE FULL PROGRAM, PLEASE SEE PAGE 154

14:30 - 14:45

SHORT BREAK

14:45 - 16:15 SHEIKH RASHID E

SCIENTIFIC SESSION: MT (MAIN TOPICS): MT5C: MS AND DEMYELINATING DISORDER

Chairs: L. Negrotto (Argentina)
H. Tremlett (Canada)

14:45 MODIFIABLE ENVIRONMENTAL FACTORS – ROLE AND IMPACT OF (INCLUDING EVIDENCE FOR INTERVENTION)
L. Negrotto (Argentina)

15:15 COMORBIDITIES – IMPACT ON DISEASE EVOLUTION, PROGRESSION AND TREATMENT RESPONSE
H. Tremlett (Canada)

15:45 THE ROLE OF VITAMIN D AND MS IN THE MIDDLE EAST
B. Yamout (Lebanon)
14:45 - 16:15 SHEIKH MAKTOUM A

SCIENTIFIC SESSION: MT (MAIN TOPICS): MT6C: TROPICAL AND GEOGRAPHIC NEUROLOGY

Chairs: P. Preux (France)
       A.G. Diop (Senegal)

NON TRANSMISSIBLE DISEASES

14:45 BURDEN OF COGNITIVE DISORDERS IN SUBSAHARAN AFRICA
       A. Ogunniyi (Nigeria)

15:15 ADDRESSING NEEDS IN NEUROVASCULAR DISEASES IN SUBSAHARAN AFRICA
       A.G. Diop (Senegal)

15:45 EPILEPSY, HOW TO MOVE FORWARD IN ACCESS TO CARE IN TROPICAL AREAS?
       P.M. Preux (France)

14:45 - 16:15 SHEIKH MAKTOUM C

SCIENTIFIC SESSION: TOPICS: T11: BRAIN-COMPUTER INTERFACES AND ROBOTICS

Chairs: O. Aszmann (Austria)
       D. Farina (United Kingdom)

MAN-MACHINE INTERFACING AND REHABILITATION AFTER LIMB LOSS VIA ARTIFICIAL BIOScreens

14:45 BIONIC RECONSTRUCTION AFTER SEVERE LIMB TRAUMA AND LIMB LOSS
       O. Aszmann (Austria)

15:15 NEURAL CONTROL OF OSSEO-NEUROMUSCULAR ARTIFICIAL LIMBS AND DECODING OF MOTOR VOLITION AS NEUROREHABILITATION TOOLS
       M. Ortiz Catalan (Sweden)

15:45 MAN-MACHINE INTERFACING BY DECODING SPINAL MOTOR NEURONS
       D. Farina (United Kingdom)
14:45 - 16:15  SHEIKH MAKTOUM D

SCIENTIFIC SESSION: TOPICS: T12: AUTOIMMUNE NEUROLOGICAL DISORDERS

Chairs: E. Shosha (Bahrain)
S. Irani (United Kingdom)

14:45  NOVEL BIOMARKER DISCOVERY IN AUTOIMMUNE NEUROLOGY: BUILDING PHENOTYPE SPECIFIC TEST PROFILES
S. Pittcock (USA)

15:15  THE AUTOANTIBODY MEDIATED EPILEPSIES
S. Irani (United Kingdom)

15:45  AUTOIMMUNE AQUAPORIN CHANNELOPATHIES AND MOGOPATHIES; PROPINQUITY AND DIVERGENCE
E. Shosha (Canada)

14:30 - 16:00  SHEIKH MAKTOUM B

TEACHING COURSE: TC 12: NEUROMUSCULAR DISEASES: ADVANCES IN THE DIAGNOSIS AND TREATMENT OF IMMUNE-MEDIATED NEUROMUSCULAR DISORDERS

Chairs: M. Dimachkie (USA)
A. Al Madani (United Arab Emirates)

14:30  STATE-OF-THE-ART TREATMENT OF IMMUNE NEUROPATHIES
A. Al Madani (United Arab Emirates)

15:00  THE ROLE OF AUTO-ANTIBODIES IN IDIOPATHIC INFLAMMATORY MYOPATHIES
K. Claeys (Belgium)

15:30  MYASTHENIA GRAVIS: SUBGROUP CLASSIFICATION AND THERAPEUTIC STRATEGIES
M. Dimachkie (USA)
14:45 - 16:15 SHEIKH RASHID A

**SCIENTIFIC SESSION: TOPICS: T14: BRAIN DEATH, THE GREY ZONE AND PERSISTENT VEGETATIVE STATE**

Chair: A. Owen (Canada)

**IMAGING IN THE ACUTE BRAIN INJURED STATE; DIAGNOSIS AND PROGNOSIS**

14:45 **PROGNOSIS OF ANOXIC-ISCHEMIC ENCEPHALOPATHY: USING CLINICAL ASSESSMENT, ELECTROPHYSIOLOGY, BIOMARKERS AND STRUCTURAL IMAGING**

B. Young (Canada)

15:15 **FUNCTIONAL NEUROIMAGING IN THE ACUTE BRAIN INJURED STATE; DIAGNOSIS AND PROGNOSIS**

A. Owen (Canada)

15:45 **IMAGING IN THE ACUTE BRAIN INJURED STATE; ETHICAL CONSIDERATIONS**

C. Weijer (Canada)

14:45 - 16:15 SHEIKH RASHID B

**SCIENTIFIC SESSION: TOPICS: T15: HOW USEFUL IS BIG DATA IN NEUROLOGY?**

Chairs: S. Baranzini (USA)
D. Katabi (USA)

14:45 **INTEGRATION OF ELECTRONIC MEDICAL RECORDS WITH A KNOWLEDGE NETWORK TO ENABLE MULTI-SCALE UNDERSTANDING OF NEUROLOGICAL DISEASES**

S. Baranzini (USA)

15:15 **TEMPORAL DISEASE TRAJECTORIES CONDENSED FROM POPULATION-WIDE REGISTRY DATA COVERING MILLIONS OF PATIENTS**

D. Katabi (USA)

15:45 **UNCOVERING NEUROLOGICAL DISEASE RELATIONSHIPS THROUGH THE INCOMPLETE INTERACTOME**

A. Sharma (USA)
14:45 - 16:15 ABU DHABI A

REGIONAL SYMPOSIUM SESSION: EUROPEAN REGIONAL SYMPOSIUM

Chairs: C. Bassetti (Switzerland)  
G. Deuschl (Germany)

14:45 ADVANCES IN POST STROKE NEUROREHABILITATION - FROM NEURO FUNDAMENTALS TO EVIDENCE BASED MEDICINE  
D. Muresanu (Romania)

15:10 REGIONAL DISPARITIES OF NEUROLOGIC CARE ACROSS EUROPE: THE EXAMPLE OF ACUTE STROKE CARE  
G. Deuschl (Germany)

15:35 SLEEP AND STROKE: GUILT BY ASSOCIATION  
C. Bassetti (Switzerland)

16:00 DISCUSSION

14:45 - 16:15 ABU DHABI B

REGIONAL SYMPOSIUM SESSION: PAN-AFRICAN REGIONAL SYMPOSIUM: ERA OF NCD PANDEMIC IN AFRICAN NEUROLOGY

Chairs: A. Ogun (Nigeria)  
F. Abd-Allah (Egypt)

14:45 CHALLENGES AND OPPORTUNITIES IN THE PREVENTION AND TREATMENT OF STROKE IN AFRICA: PERSPECTIVES FROM ACROSS THE CONTINENT  
A. Ogun (Nigeria)

15:15 CHALLENGES AND OPPORTUNITIES IN THE PREVENTION AND TREATMENT OF EPILEPSY IN AFRICA: PERSPECTIVES FROM ACROSS THE CONTINENT  
L. Tucker (South Africa)

15:45 THE HIDDEN THREAT OF THE DEMENTIAS IN AFRICA  
A. Charway-Felli (Ghana)
14:45 - 16:15  

FREE PAPERS 13 - MOTOR NEURON DISEASE

**Chairs:** M. Kiernan (Australia)  
S. Boholega (Saudi Arabia)

**14:45 INTRATHecal ADMINISTRATION OF AVXS-101 GENE-REPLACEMENT THERAPY (GRT) FOR SPINAL MUSCULAR ATROPHY TYPE 2 (SMA2): PHASE 1/2A STUDY (STRONG)**


**14:55 EFFECT OF PHENOTYPIC PRESENTATION ON SURVIVAL IN ALS-FTD.**

R. Ahmed, E. Devenney, J. Hodges, O. Piguet, M. Kiernan (Australia)

**15:05 C9ORF72 HEXANUCLEOTIDE REPEAT EXPANSION IN INDIAN ALS PATIENTS: A COMMON FOUNDER AND ITS GEOGRAPHICAL PREDILECTION**


**15:15 BURDEN OF ILLNESS OF SPINAL MUSCULAR ATROPHY TYPE 1 (SMA1)**


**15:25 NON-CODING REPEAT EXPANSIONS IN THE ATXN8OS GENE ARE IDENTIFIED IN JAPANESE PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS**

M. Hirano, M. Samukawa, C. Isono, K. Saigoh, Y. Nakamura, S. Kusunoki (Japan)

**15:35 THE VALUE OF ONASEMNogene ABEPARVOVEC (AVXS-101) GENE-REPLACEMENT THERAPY FOR SPINAL MUSCULAR ATROPHY TYPE 1**

O. Dabbous, D.M. Sproule, D.E. Feltner, M. Droege, F. Khan, R. Arjunji (USA)

**15:45 EFFECT OF FLAVONOIDS FROM TRADITIONAL HERBAL COCKTAILS AGAINST TAUPATHY AND NEURONAL OXIDATIVE STRESS IN A MODEL OF DROSOPHILA MELANOGASTER: RELEVANCE TO MOTOR NEURODEGENERATION**

G. Chandran, J.B. Chauhan (India)

**15:55 PHENOTYPIC AND GENETIC HETEROGENEITY OF ADULT PATIENTS WITH HEREDITARY SPASTIC PARAPLEGIA FROM SERBIA**


**16:05 THE RESTORE REGISTRY: A RESOURCE FOR MEASURING AND IMPROVING SPINAL MUSCULAR ATROPHY OUTCOMES**

ACCELERATING THE PACE OF CHANGE

WEDNESDAY
OCTOBER 30, 2019

WCN 2019
XXIV WORLD CONGRESS OF NEUROLOGY
DUBAI, UNITED ARAB EMIRATES, OCTOBER 27-31 2019

*Refer to the DHA full Brand Manual for further details.
WEDNESDAY, OCTOBER 30, 2019

07:00 - 08:00  
**TEACHING COURSE: TC 16: NEUROIMAGING**

J. Masdeu (USA)

08:00 - 08:30  
**PLENARY LECTURE 7: GENOMICS AND NEURODEGENERATION**

Chairs: A. Guekht (Russia)  
L. Cui (China)

08:00  WHAT IS GENOMICS TEACHING US ABOUT NEURODEGENERATION AND WHAT SHOULD WE DO ABOUT IT?  
J. Hardy (United Kingdom)

08:30 - 09:00  
**PLENARY LECTURE 8: MULTIPLE SCLEROSIS**

Chairs: A. Thompson (United Kingdom)  
R. Shakir (United Kingdom)

08:30  MULTIPLE SCLEROSIS  
M. Tintore (Spain)
SCIENTIFIC SESSION: MT (MAIN TOPICS): MT7A: HEADACHE AND PAIN

Chairs: P. Pozo-Rosich (Spain)
J. Al-Hashel (Kuwait)

INSIGHTS INTO THE MIGRAINE BRAIN: AN INNOVATIVE PERSPECTIVE ON THE IMPORTANCE OF TREATMENT

09:00 WHY DO WE HAVE TO TREAT MIGRAINE PROPERLY? INSIGHTS INTO THE MIGRAINE BRAIN
P. Pozo-Rosich (Spain)

09:30 BOTULINUM TOXIN IN MIGRAINE: RATIONALE AND PATIENT SELECTION
J. Al-Hashel (Kuwait)

10:00 CGRP ANTAGONISM AND MIGRAINE: WHERE ARE WE NOW?
U. Reuter (Germany)

SCIENTIFIC SESSION: MT (MAIN TOPICS): MT8A: NEUROMUSCULAR DISEASES

Chairs: M. de Visser (The Netherlands)
E. Cupler (Saudi Arabia)

MUSCLE SYMPOSIUM

09:00 INFLAMMATORY MYOPATHIES
M. De Visser (The Netherlands)

09:30 GENETIC DISTAL MYOPATHIES
K. Claeys (Belgium)

10:00 THE DIAGNOSIS AND TREATMENT OF LATE-ONSET POMPE DISEASE
E. Cupler (Saudi Arabia)
09:00 - 10:30  SHEIKH MAHTOUM C

**SCIENTIFIC SESSION: TOPICS: T15A: CHILD NEUROLOGY**

Chairs: I. Tein (Canada)
J. Wilmshurst (South Africa)

**CHALLENGES IN CHILD NEUROLOGY CARE**

09:00  **SMA AND DMD: WHAT IS BEST PRACTICE CARE? – THE ETHICAL ISSUES**
H. Topaloglu (Turkey)

09:30  **MITOCHONDRIAL DISEASE – NEW AND IMPORTANT CONDITIONS TO RECOGNIZE**
I. Tein (Canada)

10:00  **AUTOIMMUNE ENCEPHALITIDES – WHAT’S NEW, CLINICAL CLUES, AND BEST CARE PRACTICE**
R. Dale (Australia)

---

09:00 - 10:30  SHEIKH MAHTOUM B

**TEACHING COURSE: TC 18: NEURO-ONCOLOGY PART I**

Chairs: P. Wen (USA)
M. Van den Bent (The Netherlands)

09:00  **MANAGEMENT OF MEDICAL AND NEUROLOGIC COMPLICATIONS IN BRAIN TUMOR PATIENTS**
P. Wen (USA)

09:30  **WHO CLASSIFICATION OF BRAIN TUMORS AND APPROACH TO LOWER GRADE GLIOMAS**
M. Van den Bent (The Netherlands)

10:00  **STANDARD OF CARE IN GLIOBLASTOMAS**
M. Weller (Switzerland)

---

09:00 - 10:30  SHEIKH RASHID A

**TEACHING COURSE: TC 19: DEMENTIA: ATYPICAL AND TYPICAL PRESENTATIONS OF ALZHEIMER DISEASE PART I**

Chairs: M. El Alaoui Faris (Morocco)
A. Ogunniyi (Nigeria)

09:00  **DEMENTIA IN ARAB COUNTRIES**
M. El Alaoui Faris (Morocco)

09:30  **DEMENTIA IN AFRICA**
A. Ogunniyi (Nigeria)

10:00  **DEMENTIA IN ASIA**
E. Krishnamoorthy (India)
09:00 - 10:30  
**SHEIKH RASHID B**

**TEACHING COURSE: TC 20: NEURO-OETOLOGY: THE DIZZY PATIENT PART I**

Chairs: C. Tilikete (France)  
K.P. Weber (Switzerland)

09:00  **HISTORY TAKING AND KEY SYMPTOMS**  
T. Brandt (Germany)

09:30  **WHICH ADDITIONAL INSTRUMENT-BASED TESTS ARE NECESSARY?**  
K.P. Weber (Switzerland)

10:00  **ACUTE PERIPHERAL VERSUS ACUTE CENTRAL VESTIBULOPATHY**  
J.S. Kim (Republic of Korea)

09:00 - 10:30  
**ABU DHABI A**

**TEACHING COURSE: TC 21: NEUROLOGY AND INTERNAL MEDICINE PART I**

Chairs: S. Lewis (USA)  
E. Shosha (Bahrain)

09:00  **MONOCLONAL GAMMOPATHIES AND NEUROPATHY**  
M. Reilly (United Kingdom)

09:30  **INTOXICATIONS AND NEUROLOGIC DISEASE**  
A. Awada (Lebanon)

10:00  **NEUROLOGICAL MANIFESTATIONS OF RHEUMATOLOGICAL DISEASE**  
E. Shosha (Bahrain)
09:00 - 10:30  ABU DHABI B

FREE PAPERS 14 - HEADACHE

Chairs: A. Aljishi (Bahrain)
M. Campero (Chile)

09:00 CALCITONIN GENE RELATED PEPTIDE IN PERIPHERAL BLOOD AS A DIAGNOSTIC MARKER IN RECURRENT PAINFUL OPHTHALMOPLEGIC NEUROPATHY/ OPHTHALMOPLEGIC MIGRAINE
A.K. K V, A. Takkar Kapila, V. Lal, R. Minz, W. P. Singh, D. Katoch (India)

09:10 EFFICACY OF FREMANEZUMAB BY COUNTRY IN PATIENTS WITH DOCUMENTED INADEQUATE RESPONSE TO 2-4 CLASSES OF MIGRAINE PREVENTIVE MEDICATIONS IN THE MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED FOCUS STUDY
E.L.H. Spierings, X. Ning, J.M. Cohen, V. Ramirez-Campos, R. Yang, U. Reuter (USA)

09:20 BURDEN OF MIGRAINE ACROSS CHINA, ISRAEL, RUSSIA, SOUTH KOREA, AND TURKEY: RESULTS FROM A SYSTEMATIC LITERATURE REVIEW
H. Benhaddi, R. Zeidman, R.C. Verena, S. McCabe (Belgium)

09:30 ACUTE AND PREVENTIVE TREATMENT USE IN A PHASE-3 RANDOMIZED TRIAL OF GALCANEZUMAB IN CHRONIC CLUSTER HEADACHE
M. Lanteri-Minet, K. Kalidas, T. Oakes, J. Bardos, C. Zhou, R. Wenzel, J.Y. Yang, S. Aurora (France)

09:40 HIGH ALTITUDE HEADACHE AMONG TOURISTS VISITING THE HIGH ALTITUDE CITY OF LA PAZ BOLIVIA AT 3.600 METERS ABOVE SEA LEVEL

09:50 EVALUATION OF DEPRESSION IN PEOPLE WITH PRIMARY HEADACHE
T. Byambasuren, O. Luvsannorov, J. Batkhurel (Mongolia)

10:00 EFFECT OF ACUPUNCTURE ON POST- DURAL PUNCTURE HEADACHE; RANDOMIZED CLINICAL TRIAL
S. Esmaeili, R. Alizadeh, M. Mojtabah (Iran)

10:10 ODDS RATIOS FOR RESPONSE TO FREMANEZUMAB IN MIGRAINE PATIENTS WITH INADEQUATE RESPONSE TO 2-4 MIGRAINE PREVENTIVE MEDICATION CLASSES: RESULTS OF THE FOCUS PHASE 3B STUDY
H.C. Diener, X. Ning, M. Galic, J.M. Cohen, V. Ramirez-Campos, R. Yang, M. Ashina (Germany)

10:20 REVERSION FROM CHRONIC TO EPISODIC MIGRAINE IN PATIENTS WITH INADEQUATE RESPONSE TO 2-4 CLASSES OF MIGRAINE PREVENTIVE TREATMENTS IN THE FOCUS PHASE 3B STUDY
R.B. Lipton, J. Ailani, V. Ramirez-Campos, J.M. Cohen, R. Yang, M. Galic, X. Ning, R. Halker Singh (USA)
09:00 - 10:30  

FREE PAPERS 15 - NEUROPHYSIOLOGY

Chairs: A. Oday Hatem (Iraq)  
J. England (USA)

09:00  ASYMMETRY INDEX OF BLINK REFLEX RECOVERY CYCLE DIFFERENTIATES EARLY PARKINSON'S DISEASE FROM ATYPICAL PARKINSONIAN SYNDROMES  

09:10  MULTIMODAL NEUROLOGICAL EVALUATION OF PATIENTS WITH HEPATIC CIRRHOSIS  
N. Fim, L. Costa, K. Alves, F. Romeiro, L.E. Betting (Brazil)

09:20  CLINICAL, ELECTROPHYSIOLOGICAL AND ULTRASONOGRAPHIC CORRELATION OF CARPAL TUNNEL SYNDROME  
S. Vasireddy, S. Sreekanta swamy, N. Boraiah, R. Kollu (India)

09:30  POLYMORPHISM OF THE COMT GENE AND VITAL EXHAUSTION IN OPEN POPULATION OF 45-64 YEARS. INTERNATIONAL EPIDEMIOLOGICAL PROGRAMS: WHO MONICA, HAPIEE  
V. Gafarov, E. Gromova, D. Panov, I. Gagulin, A. Gafarova, V. Maximov (Russia)

09:40  GENDER HAS A SIGNIFICANT EFFECT ON NORMAL NERVE CONDUCTION VALUES  
K. Al-Salmi (Oman)

09:50  MEMORY NEURAL CIRCUITS PLASTICITY: FOCUSING ON THE MEANING OF THE WORDS  

10:00  SPECTRUM OF ELECTROPHYSIOLOGY FINDINGS IN METABOLIC DISORDERS  
S.K. N S, N.S.P. Parimi (India)

10:10  RECRUITMENT OF MOTOR UNITS AND ACTIVATION OF ASSOCIATIVE MOTOR NEURONS  
J. Pinheiro de Carvalho, R. Iegoroff, R. Costa de Aguiar Valim, G. Cherres Xavier Esteves, P.A. Ribeiro Champi, A.J. Godoy (Brazil)

10:20  DEMOGRAPHIC AND CLINICAL FACTORS ASSOCIATED WITH ROUTINE OUTPATIENT ELECTROENCEPHALOGRAPHY (EEG) FINDINGS AT KING ABDULAZIZ UNIVERSITY HOSPITAL IN JEDDAH, SAUDI ARABIA  
H. Tayeb, B. Yaghmoor, A. Zamzami, A. Almalki, F. Alzaidi, A. Alhusaini, M. Altuwaijry, Y. Mandorah, A. Baduwailan, R. Alyoubi (Saudi Arabia)

10:30 - 11:00  

EXHIBITION AREA

COFFEE, POSTER VIEWING AND EXHIBITION VISIT
11:00 - 12:30 SHEIKH RASHID E

**SCIENTIFIC SESSION: MT (MAIN TOPICS): MT7B: HEADACHE AND PAIN**

Chairs: S. Wang (Taiwan R.O.C.)
S. Aidi (Morocco)

**RARE HEADACHE: PATHOPHYSIOLOGY AND TREATMENT**

11:00 **REVERSIBLE CEREBRAL VASOCONSTRICTION SYNDROME**  
A. Ducros (France)

11:30 **SPONTANEOUS INTRACRANIAL HYPOTENSION**  
S.J. Wang (Taiwan R.O.C.)

12:00 **IDIOPATHIC INTRACRANIAL HYPERTENSION**  
S. Aidi (Morocco)

---

11:00 - 12:30 SHEIKH MAKTOUM A

**SCIENTIFIC SESSION: MT (MAIN TOPICS): MT8B: NEUROMUSCULAR DISEASES**

Chairs: K. El Salem (Jordan)  
M. Dimachkie (USA)

11:00 **NEUROMUSCULAR JUNCTION SYMPOSIUM**  
M. Dimachkie (USA)

11:30 **CONGENITAL MYASTHENIC SYNDROMES**  
M. Milone (USA)

12:00 **LAMBERT-EATON MYASTHENIC SYNDROMES**  
K. El Salem (Jordan)
11:00 - 12:30 "SCIENTIFIC SESSION: TOPICS: T15B: CHILD NEUROLOGY"

SHEIKH MAKTOM C

**Chairs:** I. Tein (Canada)
H. Cross (United Kingdom)

**MYTHS AND FACTS IN CHILDREN WITH EPILEPSY**

11:00 **NEW WAYS FORWARD IN CHILDHOOD EPILEPSY – FACT OR HYPE**
H. Cross (United Kingdom)

11:30 **ADHD AND EPILEPSY – MYTHS AND FACTS**
J. Wilmshurst (South Africa)

12:00 **EPILEPSY SURGERY – THE ROLE FOR EARLIER INTERVENTION AND WHEN TO WEAN AEDS**
K. Braun (The Netherlands)

11:00 - 12:30 "TEACHING COURSE: TC 18: NEURO-ONCOLOGY PART II"

SHEIKH MAKTOM B

**Chairs:** P. Wen (USA)
M. Van den Bent (The Netherlands)

11:00 **APPROACH TO NEUROLOGIC COMPLICATIONS OF IMMUNOTHERAPIES AND OTHER NOVEL CANCER THERAPIES**
J. Degroot (USA)

11:30 **DIAGNOSIS AND MANAGEMENT OF METASTASES TO THE NERVOUS SYSTEM**
E. Le Rhun (France)

12:00 **APPROACH TO NEW TUMOR LIKE LESION(S) ON MRI**
L. Nayak (USA)
11:00 - 12:30  SHeikh Rashid A

**Teaching Course: TC 19: Dementia: Atypical and Typical Presentations of Alzheimer's Disease Part II**

**Chairs:** S. Cappa (Italy)
M. Husain (United Kingdom)

**11:00**  Amnesic Alzheimer's Disease
M. Ben Jebara (Tunisia)

**11:30**  Primary Progressive Aphasia
S. Cappa (Italy)

**12:00**  Posterior Cortical Atrophy
M. Husain (United Kingdom)

11:00 - 12:30  SHeikh Rashid B

**Teaching Course: TC 20: Neuro-Otology: The Dizzy Patient Part II**

**Chairs:** M. Dieterich (Germany)
J.S. Kim (Republic of Korea)

**11:00**  Cerebellar Ocular Motor and Vestibular Disorders
C. Tilikete (France)

**11:30**  Imaging Vestibular Function and Disorders
M. Dieterich (Germany)

**12:00**  The Chronic Dizzy Patient
A. Bronstein (United Kingdom)

11:00 - 12:30  Abu Dhabi A

**Teaching Course: TC 21: Neurology and Internal Medicine Part II**

**Chairs:** S. Lewis (USA)
E. Shosha (Bahrain)

**11:00**  Neurologic Complications of Cardiac Disease and Cardiac Surgery
A. Rabinstein (USA)

**11:30**  Vitamins and Minerals and Neurologic Disease
S. Lewis (USA)

**12:00**  Nervous System Complications of HIV
N. Qadi (Saudi Arabia)
11:00 - 12:30

FREE PAPERS 16 - FUNCTIONAL DISORDERS AND BEHAVIORAL NEUROLOGY

Chairs: I. Biran (Israel)
I. Alsharoqi (Bahrain)

11:00 POST STROKE DEPRESSION
A. Hussein, I. Idris, A. A.Omer, A. Siddig, M. Abbasher, H. Abbashar, K. Mohamed Ahmed, Abbasher (Sudan)

11:10 ONE DISEASE OR THREE: IS FRONTAL TEMPORAL DEMENTIA – MOTOR NEURON DISEASE A DISTINCT ENTITY?
Z. Long, M. Irish, D. Foxe, J. Hodges, O. Piguet, J. Burrell (Australia)

11:20 DEPRESSION AND QUALITY OF LIFE AFTER CEREBRAL VENOUS SINUS THROMBOSIS
N. Thorat, S. Aralikatte, Onkarappa, R. Naik, Karkal (India)

11:30 ZEITGEBER MEDIATED CIRCADIAN DYSTONIA RESULTED IN NEURONAL EXCITOTOXICITY, HIPPOCAMPAL STRESS AND DEMENTIA IN RAT
P. Pr, R. Goyal (India)

11:40 CEREBROVASCULAR AUTOREGULATION IMPAIRMENTS AND POSTOPERATIVE COGNITIVE DETERIORATION AFTER CARDIAC SURGERY
Y. Hamarat, V. Petkus, R. Zakelis, B. Kumpaitiene, M. Svagzdiene, E. Sirvinskas, S. Krakauskaite, A. Ragauskas, R. Benetis (Lithuania)

11:50 AURAS IN PSYCHOGENIC NON-EPILEPTIC SEIZURES
A. Asadi-Pooya, Z. Bahrami (Iran)

12:00 FRONTAL PARietal DYSFUNCTION DURING COGNITIVE REAPPRAISAL IN ANXIETY DISORDER: A META-ANALYSIS OF FUNCTIONAL MAGNETIC RESONANCE IMAGING STUDIES
H.Y. Wang, X.X. Zhang, B.W. Zhang, X.L. Li, Z.R. Yan (China)

12:10 NEW HYPOTHESIS: DYSFUNCTIONAL MECHANISM OF SELF-REFERENCE NETWORK PATHWAY CONTRIBUTES TO ALZHEIMER’S DISEASE PATHOGENESIS
P.H. Wei, F. Bai (China)

12:20 SEIZURE MIMICS IN CHILDREN- AWARENESS DETECTS THE ABNORMALITY
P.A.M. Kunju, M. Sreedharan, M. Iype, A. Jain R (India)
FREE PAPERS 17 - NEUROIMAGING

11:00 DIFFUSION PROPERTIES OF MAJOR WHITE MATTER TRACTS IN INDIVIDUALS WHITE MATTER HYPERINTENSITY
H. Chen, Y. Xu (China)

11:10 CEREBRAL MICROBLEEDS: PREVALENCE AND RISK FACTORS FROM UK BIOBANK WITH 3.0T SWI SEQUENCE
D. Lu, S.M. Hugh, J. Liu, M. Traylor (China)

11:20 DIFFUSION FIBER TRACTOGRAPHY ON PHONONOGICAL LOOP WITH LOGOPENIC APHASIA TAU PATHOLOGY: FIBER-SPECIFIC WHITE MATTER REDUCTIONS IN ALZHEIMER’S DISEASE, “IS IT A CAUSAL OR CASUAL LINK?”
V.H.Y. Kurra, G. Elumalai, P. Maiti, C. Vadiyala, G. Vinodhanand, N.A.S.V. Ghanta (USA)

11:30 HUMAN VISUAL PROCESSING FOR SPATIAL 3-D IMAGING RECOGNITION: CORTICAL CONNECTIVITY DEFICITS IN PARKINSON’S SPATIAL PERCEPTUAL VISUAL PATHWAY
G. Vinodhanand, G. Elumalai, P. Maiti, C. Vadiyala (Guyana)

11:40 DEEP LEARNING BASED APPLICATION FOR VIDEOFLUOROSCOPIC SWALLOWING STUDY (VFSS): A PILOT STUDY
S.J. Lee, S.I. Choi, J.Y. Ko, H. Kim (Republic of Korea)

11:50 USE OF PET CT SCAN FOR EARLIER DIAGNOSIS OF CENTRAL SKULL-BASE OSTEOMYELITIS – A STEP BEYOND CONVENTIONAL MRI SCAN
S. Bhattacharjee, A. Ram, B. Maramattom, Varkey (India)

12:00 DIFFUSION IMAGING FIBRE TRACTOGRAPHIC ANALYSIS FOR AUDITORY SACCADIC ATTENTION DEFICIT (ASAD) IN PROGRESSION STAGES OF ALZHEIMER’S DISEASE
C. Vadiyala, G. Elumalai, P. Maiti (Guyana)

12:10 NEURAL-CORTICAL CONNECTIVITY ANALYSIS IN CORRELATIONS WITH “HOW” STREAM VISUAL PATHWAYS IN DISEASE PROGRESSION STAGES OF ALZHEIMER’S DISEASE: OPTIC ATAXIA IN ALZHEIMER’S
G. Vinodhanand, G. Elumalai, P. Maiti, C. Vadiyala (Guyana)

12:20 TEMPORAL LOBE EPILEPSY WITH DEPRESSIVE SYMPTOMS: INFLUENCE ON NEURONAL DAMAGE MEASURED BY PROTON MAGNETIC RESONANCE SPECTROSCOPY
L. Pimentel-Silva, M. Nogueira, T. Zanão, C. Yasuda, F. Cendes (Brazil)

12:30 - 14:30 EXHIBITION AREA
LUNCH BREAK, POSTER VIEWING AND EXHIBITION VISIT
13:00 - 14:00

TOURNAMENT OF THE MINDS: SEMI-FINAL

Chairs: T. Kanda (Japan)
N. Davies (United Kingdom)

13:00 - 14:00

TOURNAMENT OF THE MINDS: SEMI-FINAL

Chairs: F. Belahsen (Morocco)
R. Stark (Australia)
S. Servidei (Italy)

13:00 - 14:30

SPONSORED SYMPOSIUM -NON CME/CPD CREDIT

FOR THE FULL SESSION, PLEASE SEE PAGE 155

14:30 - 14:45

SHORT BREAK

14:45 - 16:15

SCIENTIFIC SESSION: MT (MAIN TOPICS): MT7C: HEADACHE AND PAIN

Chairs: M. Campero (Chile)
S. Dib-Hajj (USA)

WHAT WE HAVE LEARNED FROM THE CRANIAL NEURALGIAS FOR THE TREATMENT OF PAROXYSMAL PAIN

14:45 TRIGEMINAL NEURALGIA AND OTHER AUTONOMIC CEPHALGIAS
A. Al Madani (United Arab Emirates)

15:15 SPONTANEOUS ACTIVITY OF NOCICEPTORS IN THE PATHOPHYSIOLOGY OF NEUROPATHIC PAIN
M. Campero (Chile)

15:45 SODIUM CHANNEL BLOCKERS IN THE TREATMENT OF NEUROPATHIC PAIN
S. Dib-Hajj (USA)
14:45 - 16:15 SHEIKH MAKTOUM A

SCIENTIFIC SESSION: MT (MAIN TOPICS): MT8C: NEUROMUSCULAR DISEASES

Chairs: M. Reilly (United Kingdom)
M. Kiernan (Australia)

NEUROPATHY SYMPOSIUM

14:45 DISTAL MOTOR NEUROPATHIES
M. Kiernan (Australia)

15:15 AN APPROACH TO GENETIC NEUROPATHY
M. Reilly (United Kingdom)

15:45 CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
M. Al Jumah (Saudi Arabia)

14:45 - 16:15 SHEIKH MAKTOUM C

SCIENTIFIC SESSION: TOPICS: T17: WFN/WPA JOINT SESSION: PSYCHIATRIC ASPECTS OF NEUROLOGY

Chairs: H. Herrman (Australia)

PARTNERSHIPS IN CARE FOR DEMENTIA WORLWIDE

14:45 RESEARCH DIAGNOSTIC CRITERIA FOR NEUROCOGNITIVE DISORDERS USING THE BIOMARKER APPROACH
P. Sachdev (Australia)

15:15 STAGING OF CARE FOR PEOPLE WITH DEMENTIA: A GLOBAL EFFORT
M. Semaru (United Kingdom)

15:45 GLOBAL GOVERNMENTAL AND NONGOVERNMENTAL ACTION ON DEMENTIA
H. Herrman (Australia)
14:45 - 16:15  SHEIKH MAKTOUM D

SCIENTIFIC SESSION: TOPICS: T18: ENVIRONMENT AND NEUROLOGY

Chairs: M. Wasay (Pakistan)
J. Reis (France)

14:45  ENVIRONMENT AND STROKE
M. Wasay (Pakistan)

15:15  ENVIRONMENTAL NEUROTOXINS IN FOOD IN A PERSPECTIVE OF GLOBAL HEALTH APPROACH
G. Román (USA)

15:45  GLOBAL CHANGES (CLIMATE, CHEMICAL CONTAMINATION, AIR POLLUTION) AND NEUROLOGICAL IMPACTS
J. Reis (France)

14:45 - 16:15  SHEIKH MAKTOUM B

SCIENTIFIC SESSION: TOPICS: T19: THE MICROBIOME AND NEUROLOGY

Chairs: J. Correale (Argentina)
H. Tremlett (Canada)

14:45  INTESTINAL MICROBIOTA AND NEUROLOGICAL DISEASE
H. Wekerle (Germany)

15:15  THE MICROBIOME, INNATE IMMUNITY AND MS
J. Correale (Argentina)

15:45  THE GUT MICROBIOTA IN THE MS PATIENT; A FOCUS ON PAEDIATRICS
H. Tremlett (Canada)
14:45 - 16:15  

**FREE PAPERS 18 - EPILEPSY 2**

Chairs: R. Stark (Australia)  
H. Hosny (Egypt)

14:45  **EVALUATION OF GREY AND WHITE MATTER STRUCTURAL DIFFERENCE BETWEEN HOT WATER EPILEPSY AND JUVENILE MYOCLONIC EPILEPSY WITH MULTIMODAL MULTIVARIATE APPROACH USING MCCA AND JOINT ICA**  

14:55  **PROGRESS OF EPILEPSY CONTROL IN CHINA IN RECENT YEARS**  
S. Li, Z. Hong, W. Wang, Y. Wang, J. Zhang, G. Luan (China)

15:05  **SUB-SAHARAN STUDY OF PHOTOPAROXYSMAL RESPONSE IN A REFERENCE EPILEPSY LAB**  
A.M. Magnerou, D.H. Toffa, A. Basse, A.D. Sow, L.B. Seck, M. Ndiaye (Cameroon)

15:15  **PROGNOSTIC VALUE OF EEG IN CRITICALLY ILL PATIENTS: ANALYSIS OF 501 CASES**  
G.K. Dash, S.A. Adukia (India)

15:25  **EPILEPSY IN GUINEA: THE EXPERIENCE OF A FREE CONSULTATION**  
C. Fodé Abass, F. Sakadi, A. Nana Rahamatou, Tassiou, B. Amadou Talibé, N.W. Arcel Steven, B. Aissatou, Kenda, B. Souleymane, Djigué, C. Amara, F. Mateen, Jasmine (Guinea Republic)

15:35  **SCREENING TOOLS FOR DEPRESSION IN EPILEPSY – A COMBINATION INCREASES DETECTION RATE**  
T.J. Von Oertzen, N. Thamm, G. Schwarz, A.M. Hengsberger, J. Wagner, G. Puttenger (Austria)

15:45  **INTRACTABLE SEIZURES, PREDICTION, PROGNOSTIC FACTORS, INTRACTABILITY: A SYSTEMATIC REVIEW**  
S. Shaafi, N. Ghaemian (Iran)

15:55  **REFRACTORY EPILEPSY WITH EPILEPTIC SPASMS: CLINICAL CHARACTERISTICS AND PREDICTORS OF OUTCOME AFTER SURGERY.**  
S.J. Sattaluri, S. Vooturi, M. Panigrahi, R. Vadapalli (India)

16:05  **SEX DIFFERENCES IN DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF PSYCHOGENIC NONEPILEPTIC SEIZURES: A RETROSPECTIVE MULTICENTER INTERNATIONAL STUDY**  
14:45 - 16:15

FREE PAPERS 19 - MOVEMENT DISORDERS 2

Chairs: K. Bhatia (United Kingdom)
        C. Khamis (Lebanon)

14:45 VARIATIONS IN THE VENTRAL VISUAL PATHWAY’S CONNECTIVITY: CORTICAL INTERACTIONS EVALUATED FOR STRUCTURAL ALTERATIONS IN VISUAL PERCEPTUAL ABNORMALITIES IN PARKINSON’S DISEASE
E. Ganesh, G. Vinodhanand, C. Vadiyala, H. Chaterjee, V.H. Yadav Kurra (Guyana)

14:55 ASSOCIATION OF POTENTIAL PREMOTOR CLINICAL FEATURES WITH AGE OF SYMPTOM ONSET IN PARKINSON’S DISEASE
D. SELÇUK DEMİR ELİ, G. Genç, N. Gönderten, S. Bulut (Turkey)

15:05 COGNITIVE PROFILE OF PARKINSON’S DISEASE WITH AND WITHOUT DEFICITS IN MOTOR SPEED
V.N.S. Hegde, N. Kamble, R. Yadav, P. Kumar Pal (India)

15:15 OPICAPONE ODDS RATIO IN RELATIVE OFF-TIME REDUCTION: A POST-HOC ANALYSIS FROM COMBINED BIPARK-I AND II DATA
F. Rocha, W. Poewe, O. Rascol, A. Lees, J. Ferreira, A. Santos, D. Magalhaes, P. Soares-da-Silva (Portugal)

15:25 THE URGE TO MOVE IN RESTLESS LEGS SYNDROME ASSOCIATED WITH PARKINSON’S DISEASE: A MOTOR IMPULSE CONTROL DISORDER?
A. Marques, L. Fantini, C. Lambert, B. Pereira, T. Vidal, F. Durif (France)

15:35 MOTOR LEARNING AND LONG DURATION RESPONSE TO LEVODOPA IN PARKINSON’S DISEASE

15:45 PATTERN ANALYSIS OF FDG PET IN ATYPICAL PARKINSONISM - AN INNOVATIVE APPROACH.
S. Balakrishnan, S. Narasimhan, P. Chandra (India)

15:55 INFECTIONS AS A CAUSE OF MOVEMENT DISORDERS- A SERIES OF THREE UNUSUAL CASES
D. Garg, R. Dhamija, Kumar (India)

16:05 EPIDEMIOLOGY, MOLECULAR GENETICS, AND NEW TREATMENT OPTIONS FOR AROMATIC AMINO ACID DECARBOXYLASE DEFICIENCY
THURSDAY, OCTOBER 31, 2019

07:00 - 08:00 SHEIKH MAKTOUN B

TEACHING COURSE: TC 22: HEADACHE

R. Stark (Australia)

08:00 - 08:30 SHEIKH RASHID E

PLENARY LECTURE 9: BARUCHA AWARD LECTURE: BRAIN-MACHINE INTERFACES

Chairs: R. Kaji (Japan)
M. Freedman (Canada)

08:00 BRAIN-MACHINE INTERFACES: FROM BASIC SCIENCES TO NEUROREHABILITATION
M. Nicolelis (USA)

08:30 - 09:00 SHEIKH RASHID E

PLENARY LECTURE 10: THE PROMISE OF THE BRAIN INITIATIVE® FOR THOSE WITH NEURO/MENTAL/SUBSTANCE ABUSE DISORDERS

Chairs: R. Shakir (United Kingdom)
V. Hachinski (Canada)

08:30 THE PROMISE OF THE BRAIN INITIATIVE® FOR THOSE WITH NEURO/MENTAL/SUBSTANCE ABUSE DISORDERS
W.J. Koroshetz (USA)
09:00 - 10:30  SHEIKH RASHID E

SCIENTIFIC SESSION: MT (MAIN TOPICS): MT8D: NEUROMUSCULAR DISEASES

Chairs: M. Chokri (Tunisia)
M. Al Jumah (Saudi Arabia)

NEUROMUSCULAR DISEASE – NEW THERAPIES

09:00  INFECTIOUS NEUROPATHIES
A.E. Ahmed (Sudan)

09:30  SPINAL MUSCULAR ATROPHY
M. Chokri (Tunisia)

10:00  FAMILIAL AMYLOID POLYNEUROPATHY
V. Planté-Bordeneuve (France)

09:00 - 10:30  SHEIKH MAKTOUM A

SCIENTIFIC SESSION: TOPICS: T20A: NEURO-OTOLOGY

Chairs: K.P. Weber (Switzerland)
A. Shaikh (USA)

VESTIBULAR FUNCTION AND DISORDERS OF THE BRAINSTEM AND CEREBELLUM

09:00  DISSECTING PERIPHERAL VESTIBULAR DISEASE PATTERNS WITH MODERN DIAGNOSTICS
K. Weber (Switzerland)

09:30  VESTIBULAR DISORDERS IN CEREBELLAR AND BRAINSTEM STROKES
J.S. Kim (Republic of Korea)

10:00  VESTIBULAR DISORDERS IN ROLL PLANE FROM BRAINSTEM TO CORTEX
M. Dieterich (Germany)
09:00 - 10:30 SHEIKH MAKTOUM B

SCIENTIFIC SESSION: TOPICS: T21: HISTORY OF NEUROLOGY: NEUROSCIENCES IN MEDIEVAL ARAB MEDICINE

Chairs: C. Hicham (Morocco)
S. Al-Rukn (United Arab Emirates)

09:00 PAIN AND NEUROLOGY IN AVICENNA’S WORK
O. Tashani (United Kingdom)

09:30 ARAB AND THE GLORY OF MEDIEVAL ERA IN MEDICINE
S. Al-Rukn (United Arab Emirates)

10:00 NEUROLOGY IN THE TAYSSIR OF IBN ZUHR
C. Hicham (Morocco)

09:00 - 10:30 SHEIKH MAKTOUM C

SCIENTIFIC SESSION: TOPICS: T22A: PALLIATIVE CARE

Chairs: D. Oliver (United Kingdom)
J. Miyasaki (Canada)

SESSION 1 – PALLIATIVE CARE IN NEUROLOGY – DEVELOPMENTS OF COLLABORATION

09:00 PALLIATIVE CARE IN NEUROLOGY – COLLABORATION
D. Oliver (United Kingdom)

09:30 PALLIATIVE CARE AND MOVEMENT DISORDERS
J. Miyasaki (Canada)

10:00 THE ROLE OF PALLIATIVE CARE IN STROKE
P. Eastman (Australia)
09:00 - 10:30 SHEIKH MAKTOUM D

SCIENTIFIC SESSION: TOPICS: T23A: PRIONS AND NEURODEGENERATIVE DISEASES

Chairs: H. Mizusawa (Japan)
       S. Mead (United Kingdom)

PRION-LIKE MECHANISMS IN NEURODEGENERATIVE DISEASES

09:00 IATROGENIC ABETA TRANSMISSION
H. Mizusawa (Japan)

09:30 ALPHA-SYNUCLEIN – CAN IT FORM PRIONS?
M. Hasegawa (Japan)

10:00 PRION-LIKE BEHAVIOUR OF TAU PROTEIN
M. Goedert (United Kingdom)

09:00 - 10:30 SHEIKH RASHID A

TEACHING COURSE: TC24: NEUROIMAGING

Chairs: M. Filippi (Italy)
       J. Masdeu (USA)

09:00 DIAGNOSIS OF MS
M. Filippi (Italy)

09:22 IMAGING OF STROKE: HIGHLIGHTS
S. Warach (USA)

09:45 CONTRIBUTION OF MRI FOR EARLY DIAGNOSIS OF DEMENTIA
F. Agosta (Italy)

10:07 MOLECULAR IMAGING FOR DIFFERENTIAL DEMENTIA DIAGNOSIS
J. Masdeu (USA)
11:00 - 12:30  SWEIKH RASHID B

TEACHING COURSE: TC25: AUTOIMMUNE NEUROLOGIC DISORDERS: IMMUNE MEDIATED DISORDERS OF THE CNS: PHENOTYPES, TREATMENT AND PATHOPHYSIOLOGY

Chairs: S. Pittock (USA)  
S. Irani (United Kingdom)

11:00 THE AUTOANTIBODY- MEDIATED BRAIN DISEASES  
S. Irani (United Kingdom)

11:30 AUTOIMMUNE SPINAL CORD DISORDERS  
S. Pittock (USA)

12:00 THE STIFF PEOPLE SYNDROMES AND THEIR PATHOPHYSIOLOGY  
C. Sommer (Germany)

09:00 - 10:30  ABU DHABI A

TEACHING COURSE: TC26: CHILD NEUROLOGY: PRACTICAL APPROACHES TO DIAGNOSIS OF CHALLENGING PROBLEMS IN CHILD NEUROLOGY

Chairs: I. Tein (Canada)  
R. Dale (Australia)

09:00 OVERVIEW AND CLINICAL APPROACH TO CONGENITAL MYOPATHIES  
H. Topaloglu (Turkey)

09:30 APPROACH TO MUSCLE CRAMPS, EXERCISE INTOLERANCE AND RECURRENT MYOGLOBINURIA  
I. Tein (Canada)

10:00 APPROACH TO THE CHILD WITH ACQUIRED DEMYELINATING DISORDERS  
R. Dale (Australia)
09:00 - 10:30

SCIENTIFIC SESSION: TOPICS: T23: DEMENTIAS ACROSS DIFFERENT POPULATIONS, CULTURE AND LANGUAGES

Chairs: G. Logroscino (Italy)
T. Bak (United Kingdom)

09:00    THE SEARCH FOR DIFFERENT PATTERN OF DEMENTIAS IN LARGE GEOGRAPHIC AREAS AROUND THE WORLD.
G. Logroscino (Italy)

09:30    ASSESSMENT OF COGNITIVE DISORDERS IN THE ARABIC LANGUAGE
M. Ben Abdeljilil (Morocco)

10:00    NEUROPSYCHOLOGICAL AND FUNCTIONAL ASSESSMENT ACROSS DIFFERENT CULTURES AND CONTINENTS
T. Bak (United Kingdom)
FREE PAPERS 20 - MISCELLANEOUS 1

Chairs: A. Shereef (Saudi Arabia)
J. Inshasi (United Arab Emirates)

09:00 NEUROLOGY RESIDENTS VERSUS A MOBILE MEDICAL APPLICATION IN DEDUCING DIFFERENTIAL DIAGNOSES IN MOVEMENT DISORDERS: A MULTI-CENTER, CROSS-SECTIONAL, OBSERVATIONAL STUDY
V. Vishnu, P.W. Vinny, R. Rajan, V. Goyal, P. Srivastava, V. Lal, P. Sylaja, L. Narasimhan, S.N. Dwivedi, P.P. Nair, D. Ramachandran, A. Gupta (India)

09:10 IDIOPATHIC SUDDEN SENSORINEURAL HEARING LOSS: LABYRINTHITIS OR ISCHEMIA? CONSIDERATION BASED ON VHIT AND CVEMP
T. Murofushi, M. Tsubota, S. Daiji (Japan)

09:20 CEREBRAL HEMODYNAMICS IN PATIENTS WITH EXTRACRANIAL INTERNAL CAROTID ARTERY DISEASE
G. Oidovdorj, L. Natsagdorj, B. Dagvajantsan, S. Jambal (Mongolia)

09:30 RETRIEVABLE STENT THROMBECTOMY IN ACUTE ISCHEMIC STROKE: IS IT BENEFICIAL IN THE ELDERLY?
F. Perren, O. Kargiotis, A. Terruzzi, D. Krieger, G. Tsivgoulis, V. Mendes Pereira (Switzerland)

09:40 TELENEUROLOGY FROM 2014 TO 2019 IN FRANCE: RESULTS FROM A NATIONAL MANDATORY HOSPITAL SURVEY CONDUCTED BY THE MINISTRY OF HEALTH
R. Ohannessian, S. Deltour, E. Medeiros de Bustos, T. Moulin (France)

09:50 PATIENTS WITH FIBROMYALGIA DISPLAY TWO DIFFERENT CLINICAL PROFILES BASED ON THEIR GABAERGIC EEG MARKERS: PRELIMINARY RESULTS
C. Mancini, C. Wicht, M. Mouthon, S. Goetz, J. Chabwine (Switzerland)

10:00 AN EVALUATION OF THE TREATMENT AND PROGNOSIS OF PATIENTS WITH IDIOPATHIC INTRACRANIAL HYPERTENSION AT THE NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY, MEXICO
A. Leyva-Rendón, K.M. Castro Gutiérrez, D.G. Zuñiga (Mexico)

10:10 EFFICIENCY AND EFFECTIVENESS OF COMBINED CELL THERAPY IN PREVIOUSLY CHRONIC AND COMPLETE SPINAL CORD INJURY SUBJECTS
M.T. Moviglia Brandolino, G.A. Moviglia, S. Picone, D. Couto (Argentina)

10:20 NEUROPHYSIOLOGICAL CHARACTERISTICS OF VESTIBULAR MIGRAINE, MENIERE’S DISEASE AND VESTIBULAR MIGRAINE/MENIERE’S DISEASE OVERLAPPING SYNDROME
T. Murofushi, M. Tsubota, D. Suzuki, R. Suizu (Japan)

10:30 - 11:00 EXHIBITION AREA

COFFEE BREAK
11:00 - 12:30  SHEIKH RASHID E

SCIENTIFIC SESSION: MT (MAIN TOPICS): MT7D: HEADACHE AND PAIN

Chairs:  N. Attal (France)
         D. Bennett (United Kingdom)

NEUROPATHIC PAIN: UPDATE ON PATHOPHYSIOLOGY, DIAGNOSTICS AND TREATMENT

11:00  WHAT MAKES A NEUROPATHY PAINFUL?
       C. Sommer (Germany)

11:25  GENETIC CAUSES OF PAIN
       D. Bennett (United Kingdom)

11:50  THE ROLE OF CORNEAL CONFOCAL MICROSCOPY IN THE DIAGNOSIS OF NEUROPATHIC PAIN
       R. Malik (Qatar)

12:05  TREATMENT OF NEUROPATHIC PAIN: AN UPDATE
       N. Attal (France)

11:00 - 12:30  SHEIKH MAKTOUM A

SCIENTIFIC SESSION: TOPICS: T20B: NEURO-OTOLOGY

Chairs:  C. Lopez (France)
         M. Dieterich (Germany)

VESTIBULAR FUNCTION AND DISORDERS OF THE CORTEX

11:00  CORTICAL CONTROL AND DISORDERS OF EYE MOVEMENTS
       A. Shaikh (USA)

11:30  THE VESTIBULAR SYSTEM AND BODY SCHEMA
       C. Lopez (France)

12:00  PERCEPTION OF SELF-MOTION AND ITS DISTURBANCE
       K. Cullen (USA)
11:00 - 12:30  SHEIKH MAHTOUM C

SCIENTIFIC SESSION: TOPICS: T22B: PALLIATIVE CARE

Chairs: D. Oliver (United Kingdom)  
J. Miyasaki (Canada)

SESSION 2 – ETHICAL AND CULTURAL ASPECTS OF PALLIATIVE CARE

11:00  CULTURAL ASPECTS OF CARE  
O. Shamieh (Jordan)

11:30  ETHICAL ASPECTS OF CARE – WITHDRAWAL OF TREATMENT AT THE END OF LIFE  
I. Baker (United Kingdom)

12:00  END OF LIFE DECISION MAKING - ADVANCE CARE PLANNING / REQUESTS FOR HASTENED DEATH  
S. Payne (United Kingdom)

11:00 - 12:30  SHEIKH MAHTOUM D

SCIENTIFIC SESSION: TOPICS: T23B: PRIONS AND NEURODEGENERATIVE DISEASES

Chairs: S. Mead (United Kingdom)  
H. Mizusawa (Japan)

PRION DISEASES AND ITS TREATMENT

11:00  ABNORMAL PRION PROTEINS  
O. Andreoletti (France)

11:30  PRION DISEASES AND POSSIBLE TREATMENTS  
S. Mead (United Kingdom)

12:00  A NEW EMERGING PRION DISEASE IN CAMELS – WHAT WE KNOW?  
G. Vaccari (Italy)
09:00 - 10:30 SHEIKH RASHID B

TEACHING COURSE: TC25: AUTOIMMUNE NEUROLOGIC DISORDERS: ASPECTS OF AUTOIMMUNE NEUROLOGICAL DISEASES

Chairs: S. Pittock (USA)
      S. Irani (United Kingdom)

09:00 AUTOIMMUNE MOVEMENT DISORDERS
R. Dale (Australia)

09:30 THE RATIONALE USE OF IMMUNOTHERAPIES IN CHILDREN
E. Wirrell (USA)

10:00 CEREBRAL NERVOUS SYSTEM VASCULITIS
H. El Otmani (Morocco)

11:00 - 12:30 ABU DHABI A

TEACHING COURSE: TC26: CHILD NEUROLOGY: PRACTICAL APPROACHES TO CHALLENGES IN CHILDHOOD EPILEPSY AND NEUROINFECTIONS

Chairs: J. Wilmshurst (South Africa)
       H. Cross (United Kingdom)

11:00 APPROACH FOR INVESTIGATION OF INFANTS WITH SEIZURES AND EPILEPTIC ENCEPHALOPATHY
E. Wirrell (USA)

11:30 NEW ILAE RECOMMENDATIONS FOR CLASSIFICATION OF SEIZURES
H. Cross (United Kingdom)

12:00 SSPE – MARKERS FOR EARLY RECOGNITION AND INTERVENTION
J. Wilmshurst (South Africa)
11:00 - 12:30

FREE PAPERS 21 - NEUROREHABILITATION

Chairs: D. Muresanu (Romania)
        C. Pistarini (Italy)

11:00  A NEW DEVELOPED NON-INVASIVE CORTICAL STIMULATION ON MIRROR NEURONS IN CHILDREN WITH AUTISM SPECTRUM DISORDERS
        H. Hadoush, M. Nazzal, N. A. Almasri, H. Khalil, M. Alafeef (Jordan)

11:10  TARGETED DELIVERY OF ERYTHROPOIETIN COMBINED WITH NANOPARTICLES UNDER MAGNETIC GUIDANCE

11:20  FACIAL SYNKINESIS IN PATIENTS WITH LONG-STANDING BELL'S PALSY IS A REVERSIBLE CONSEQUENCE OF DISRUPTION OF RECIPROCAL INHIBITION CAUSED BY PROLONGED ABSENCE OF PROPRIOCEPTIVE FEEDBACK
        A. Pashov, O. Pashova (The Netherlands)

11:30  VIRTUAL REALITY BASED NEURO-REHABILITATION IN ACUTE STROKE: A PROSPECTIVE COHORT STUDY OF ITS EFFECTIVENESS FOR UPPER LIMB MOTOR RECOVERY
        M. Thakre, C. Sankhala, P. Vengurlekar, G. Garipelli (India)

11:40  BOS-TECHNOLOGIES OF REHABILITATION IN PATIENTS WITH PARKINSONISM
        Y. Bykov, T. Bender (Russia)

11:50  THE RELATIONSHIP OF THE OCCUPATIONAL CIRCUMSTANCES AND COMMUNITY INTEGRATION IN SCHIZOPHRENIA
        G. Akyurek, H. Isik, G. Bumin (Turkey)

12:00  REFLECTIONS OF MIRROR THERAPY ON THE FUNCTIONAL RECOVERY AFTER STROKE
        M. Mandeep, D. Khurana (India)

12:10  ROLE OF BOTULINUM TOXIN A IN CEREBRAL PALSY – 15 YRS EXPERIENCE
        P.A.M. Kunju, R. ismail, M. Sreedharan, M. Iype (India)

12:20  REHABILITATION ISSUES IN STROKE PATIENTS: ASIAN PERSPECTIVES
        S. Pramod, B. Patidar (India)
11:00 - 12:30

DUBAI C

FREE PAPERS 22 - MISCELLANEOUS 2

Chairs: C. Meshram (India)
       C. Kennard (United Kingdom)

11:00 ALEXITHYMIA AND EMOTIONAL AWARENESS ARE NEGATIVELY ASSOCIATED WITH SLEEP PARAMETERS IN PATIENTS WITH MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME – AN EXPLORATORY STUDY
   I. Bileviciute-Ljungar, D. Maroti, D. Friberg (Sweden)

11:10 EPIDEMIOLOGY OF LOW BACK PAIN
   I. Vyshlova, S. Karpov, A. Bairamkulova (Russia)

11:20 GLAUCOMA AND CEREBRAL BLOOD FLOW AUTOREGULATION: PILOT STUDY
   Y. Hamarat, V. Petkus, M. Deimantavicius, L. Bartusis, V. Putynaite, P. Lucinskas,
   A. Daveckaita, L. Siaudvytye, E. Maciuailitye, I. Januleviciene, A. Harris, A. Ragauskas
   (Lithuania)

11:30 STRESS-LOAD AND IT’S CORRELATION WITH INFECTIONS IN PATIENTS WITH MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME
   I. Bileviciute-Ljungar (Sweden)

11:40 NEUROLOGICAL MANIFESTATIONS OF DENGUE FEVER: DATA FROM A TERTIARY CARE MEDICAL COLLEGE IN KERALA.
   P.A.M. Kunju, A. Jain R (India)

11:50 ASSOCIATION OF IDH1 MUTATION WITH SURVIVAL OF GLIOMA PATIENTS IN INDONESIA
   R.G. Malueka, E.K. Dwianingsih, H.F. Bayuangga, I.W. Argo, A.D. Donurizki, S. Shaleh,
   A.S. Wicaksono, K. Dananjoyo, A. Asmedi, R.A. Hartanto (Indonesia)

12:00 SUBJECTIVE AND OBJECTIVE NEUROLOGICAL FINDINGS INDUCED BY LOW-DOSE ARSENIC CONTAMINATED DRINKING WATER IN MYANMAR
   Y. Hishikawa, K.Z. Thant, M. Maruyama, Y. Kuroda (Japan)

12:10 ETHICAL ISSUES IN PHASE I TRIALS OF NEUROLOGICAL DISORDERS: AN EXAMINATION OF THE NEURALSTEM ALS PHASE I TRIAL
   M. Yarborough, N.C. Joyce (USA)

12:20 TREATMENT PATTERNS AND OUTCOME IN CEREBRAL VENOUS SINUS THROMBOSIS (CSVT)
   S.P. Gorthi, N. Ashwini, M. Thumbi, P. Varsha (India)

12:30 - 12:45

SHORT BREAK
13:00 - 14:00

**TOURNAMENT OF THE MINDS: FINAL**

Chairs: R. Stark (Australia)
N. Davies (United Kingdom)
F. Belahsen (Morocco)

14:00 - 14:30

**CLOSING CEREMONY**

14:00  ELSEVIER AWARDS: BILL CARROLL (WFN PRESIDENT) AND PETER BAKKER (ELSEVIER)

14:05  ANGELA VINCENT YOUNG INVESTIGATOR AWARD – BILL CARROLL (WFN PRESIDENT) AND STEVEN LEWIS (EDUCATION COMMITTEE CHAIR)

14:10  MUNSAT AWARD PRESENTATION – BILL CARROLL (WFN PRESIDENT) AND WOLFGANG GRISOLD (WFN SECRETARY GENERAL)

14:15  LOCAL CLOSING REMARKS AND HAND-OVER TO WCN 2021 PRESIDENT – SUHAIL AL RUKHN (2019 CONGRESS PRESIDENT)

14:20  WCN 2021 INTRODUCTION
INDEX OF AUTHORS

WCN 2019
XXIV WORLD CONGRESS OF NEUROLOGY
DUBAI, UNITED ARAB EMIRATES, OCTOBER 27-31 2019
## INDEX OF AUTHORS

The index is an alphabetical listing of names of speakers, session chairs and abstract authors and co-authors involved in the Scientific Program.

<table>
<thead>
<tr>
<th>Author</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbashar, H.</td>
<td>112</td>
</tr>
<tr>
<td>Abbasher, M.</td>
<td>112</td>
</tr>
<tr>
<td>Abd-Allah, F.</td>
<td>38, 99</td>
</tr>
<tr>
<td>Abdelkader, A.A.</td>
<td>57</td>
</tr>
<tr>
<td>Abdel-Naseer, M.</td>
<td>76</td>
</tr>
<tr>
<td>Abdulla, F.</td>
<td>39</td>
</tr>
<tr>
<td>Abdullah, M.</td>
<td>93</td>
</tr>
<tr>
<td>Abolfazli, R.</td>
<td>94</td>
</tr>
<tr>
<td>Abu Al-Melh, M.</td>
<td>72</td>
</tr>
<tr>
<td>Abuelwafa, N.</td>
<td>93</td>
</tr>
<tr>
<td>Acharya, M.K.</td>
<td>45</td>
</tr>
<tr>
<td>Acosta, J.</td>
<td>67</td>
</tr>
<tr>
<td>Adamec, I.</td>
<td>69</td>
</tr>
<tr>
<td>Adel Kishk, N.</td>
<td>57</td>
</tr>
<tr>
<td>Adukia, S.A.</td>
<td>117</td>
</tr>
<tr>
<td>Aggarwal, A.</td>
<td>53</td>
</tr>
<tr>
<td>Aglave, V.</td>
<td>69</td>
</tr>
<tr>
<td>Agosta, F.</td>
<td>124</td>
</tr>
<tr>
<td>Agrawal, C.</td>
<td>67</td>
</tr>
<tr>
<td>Aguiar, J.</td>
<td>88</td>
</tr>
<tr>
<td>Ahmad, I.</td>
<td>49, 55</td>
</tr>
<tr>
<td>Ahmad, W.</td>
<td>45</td>
</tr>
<tr>
<td>Ahmed, A.</td>
<td>93</td>
</tr>
<tr>
<td>Ahmed, A.E.</td>
<td>122</td>
</tr>
<tr>
<td>Ahmed, H.</td>
<td>93</td>
</tr>
<tr>
<td>Ahmed, R.</td>
<td>100</td>
</tr>
<tr>
<td>Ahmed, S.</td>
<td>39, 69</td>
</tr>
<tr>
<td>Aidi, S.</td>
<td>109</td>
</tr>
<tr>
<td>Ailani, J.</td>
<td>107</td>
</tr>
<tr>
<td>Airas, L.</td>
<td>69</td>
</tr>
<tr>
<td>Aissatou, B.</td>
<td>117</td>
</tr>
<tr>
<td>Akhmadeeva, G.</td>
<td>87</td>
</tr>
<tr>
<td>Akram, Q.</td>
<td>45</td>
</tr>
<tr>
<td>Akyurek, G.</td>
<td>131</td>
</tr>
<tr>
<td>Akzhigitov, R.</td>
<td>57</td>
</tr>
<tr>
<td>Alabbas, M.</td>
<td>37</td>
</tr>
<tr>
<td>Alafeef, M.</td>
<td>131</td>
</tr>
<tr>
<td>Al-Ajlan, F.</td>
<td>53</td>
</tr>
<tr>
<td>Alajmi, A.</td>
<td>39</td>
</tr>
<tr>
<td>Al Asmi, A.</td>
<td>39</td>
</tr>
<tr>
<td>Aldaajani, Z</td>
<td>46</td>
</tr>
<tr>
<td>Aldakheel, A.</td>
<td>33, 64</td>
</tr>
<tr>
<td>Alem, M.</td>
<td>57</td>
</tr>
<tr>
<td>Alessi, R.</td>
<td>117</td>
</tr>
<tr>
<td>Alhammad, R.</td>
<td>75</td>
</tr>
<tr>
<td>Al Harbi, A.</td>
<td>39</td>
</tr>
<tr>
<td>Al-Hashel, J.</td>
<td>73, 91, 104</td>
</tr>
<tr>
<td>Alhawai, A.</td>
<td>57</td>
</tr>
<tr>
<td>Alhusaini, A.</td>
<td>108</td>
</tr>
<tr>
<td>Ali, A.</td>
<td>45</td>
</tr>
<tr>
<td>Alizadeh, R.</td>
<td>107</td>
</tr>
<tr>
<td>Al Jarallah, A.</td>
<td>75</td>
</tr>
<tr>
<td>Aljishi, A.</td>
<td>107</td>
</tr>
<tr>
<td>Al Jumah, M.</td>
<td>115, 122</td>
</tr>
<tr>
<td>Alkhalihi, H.</td>
<td>75</td>
</tr>
<tr>
<td>Al Khathaami, A.</td>
<td>37</td>
</tr>
<tr>
<td>Alkindi, M.</td>
<td>39</td>
</tr>
<tr>
<td>Alkuraya, F.</td>
<td>33</td>
</tr>
<tr>
<td>Allen, L.</td>
<td>51</td>
</tr>
<tr>
<td>Almadani, A.</td>
<td>57</td>
</tr>
<tr>
<td>Al Madani, A.</td>
<td>58, 97, 114</td>
</tr>
<tr>
<td>Al Malik, Y.</td>
<td>39</td>
</tr>
<tr>
<td>Almalki, A.</td>
<td>108</td>
</tr>
<tr>
<td>Almasri, N.A.</td>
<td>131</td>
</tr>
<tr>
<td>Alnajashi, H.</td>
<td>39</td>
</tr>
<tr>
<td>Alobaidy, A.</td>
<td>39</td>
</tr>
<tr>
<td>Alorainy, I.</td>
<td>75</td>
</tr>
<tr>
<td>Alotaibi, A.</td>
<td>75</td>
</tr>
<tr>
<td>Al Qadi, K.</td>
<td>57</td>
</tr>
<tr>
<td>Al Rasheed, A.</td>
<td>39</td>
</tr>
<tr>
<td>Alroughhani, R.</td>
<td>35, 39, 69, 89</td>
</tr>
<tr>
<td>Alrukn, S.</td>
<td>57</td>
</tr>
<tr>
<td>Al-Rukn, S.</td>
<td>40, 123</td>
</tr>
<tr>
<td>Alsagob, M.</td>
<td>75</td>
</tr>
<tr>
<td>Al Said, Y.</td>
<td>57</td>
</tr>
<tr>
<td>Al-Salmi, K.</td>
<td>108</td>
</tr>
<tr>
<td>Al Shahrami, A.</td>
<td>57</td>
</tr>
<tr>
<td>Alsharoqi, I.</td>
<td>39</td>
</tr>
<tr>
<td>Alsharoqi, I.</td>
<td>112</td>
</tr>
<tr>
<td>Alshekaili, J.</td>
<td>39</td>
</tr>
<tr>
<td>Alskaini, M.</td>
<td>37</td>
</tr>
<tr>
<td>Alsulaimi, M.</td>
<td>39</td>
</tr>
<tr>
<td>Althobaity, A.</td>
<td>39</td>
</tr>
<tr>
<td>Althubaiti, I.</td>
<td>39</td>
</tr>
<tr>
<td>Altuwajiry, M.</td>
<td>108</td>
</tr>
<tr>
<td>Alva-Diaz, C.</td>
<td>87</td>
</tr>
<tr>
<td>Alves, K.</td>
<td>108</td>
</tr>
<tr>
<td>Alyoubi, R.</td>
<td>108</td>
</tr>
<tr>
<td>Alzaidif, R.</td>
<td>108</td>
</tr>
<tr>
<td>Alzarooni, H.</td>
<td>57</td>
</tr>
<tr>
<td>Alzawahma, M.</td>
<td>39</td>
</tr>
<tr>
<td>Amadou Talibé, B.</td>
<td>117</td>
</tr>
<tr>
<td>Amalnath, D.</td>
<td>75</td>
</tr>
<tr>
<td>Amara, C.</td>
<td>117</td>
</tr>
<tr>
<td>Ambawat, S.</td>
<td>100</td>
</tr>
<tr>
<td>Andal, V.M.</td>
<td>57</td>
</tr>
<tr>
<td>Andel, R.</td>
<td>51</td>
</tr>
<tr>
<td>Anderson, F.A.</td>
<td>100</td>
</tr>
<tr>
<td>Andreoletti, O.</td>
<td>129</td>
</tr>
<tr>
<td>Angelucci, F.</td>
<td>51</td>
</tr>
<tr>
<td>Anikin, A.</td>
<td>93</td>
</tr>
<tr>
<td>Annamária, J.</td>
<td>67</td>
</tr>
<tr>
<td>Ansari, R.</td>
<td>69</td>
</tr>
<tr>
<td>Antonini, A.</td>
<td>67</td>
</tr>
<tr>
<td>Arafat, A.</td>
<td>93</td>
</tr>
<tr>
<td>Aralikatte Onkarapapp, S.</td>
<td>87</td>
</tr>
<tr>
<td>Aralikatte, S.</td>
<td>112</td>
</tr>
<tr>
<td>Aravinthan, M.</td>
<td>94</td>
</tr>
<tr>
<td>Arcel Steven, N.W.</td>
<td>117</td>
</tr>
<tr>
<td>Arciniegas, D.</td>
<td>36</td>
</tr>
<tr>
<td>Area-Gomez, E.</td>
<td>56</td>
</tr>
<tr>
<td>Argo, I.W.</td>
<td>132</td>
</tr>
<tr>
<td>Arjunji, R.</td>
<td>100</td>
</tr>
<tr>
<td>Arnaldi, D.</td>
<td>63</td>
</tr>
<tr>
<td>Arnold, D.L.</td>
<td>87</td>
</tr>
<tr>
<td>Aroni Paytan, A.</td>
<td>117</td>
</tr>
<tr>
<td>Arunachal, G.</td>
<td>75</td>
</tr>
<tr>
<td>Asadi-Pooya, A.</td>
<td>112, 117</td>
</tr>
<tr>
<td>Ashayeriah-madabad, H.</td>
<td>88</td>
</tr>
<tr>
<td>Name</td>
<td>Pages</td>
</tr>
<tr>
<td>-----------------------</td>
<td>-------</td>
</tr>
<tr>
<td>Ashayeriah-mabad, R.</td>
<td>88</td>
</tr>
<tr>
<td>Ashina, M.</td>
<td>107</td>
</tr>
<tr>
<td>Ashwini, N.</td>
<td>132</td>
</tr>
<tr>
<td>Asmedi, A.</td>
<td>132</td>
</tr>
<tr>
<td>Aszmann, O.</td>
<td>96</td>
</tr>
<tr>
<td>Atchayaram, N.</td>
<td>100</td>
</tr>
<tr>
<td>Attal, N.</td>
<td>128</td>
</tr>
<tr>
<td>Aung, M.N.</td>
<td>132</td>
</tr>
<tr>
<td>Aurora, S.</td>
<td>107</td>
</tr>
<tr>
<td>Avasti, S.</td>
<td>93</td>
</tr>
<tr>
<td>Awada, A.</td>
<td>76, 106</td>
</tr>
<tr>
<td>Babtain, F.</td>
<td>57</td>
</tr>
<tr>
<td>Badri, M.</td>
<td>37</td>
</tr>
<tr>
<td>Baduwailan, A.</td>
<td>108</td>
</tr>
<tr>
<td>Bae, H.J.</td>
<td>88</td>
</tr>
<tr>
<td>Baesa, S.</td>
<td>57</td>
</tr>
<tr>
<td>Bahador, M.</td>
<td>88</td>
</tr>
<tr>
<td>Baharvahdat, H.</td>
<td>88</td>
</tr>
<tr>
<td>Bahrami, Z.</td>
<td>112, 117</td>
</tr>
<tr>
<td>Bai, F.</td>
<td>112</td>
</tr>
<tr>
<td>Bairamkulova, A.</td>
<td>132</td>
</tr>
<tr>
<td>Baitimerov, A.</td>
<td>87</td>
</tr>
<tr>
<td>Baker, I.</td>
<td>86, 129</td>
</tr>
<tr>
<td>Bak, T.</td>
<td>126</td>
</tr>
<tr>
<td>Balakrishnan, S.</td>
<td>118</td>
</tr>
<tr>
<td>Balasubramani, V.</td>
<td>93</td>
</tr>
<tr>
<td>Baranzini, S.</td>
<td>98</td>
</tr>
<tr>
<td>Barata, C.</td>
<td>88</td>
</tr>
<tr>
<td>Bardos, J.</td>
<td>107</td>
</tr>
<tr>
<td>Bartels, E.</td>
<td>38</td>
</tr>
<tr>
<td>Barton, J.</td>
<td>73, 90</td>
</tr>
<tr>
<td>Bartusis, L.</td>
<td>132</td>
</tr>
<tr>
<td>Barun, B.</td>
<td>69</td>
</tr>
<tr>
<td>Barvalia, P.</td>
<td>69</td>
</tr>
<tr>
<td>Bashir, S.</td>
<td>93</td>
</tr>
<tr>
<td>Baskar, D.</td>
<td>75</td>
</tr>
<tr>
<td>Basse, A.</td>
<td>117</td>
</tr>
<tr>
<td>Bassetti, C.</td>
<td>54, 99</td>
</tr>
<tr>
<td>Batkhurel, J.</td>
<td>107</td>
</tr>
<tr>
<td>Batra, A.</td>
<td>67</td>
</tr>
<tr>
<td>Bayuangga, H.F.</td>
<td>132</td>
</tr>
<tr>
<td>Belarbi, S.</td>
<td>76</td>
</tr>
<tr>
<td>Begam, N.</td>
<td>45</td>
</tr>
<tr>
<td>Belahsen, F.</td>
<td>73, 95, 114, 133</td>
</tr>
<tr>
<td>Benabdelliljil, M.</td>
<td>56, 126</td>
</tr>
<tr>
<td>Bender, T.</td>
<td>131</td>
</tr>
<tr>
<td>Benetis, R.</td>
<td>112</td>
</tr>
<tr>
<td>Benhaddi, H.</td>
<td>107</td>
</tr>
<tr>
<td>Ben Jebra, M.</td>
<td>111</td>
</tr>
<tr>
<td>Bennett, D.</td>
<td>128</td>
</tr>
<tr>
<td>Bennett, F.</td>
<td>67</td>
</tr>
<tr>
<td>Bentivoglio, A.</td>
<td>87</td>
</tr>
<tr>
<td>Bergmann, L.</td>
<td>67</td>
</tr>
<tr>
<td>Berner, T.</td>
<td>118</td>
</tr>
<tr>
<td>Bertoldi, M.</td>
<td>118</td>
</tr>
<tr>
<td>Betting, L.E.</td>
<td>108</td>
</tr>
<tr>
<td>Beydoun, A.</td>
<td>47, 64, 72</td>
</tr>
<tr>
<td>Bhatia, G.</td>
<td>93</td>
</tr>
<tr>
<td>Bhargava, G.K.</td>
<td>117</td>
</tr>
<tr>
<td>Bhatia, K.</td>
<td>46, 118</td>
</tr>
<tr>
<td>Bhatia, R.</td>
<td>88</td>
</tr>
<tr>
<td>Bhattacharjee, S.</td>
<td>45, 113</td>
</tr>
<tr>
<td>Bileviciute-Ljungar, I.</td>
<td>132</td>
</tr>
<tr>
<td>Biran, I.</td>
<td>112</td>
</tr>
<tr>
<td>Birouk, N.</td>
<td>52, 58</td>
</tr>
<tr>
<td>Biswas, A.</td>
<td>51</td>
</tr>
<tr>
<td>Bjelica, B.</td>
<td>75</td>
</tr>
<tr>
<td>Blau, N.</td>
<td>118</td>
</tr>
<tr>
<td>Boak, L.</td>
<td>67</td>
</tr>
<tr>
<td>Boeve, B.</td>
<td>51</td>
</tr>
<tr>
<td>Boholega, S.</td>
<td>79, 100</td>
</tr>
<tr>
<td>Boraiah, N.</td>
<td>108</td>
</tr>
<tr>
<td>Bornstein, N.</td>
<td>44</td>
</tr>
<tr>
<td>Bove, F.</td>
<td>87</td>
</tr>
<tr>
<td>Boyd, J.</td>
<td>67</td>
</tr>
<tr>
<td>Bozovic, I.</td>
<td>75, 100</td>
</tr>
<tr>
<td>Brainin, M.</td>
<td>34, 73</td>
</tr>
<tr>
<td>Brandt, T.</td>
<td>106</td>
</tr>
<tr>
<td>Braun, K.</td>
<td>110</td>
</tr>
<tr>
<td>Brochet, B.</td>
<td>69</td>
</tr>
<tr>
<td>Bronstein, A.</td>
<td>111</td>
</tr>
<tr>
<td>Brundin, P.</td>
<td>33</td>
</tr>
<tr>
<td>Buchhalter, J.</td>
<td>117</td>
</tr>
<tr>
<td>Buezas, M.</td>
<td>37</td>
</tr>
<tr>
<td>Bulut, S.</td>
<td>118</td>
</tr>
<tr>
<td>Bumin, G.</td>
<td>131</td>
</tr>
<tr>
<td>Burrell, J.</td>
<td>112</td>
</tr>
<tr>
<td>Butterfield, R.J.</td>
<td>100</td>
</tr>
<tr>
<td>Byambasuren, T.</td>
<td>107</td>
</tr>
<tr>
<td>Bykov, Y.</td>
<td>131</td>
</tr>
<tr>
<td>Caballero, M.L.</td>
<td>37</td>
</tr>
<tr>
<td>Calic, Z.</td>
<td>75</td>
</tr>
<tr>
<td>Campbell, B.</td>
<td>53, 73</td>
</tr>
<tr>
<td>Campero, M.</td>
<td>107, 114</td>
</tr>
<tr>
<td>Cao, X.</td>
<td>51</td>
</tr>
<tr>
<td>Cappa, S.</td>
<td>50, 61, 84, 90, 111</td>
</tr>
<tr>
<td>Cardenas, J.</td>
<td>68, 77</td>
</tr>
<tr>
<td>Cardenas-Rojas, A.</td>
<td>87</td>
</tr>
<tr>
<td>Carducci, C.</td>
<td>118</td>
</tr>
<tr>
<td>Carelli, V.</td>
<td>49</td>
</tr>
<tr>
<td>Carroll, W.M.</td>
<td>33, 62, 83</td>
</tr>
<tr>
<td>Castillo, S.</td>
<td>52</td>
</tr>
<tr>
<td>Castro Gutiérrez, K.M.</td>
<td>127</td>
</tr>
<tr>
<td>Cechova, K.</td>
<td>51</td>
</tr>
<tr>
<td>Cendes, F.</td>
<td>113</td>
</tr>
<tr>
<td>Chabwine, J.</td>
<td>127</td>
</tr>
<tr>
<td>Chai, Z.</td>
<td>39, 67, 94</td>
</tr>
<tr>
<td>Cha, J.K.</td>
<td>88</td>
</tr>
<tr>
<td>Chambi, M.</td>
<td>107</td>
</tr>
<tr>
<td>Chanchal, S.</td>
<td>100</td>
</tr>
<tr>
<td>Chandler, J.</td>
<td>66</td>
</tr>
<tr>
<td>Chandran, G.</td>
<td>100</td>
</tr>
<tr>
<td>Chandra, P.</td>
<td>118</td>
</tr>
<tr>
<td>Charway-Felli, A.</td>
<td>99</td>
</tr>
<tr>
<td>Chatterjee, H.</td>
<td>118</td>
</tr>
<tr>
<td>Chatterjee, H.</td>
<td>67</td>
</tr>
<tr>
<td>Chaudhuri, K.R.</td>
<td>67</td>
</tr>
<tr>
<td>Chauhan, J.B.</td>
<td>100</td>
</tr>
<tr>
<td>Chen, C.</td>
<td>34, 78, 88</td>
</tr>
<tr>
<td>Chen, H.</td>
<td>113</td>
</tr>
<tr>
<td>Cherres Xavier Esteves, G.</td>
<td>108</td>
</tr>
<tr>
<td>Chevure, J.</td>
<td>67</td>
</tr>
<tr>
<td>Chien, Y.H.</td>
<td>67</td>
</tr>
<tr>
<td>Chimagomedova, A.</td>
<td>51</td>
</tr>
<tr>
<td>Chinnery, P.</td>
<td>39, 49, 56</td>
</tr>
<tr>
<td>Chishimba, L.</td>
<td>45</td>
</tr>
<tr>
<td>Chmatalova, Z.</td>
<td>51</td>
</tr>
<tr>
<td>Chneiweiss, H.</td>
<td>66</td>
</tr>
</tbody>
</table>
Choi, S.I. 113
Chokri, M. 76, 122
Chomba, M. 45
Chopra, S. 88
Chudyk, J. 37
Chylla, M. 69
Ciardi, C. 37
Cioni, B. 87
Cirio, J.J. 37
Claeys, K. 97, 104
Cloutier, M. 100
Cohen, J. M. 107
Colak, D. 75
Comair, Y. 34
Comi, G. 87
Condori, J.W. 107
Condori, T. 107
Connolly, A. M. 100
Conway, A. M. 67
Correale, J. 116
Cortez, G. 107
Corzo, C. 88
Costa, L. 108
Costa, R. 108
Coutant, K. 69
Couto, D. 127
Craveiro, L. 94
Crawford, T.O. 100
Cronosija, L. 69
Cross, H. 93, 110, 130
Cui, L. 103
Cullen, K. 128
Cupler, E. 75, 91, 104
Dabbous, O. 100
Dagvajantsan, B. 127
Daiji, S. 127
Dale, R. 105, 125, 130
Damak, M. 76
Dananjyo, K. 132
Dangond, F. 87
Daoudi, S. 35
Darras, B.T. 100
Das, B. 45
Dash, G.K. 117
Daveckaite, A. 132
Dávid, P. 67
Davies, N. 95, 114, 133
Day, J.W. 100
Daza Restrepo, A. 117
Degroot, J. 71, 110
Dehaene, S. 61
Deimantavicius, M. 132
De Koning-Tijssen, M. 46
Del Brutto, O. 35, 42
Del Sette, M. 38
Deltour, S. 127
De Seze, J. 39
Deshpande, S. 37
De Silva, D.A. 37, 53
Detke, H. 93
Deuschl, G. 33, 99
Devenney, E. 100
de Visser, M. 78, 91, 104
De Vivo, D.C. 100
De Vriendt, E. 100
Dhamija, R. 118
Dib-Hajj, S. 114
Dickerson, B. 90
Dicken, D. 51
Diener, H.C. 107
Dieterich, M. 111, 122, 128
Dimachkie, M. 97, 109
Dionisio, P. 88
Diop, A.G. 41, 96
Disilvestro, L. 108, 118
D' , L. 117
Dogan, M.A. 88
Donurizki, A.D. 132
Donzolou, G. 108, 118
Doody, R. 67
Do Prado, G.F. 52
Dragasevic-Miskovic, N. 100
Drago, F. 108, 118
Drooge, M. 100
Drubach, D. 51
Drulovic, J. 94, 100
Ducros, A. 85, 109
Duffau, H. 84
Duran, J.C. 107
Durif, F. 118
Dwianingsih, E.K. 132
Dwivedi, S.N. 127
Eastman, P. 92, 123
Ebrahimi, H. 51
Eddy Yunus, R. 94
El Alaoui Faris, M. 33, 105
El Metwally, A. 37
El Otmani, H. 130
El Salem, K. 109
El-Sheikh, W. 93
El-shony, H. 93
El Shunnar, K. 55
El-Tamawy, M. 45
Elumala, G. 113
Elumalai, G. 67, 113
El-Zawawi, H.A. 69
England, J. 89, 108
Erat Sreedharan, S. 37
Eshraghi, A. 88
Esmaili, S. 94, 107
Espiritu, A. 57
Estiasari, R. 94
Estrada-Cuzcano, A. 100
Etemad Rezae, H. 88
Falah, M. 39
Fan, H.J. 67
Fantini, L. 118
Farina, D. 96
Faruq, M. 100
Farzan, M. 88
Fatehi, F. 75
Fathi, D. 75
Feltner, D.E. 100
Feng, L. 39, 67, 94
Ferman, T. 51
Fernandez, M.L. 57
Ferreira, J. 118
Fields, J. 51
Filippi, M. 124
Fim, N. 108
Finkel, R.S. 100
Januleviciene, I.  132
Jaswal, P.  51
Javdani Yekta, M.  88
Jayadevan, E.R.  37
Jayasinghe, C.  69
Jeon, B.  71, 79
Jeong, H.B.  88
Jeong, H.Y.  88
Jinnah, H.  53, 72
Jin, X.M.  67
Jitprapaikulsan, J.  94
Joghatayi, M.T.  94
John, S.  88
Jones, D.  51
Jordanova, A.  100
Joyce, E.  43, 56
Joyce, N.C.  132
József, J.  67
Jumah, M.  39
Jung, K.H.  88
Kaji, R.  65, 73, 78, 121
Kajita, Y.  87
Kalidas, K.  107
Kamble, N.  118
Kanagarajan, A.  57
Kanda, T.  114
Kang, M.K.  88
Kanhai, K.M.S.  94
Kantarci, K.  51
Kappos, L.  69, 94
Kaps, M.  38, 44
Karaszewski, B.  69
Kargiotos, O.  127
Karpov, S.  132
Kasatkin, D.  94
Kaspar, B.  100
Katabi, D.  98
Katoch, D.  107
Katrak, S.  74
Kaura, S.  37
Kaur, H.  88
Kavanagh, S.  100
Kawata, Y.  39
Kaya, N.  75
Kayed, D.M.  85, 91
Kayyali, H.  57
Keller, B.  87
Kenchaiah, R.  117
Kennard, C.  61, 87, 132
Kernbauer, E.  100
Kesav, P.  37
Kesraoui, S.  65, 73
Khalil, H.  131
Khalil, M.  57
Khamis, C.  118
Khan, F.  100
Khanolkar, D.  37
Khan, S.  57
Khidiyatova, I.  87
Khoury, S.  35, 42, 48, 54
Khurana, D.  131
Kiani, A.  88
Kiernan, M.  78, 85, 100, 115
Kim, B.J.  88
Kim, C.  88
Kim, C.R.  131
Kim, H.  113
Kim, J.  88
Kim, J.S.  106, 111, 122
Kim, J.T.  88
Kim, T.J.  88
Kimura, J.  52
Kim, Y.  88
Kirschner, J.  100
Kleiter, I.  39
Knapman, D.  51
Kochen, S.  117
Koduri, V.K.C.  39
Koendgen, H.  69, 94
Ko, J.Y.  113
Kollu, R.  108
Komendziński, J.  69
Koo, K.I.  131
Korczyn, A.D.  51
Koroshetz, W.J.  121
Ko, S.B.  88
Kostic, V.  100
Kovacs, N.  67
Krakauskaite, S.  112
Krbot Skoric, M.  69
Krieger, D.  127
Krishnamoorthy, E.  36, 43, 50, 105
Kukreja, P.  67
Kulkarni, S.  37
Kulshreshtha, D.  75
Kumaran, S.  88
Kumaran, S.S.  37
Kumar, N.  45, 67
Kumar Pal, P.  118
Kumar, S.  57
Kumpaitiene, B.  112
Kunju, P.A.M.  45, 112, 131-132
Kuntz, N.L.  100
Kuroda, Y.  132
Kurra, V.H.Y.  113
Kusunoki, S.  100
Kuzenkova, L.  93
Laczó, J.  51
Lal, V.  65, 73, 85, 90, 107, 127
Lambert, C.  118
Lambon Ralph, M.  84
Lane, R.  67
Lanteri-Minet, M.  84
Larsson, N.G.  49
Lastovka, V.  93
Lazar, L.M.  117
Leavitt, B.  67
Lee, B.C.  88
Lee, B.I.  54, 72
Lee, C.H.  88
Lee, E.J.  88
Lee, J.  88
Lee, J.H.  88
Lee, J.S.  88
Lee, N.C.  67
Lees, A.  118
Lee, S. H.  88
Lee, S.J.  113
Leger, J.  83
Lerch, O.  51
Le Rhun, E. 71, 110
Le, T.H. 131
Leuzzi, V. 118
Levin, O. 51
Lewis, S. 68, 74, 77, 83, 87, 106, 111
Leyva-Rendón, A. 127
Li, J.L. 39
Li, K. 45
Limachi, D. 107
Lim, J.S. 88
Ling, H. 40
Lipton, R.B. 107
Li, S. 117
L’Italien, J. 100
Liu, C.C. 51
Liu, C.Y. 39
Liu, J. 37, 69, 113
Liu, J.C. 39
Liu, M. 37, 88
Liu, Y. 51
Li, X.L. 112
Li, Y. 39
Li, Y.H. 67, 94
Li, Y.R. 67
Lochmuller, H. 75
Logroscino, G. 126
Long, Z. 112
Lopez, C. 128
Lopez, M. 37
Lourenco, S. 88
Luan, G. 117
Lucas, J. 51
Lucinskas, P. 132
Lu, C.J. 51
Lu, D. 113
Luvsannorov, O. 107
Lylk, P. 37
Ma, C.G. 39, 67, 94
Machulda, M. 51
Maciulaityte, E. 132
Madduru, N.S. 37
Magalhaes, D. 118
Magnierou, A.M. 117
Mazghanov, R. 87
Mahapatro, S. 45
Mahmoud, A. 93
Maiti, P. 67, 113
Malhotra, H. 45, 75
Malhotra, H.S. 39, 45
Malhotra, K. 75
Malik, R. 128
Malik, Y. 57
Malueka, R.G. 132
Mamychch, T. 69
Mancini, C. 127
Mandal, J. 75
Mandep, M. 131
Mandorah, Y. 108
Manfredi, G. 56
Manfrini, M. 69
Mangialasche, F.
Manianagatt, S. 37
Manna, R. 108, 118
Maramattom, B. 45, 113
Márk, H. 67
Markova, H. 51
Markovic, V. 100
Maroti, D. 132
Marques, A. 118
Martin, E.C. 87
Martinovic, V. 94
Maruyama, M. 132
Masdeu, J. 35, 42, 103, 113, 124
Mashhadinejad, M.
Masters, C. 70
Mateen, F. 117
Matoska, V. 51
Matuskova, V. 51
Maximov, V. 108
McCabe, S. 107
McNamara, J. 94
Mead, S. 124, 129
Medeiros, E. 127
Medina, M. 35, 52, 84, 89
Mehrpoor, M. 88
Mehta, L. 69
Mekky, J. 69
Melake, M. 93
Mendell, J.R. 100
Mendes Pereira, V.
Meng, S. 44, 65
Menon, B. 79
Mercuri, E. 100
Mergiannini, M. 100
Mesaros, S. 94, 100
Meshram, C. 35, 89, 132
Miao, Q. 67, 94
Mijajlovic, M. 100
Milea, D. 65, 90
Milone, M. 109
Milo, R. 42
Minz, R. 107
Mizawa, Z. 88, 94
Miyagawa, T. 51
Miyasaka, J. 76-77, 92, 123, 129
Mizusawa, H. 124, 129
Mochizuki, H. 132
Mo, H. 88
Mohamed Ahmed, K.
Mohammed Abdoh, R.
Mojtahed, M. 94, 107
Montalban, X. 35, 42, 48, 54, 87, 94
Montioli, R. 118
Morcinek, C. 94
Morris, J. 58
Mostile, G. 108, 118
Motamed, M. 94
Moulin, T. 127
Mounia, R. 64
Mouthon, M. 127
Moviglia Brandolino, M.T.
Moviglia, G.A. 127
Mukherjee, A. 51
Mulas, D. 87
Mulyadi, R. 94
Mun, S.A. 131
Muntoni, F. 100
Muresanu, D. 99, 131
Murofushi, T. 127
Murray, M. 51
<table>
<thead>
<tr>
<th>Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Musa, A.</td>
<td>93</td>
</tr>
<tr>
<td>Mustafa, A.</td>
<td>57</td>
</tr>
<tr>
<td>Myers, L.</td>
<td>117</td>
</tr>
<tr>
<td>Myint, M.Z.</td>
<td>132</td>
</tr>
<tr>
<td>Nabbout, R.</td>
<td>41</td>
</tr>
<tr>
<td>Naddaf, E.</td>
<td>75</td>
</tr>
<tr>
<td>Nafea, H.</td>
<td>57</td>
</tr>
<tr>
<td>Naffissi, S.</td>
<td>75</td>
</tr>
<tr>
<td>Naffissi, S.</td>
<td>79</td>
</tr>
<tr>
<td>Nagarjunakonda, V.S.</td>
<td>39</td>
</tr>
<tr>
<td>Nagesh, C.</td>
<td>37</td>
</tr>
<tr>
<td>Naik, K.R.</td>
<td>87</td>
</tr>
<tr>
<td>Naik, R.</td>
<td>112</td>
</tr>
<tr>
<td>Nair, P.P.</td>
<td>127</td>
</tr>
<tr>
<td>Naismith, R.T.</td>
<td>69</td>
</tr>
<tr>
<td>Nafajina, S.</td>
<td>94</td>
</tr>
<tr>
<td>Nakamura, Y.</td>
<td>100</td>
</tr>
<tr>
<td>Nalini, A.</td>
<td>75</td>
</tr>
<tr>
<td>Nana Rahamatou, A.</td>
<td>117</td>
</tr>
<tr>
<td>Narasimhan, L.</td>
<td>127</td>
</tr>
<tr>
<td>Narasimhan, S.</td>
<td>118</td>
</tr>
<tr>
<td>Nashi, S.</td>
<td>75, 100</td>
</tr>
<tr>
<td>Nasim, E.</td>
<td>39</td>
</tr>
<tr>
<td>Natarajan, B.</td>
<td>45</td>
</tr>
<tr>
<td>Natsagdorj, L.</td>
<td>127</td>
</tr>
<tr>
<td>Nawito, A.</td>
<td>57</td>
</tr>
<tr>
<td>Nayak, D.</td>
<td>57</td>
</tr>
<tr>
<td>Nayak, L.</td>
<td>63, 110</td>
</tr>
<tr>
<td>Nayanajeehwi, G.</td>
<td>69</td>
</tr>
<tr>
<td>Nazzal, M.</td>
<td>131</td>
</tr>
<tr>
<td>Ndiaye, M.</td>
<td>117</td>
</tr>
<tr>
<td>Negrotto, L.</td>
<td>95</td>
</tr>
<tr>
<td>Nehra, A.</td>
<td>88</td>
</tr>
<tr>
<td>Neves, V.</td>
<td>88</td>
</tr>
<tr>
<td>Newcombe, V.</td>
<td>49</td>
</tr>
<tr>
<td>Nguyen, C.T.</td>
<td>131</td>
</tr>
<tr>
<td>Nicholson, T.</td>
<td>117</td>
</tr>
<tr>
<td>Nicolelis, M.</td>
<td>121</td>
</tr>
<tr>
<td>Nicoletti, A.</td>
<td>108, 118</td>
</tr>
<tr>
<td>Nicotra, A.</td>
<td>67</td>
</tr>
<tr>
<td>Niederkorn, K.</td>
<td>38</td>
</tr>
<tr>
<td>Nikolaenko, M.</td>
<td>93</td>
</tr>
<tr>
<td>Ning, X.</td>
<td>107</td>
</tr>
<tr>
<td>Nishino, I.</td>
<td>75</td>
</tr>
<tr>
<td>Nogueira, M.</td>
<td>113</td>
</tr>
<tr>
<td>Norrving, B.</td>
<td>62</td>
</tr>
<tr>
<td>Novakovic, I.</td>
<td>100</td>
</tr>
<tr>
<td>Nutakki, A.</td>
<td>45</td>
</tr>
<tr>
<td>Oakes, T.</td>
<td>107</td>
</tr>
<tr>
<td>Oak, P.</td>
<td>88</td>
</tr>
<tr>
<td>Obaid, M.</td>
<td>72</td>
</tr>
<tr>
<td>Obeid, T.</td>
<td>57</td>
</tr>
<tr>
<td>Oday Hamet, A.</td>
<td>108</td>
</tr>
<tr>
<td>Odintsova, G.</td>
<td>93</td>
</tr>
<tr>
<td>Ogrinc, F.G.</td>
<td>100</td>
</tr>
<tr>
<td>Ogun, A.</td>
<td>99</td>
</tr>
<tr>
<td>Ogunniyi, A.</td>
<td>96, 105</td>
</tr>
<tr>
<td>Ohannessian, R.</td>
<td>127</td>
</tr>
<tr>
<td>Oh, M.S.</td>
<td>88</td>
</tr>
<tr>
<td>Oidovdorj, G.</td>
<td>127</td>
</tr>
<tr>
<td>Ojha, P.</td>
<td>69</td>
</tr>
<tr>
<td>Okada, H.</td>
<td>87</td>
</tr>
<tr>
<td>Okuda, S.</td>
<td>87</td>
</tr>
<tr>
<td>Oliver, D.</td>
<td>92, 123, 129</td>
</tr>
<tr>
<td>Ortiz Catalan, M.</td>
<td>96</td>
</tr>
<tr>
<td>Osakwe, N.</td>
<td>67</td>
</tr>
<tr>
<td>Owen, A.</td>
<td>61, 98</td>
</tr>
<tr>
<td>Pacheco-Barrios, K.</td>
<td>87</td>
</tr>
<tr>
<td>Paik, N.</td>
<td>43</td>
</tr>
<tr>
<td>Paik, N.J.</td>
<td>43</td>
</tr>
<tr>
<td>Palace, J.</td>
<td>39</td>
</tr>
<tr>
<td>Panandikar, G.</td>
<td>75</td>
</tr>
<tr>
<td>Pandey, S.</td>
<td>45</td>
</tr>
<tr>
<td>Panigrahi, M.</td>
<td>117</td>
</tr>
<tr>
<td>Panov, D.</td>
<td>108</td>
</tr>
<tr>
<td>Pardo-Vil-lamizar, C.A.</td>
<td>84</td>
</tr>
<tr>
<td>Parimi, N.S.P.</td>
<td>108</td>
</tr>
<tr>
<td>Parisi, J.</td>
<td>51</td>
</tr>
<tr>
<td>Park, J.M.</td>
<td>88</td>
</tr>
<tr>
<td>Parveen, S.</td>
<td>100</td>
</tr>
<tr>
<td>Pashov, A.</td>
<td>131</td>
</tr>
<tr>
<td>Pashova, O.</td>
<td>131</td>
</tr>
<tr>
<td>Patidar, B.</td>
<td>131</td>
</tr>
<tr>
<td>Patkar, D.</td>
<td>88</td>
</tr>
<tr>
<td>Patti, F.</td>
<td>39</td>
</tr>
<tr>
<td>Pavlova, E.</td>
<td>37</td>
</tr>
<tr>
<td>Payne, S.</td>
<td>86, 129</td>
</tr>
<tr>
<td>Pearlman, E.</td>
<td>93</td>
</tr>
<tr>
<td>Pekmezovic, T.</td>
<td>94</td>
</tr>
<tr>
<td>Pereira, B.</td>
<td>118</td>
</tr>
<tr>
<td>Peric, S.</td>
<td>75, 100</td>
</tr>
<tr>
<td>Perren, F.</td>
<td>127</td>
</tr>
<tr>
<td>Perussi, E.</td>
<td>34, 57</td>
</tr>
<tr>
<td>Petersen, R.</td>
<td>51, 58</td>
</tr>
<tr>
<td>Petkus, V.</td>
<td>112, 132</td>
</tr>
<tr>
<td>Phyru, K.P.</td>
<td>132</td>
</tr>
<tr>
<td>Piano, C.</td>
<td>87</td>
</tr>
<tr>
<td>Piasecka-Styczynska, K.</td>
<td>87</td>
</tr>
<tr>
<td>Pick, S.</td>
<td>117</td>
</tr>
<tr>
<td>Picone, S.</td>
<td>127</td>
</tr>
<tr>
<td>Piechowski, B.</td>
<td>88</td>
</tr>
<tr>
<td>Piguet, O.</td>
<td>90, 100, 112</td>
</tr>
<tr>
<td>Pimentel-Silva, L.</td>
<td>113</td>
</tr>
<tr>
<td>Pinheiro, J.</td>
<td>108</td>
</tr>
<tr>
<td>Pishjoo, M.</td>
<td>88</td>
</tr>
<tr>
<td>Pistorini, C.</td>
<td>43, 131</td>
</tr>
<tr>
<td>Pittcock, S.</td>
<td>94, 97, 125, 130</td>
</tr>
<tr>
<td>Plant-Borde-eneve, V.</td>
<td>85, 122</td>
</tr>
<tr>
<td>Plant, G.</td>
<td>61, 65, 73, 85, 90</td>
</tr>
<tr>
<td>Poewe, W.</td>
<td>118</td>
</tr>
<tr>
<td>Pogoryelova, O.</td>
<td>75</td>
</tr>
<tr>
<td>Polavarapu, K.</td>
<td>75, 100</td>
</tr>
<tr>
<td>Portaro, G.</td>
<td>108, 118</td>
</tr>
<tr>
<td>Pozo-Rosich, P.</td>
<td>91, 104</td>
</tr>
<tr>
<td>Pradhan, A.</td>
<td>94</td>
</tr>
<tr>
<td>Prajapati, K.</td>
<td>69</td>
</tr>
<tr>
<td>Prakash Mahajan, N.</td>
<td>75</td>
</tr>
<tr>
<td>Pramod, S.</td>
<td>131</td>
</tr>
<tr>
<td>Preethish-Kumar, V.</td>
<td>75</td>
</tr>
<tr>
<td>Preux, P.</td>
<td>84, 89, 96</td>
</tr>
<tr>
<td>Preux, P.M.</td>
<td>96</td>
</tr>
<tr>
<td>Pr, P.</td>
<td>112</td>
</tr>
<tr>
<td>Putnyaite, V.</td>
<td>132</td>
</tr>
<tr>
<td>Puttenger, G.</td>
<td>117</td>
</tr>
<tr>
<td>Pykett, M.</td>
<td>67</td>
</tr>
<tr>
<td>Qadi, N.</td>
<td>51, 78, 111</td>
</tr>
<tr>
<td>Qi, X.</td>
<td>69</td>
</tr>
</tbody>
</table>
Quidute Peroccco, A. 108
Rabilloud, M. 39
Rabinstein, A. 86, 92, 111
Rad, P. 88
Rafati, A. 88
Ragauskas, A. 112, 132
Raidah, A. 93
Rais, N. 57
Rajabkhah Ziaratgah, S. 75
Rajan, R. 127
Rakocevic-Stojanovic, V. 75
Rakocevic-Stojanovic, V. 100
Ram, A. 113
Ramachandran, D. 107
Ramirez-Campos, V. 127
Rammal, S. 57
Rammohan, K. 87
Ranawaka, U. 94
Ranjan, R. 51, 67
Rao, R.M. 57
Rascol, O. 118
Rascunà, C. 108, 118
Ravat, S. 75
Ravindranadh, C. 117
Razumovsky, A. 44
Rebocho, L. 88
Reddy, N. 75
Redkar, S. 37
Redkar, V. 37
Rei, K. 87
Reilly, M. 75, 85, 106, 115
Reis, J. 116
Respondek, G. 64
Reuter, U. 104, 107
Ribeiro Champi, P.A. 108
Riche, B. 39
Rider, F. 57
Rieckmann, P. 87, 94
Riffsy, M. 94
Riya, R. 51
Rocha, F. 118
Rodas, R. 107
Rojas, J. 107
Román, G. 116
Romeiro, F. 108
Rose Dawn, B. 117
Roser, F. 40
Roy, A. 51
Sabisz, A. 69
Sachdev, P. 43, 115
Sahraian, M. 94
Said, S. 69
Saigoh, K. 100
Saini, D. 51
Saini, J. 117
Saiz, A. 39
Sakadi, F. 117
Salih, M. 57, 75
Salomone, S. 108, 118
Samadzadeh, S. 94
Samochernyk, K. 93
Samochernyk, N. 93
Samukawa, M. 100
Sankhala, C. 131
Santos, A. 118
Sanwald Ducray, P. 67
Sara, B. 88
Sarma, P.S. 37
Sasan Nejad, P. 88
Satishchandra, P. 117
Sattaluri, S.J. 117
Savarese, M. 75
Savica, R. 51
Sawant, Y. 88
Sawchuk, T. 117
Saylor, D. 45
Schencck, C. 48, 54, 71
Schlegel, V. 67
Schmutzhard, E. 40, 65, 86
Schobel, S. 67
Schwarz, G. 117
Sciaccia, G. 108, 118
Seck, L.B. 117
Seda, J. 100
Seidi, O. 53
SELÇUK, D. 118
Semaru, M. 115
Semenov, R.V. 37
Senanayake, B. 69, 94
Seek Bae, J. 88
Seo, W.K. 88
Servais, L. 100
Servidei, S. 114
Sewram, N. 67
Shaafi, S. 117
Shabestari, M. 88
Shahid Hussain, F. 45
Shaibani, A. 58
Shaikh, A. 122, 128
Shakir, R. 35, 45, 62, 87, 103, 121
Shaleh, S. 132
Shamieh, O. 86, 129
Shamim, U. 100
Sharma, A. 98
Sharma, P. 39, 45, 100
Sharp, D. 49, 55-56
Shereef, A. 127
Shieh, P.B. 100
Shosha, E. 39, 97, 106, 111
Shradhha, R. 37
Shulga, O. 69
Siaudvytyte, L. 132
Siddig, A. 112
Silva Rodrigues, B. 108
Singh, A.K. 45
Singh, G. 51
Singh, J. 100
Singh, P. 107
Singh, R. 69
Sinha, S. 117
Sirvinskas, E. 112
Siva, A. 54
Smith, A. 67
<table>
<thead>
<tr>
<th>Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soares-da-Silva, P.</td>
<td>118</td>
</tr>
<tr>
<td>Sokic, D.</td>
<td>94</td>
</tr>
<tr>
<td>Solomatin, Y.</td>
<td>57</td>
</tr>
<tr>
<td>Sommer, C.</td>
<td>125, 128</td>
</tr>
<tr>
<td>Song, F.</td>
<td>39</td>
</tr>
<tr>
<td>Song, L.J.</td>
<td>67, 94</td>
</tr>
<tr>
<td>Song, Q.</td>
<td>88</td>
</tr>
<tr>
<td>Soni, G.</td>
<td>69</td>
</tr>
<tr>
<td>Souleymane, B.</td>
<td>117</td>
</tr>
<tr>
<td>Sow, A.D.</td>
<td>117</td>
</tr>
<tr>
<td>Spector, S.A.</td>
<td>100</td>
</tr>
<tr>
<td>Spierings, E.L.H.</td>
<td>107</td>
</tr>
<tr>
<td>Sproule, D.M.</td>
<td>100</td>
</tr>
<tr>
<td>Sreedhaean, M.</td>
<td>45</td>
</tr>
<tr>
<td>Sreedharan, M.</td>
<td>112, 131</td>
</tr>
<tr>
<td>Sreekanta, S.</td>
<td>108</td>
</tr>
<tr>
<td>Srivastava, A.</td>
<td>100</td>
</tr>
<tr>
<td>Srivastava, M.V.P.</td>
<td>37</td>
</tr>
<tr>
<td>Srivastava, P.</td>
<td>75, 127</td>
</tr>
<tr>
<td>Staikov, I.</td>
<td>87</td>
</tr>
<tr>
<td>Stamelou, M.</td>
<td>40, 67, 72</td>
</tr>
<tr>
<td>Stark, R.</td>
<td>61, 85, 91, 95, 114, 117, 121, 133</td>
</tr>
<tr>
<td>Staykov, D.</td>
<td>47</td>
</tr>
<tr>
<td>Stevens, J.</td>
<td>58, 62</td>
</tr>
<tr>
<td>Stevic, Z.</td>
<td>100</td>
</tr>
<tr>
<td>Struhal, W.</td>
<td>76-77</td>
</tr>
<tr>
<td>Subramanian, P.</td>
<td>65, 85</td>
</tr>
<tr>
<td>Sui, R.X.</td>
<td>67, 94</td>
</tr>
<tr>
<td>Suizu, R.</td>
<td>127</td>
</tr>
<tr>
<td>Sundarachari, N.V.</td>
<td>45</td>
</tr>
<tr>
<td>Sun, J.</td>
<td>57</td>
</tr>
<tr>
<td>Sun, M.Y.</td>
<td>67</td>
</tr>
<tr>
<td>Sunnerhagen, K.S.</td>
<td>34</td>
</tr>
<tr>
<td>Sun, Y.</td>
<td>51</td>
</tr>
<tr>
<td>Surculento, A.</td>
<td>107</td>
</tr>
<tr>
<td>Surolia, V.</td>
<td>100</td>
</tr>
<tr>
<td>Suzuki, D.</td>
<td>127</td>
</tr>
<tr>
<td>Svakdziene, M.</td>
<td>112</td>
</tr>
<tr>
<td>Svetel, M.</td>
<td>100</td>
</tr>
<tr>
<td>Syed, S.</td>
<td>87</td>
</tr>
<tr>
<td>Sylaja, P.</td>
<td>127</td>
</tr>
<tr>
<td>Sylaja, P.N.</td>
<td>37</td>
</tr>
<tr>
<td>Tabrizi, S.</td>
<td>67, 83</td>
</tr>
<tr>
<td>Taha, F.</td>
<td>117</td>
</tr>
<tr>
<td>Taheri, N.</td>
<td>88</td>
</tr>
<tr>
<td>Tai, C.H.</td>
<td>67</td>
</tr>
<tr>
<td>Takahashi, R.</td>
<td>33, 64, 67</td>
</tr>
<tr>
<td>Takkar Kapila, A.</td>
<td>107</td>
</tr>
<tr>
<td>Tanboon, J.</td>
<td>75</td>
</tr>
<tr>
<td>Tania, E.</td>
<td>88</td>
</tr>
<tr>
<td>Tashani, O.</td>
<td>123</td>
</tr>
<tr>
<td>Tawfeek, A.A.</td>
<td>57</td>
</tr>
<tr>
<td>Tayeb, H.</td>
<td>108</td>
</tr>
<tr>
<td>Tebartz Van Elst, L.</td>
<td>36</td>
</tr>
<tr>
<td>Tein, I.</td>
<td>105, 110, 125</td>
</tr>
<tr>
<td>Tennekoon, G.</td>
<td>100</td>
</tr>
<tr>
<td>Tepaev, R.</td>
<td>93</td>
</tr>
<tr>
<td>Terada, Y.</td>
<td>39</td>
</tr>
<tr>
<td>Terruzzi, A.</td>
<td>127</td>
</tr>
<tr>
<td>Thakre, M.</td>
<td>41, 131</td>
</tr>
<tr>
<td>Thambisetty, M.</td>
<td>43</td>
</tr>
<tr>
<td>Thamm, N.</td>
<td>117</td>
</tr>
<tr>
<td>Thankappan, B.</td>
<td>45</td>
</tr>
<tr>
<td>Thant, K.Z.</td>
<td>132</td>
</tr>
<tr>
<td>Thit, W.M.</td>
<td>132</td>
</tr>
<tr>
<td>Thomas, A.</td>
<td>100</td>
</tr>
<tr>
<td>Thompson, A.</td>
<td>48, 54, 83, 103</td>
</tr>
<tr>
<td>Thöny, B.</td>
<td>118</td>
</tr>
<tr>
<td>Thorat, N.</td>
<td>112</td>
</tr>
<tr>
<td>Thumbi, M.</td>
<td>132</td>
</tr>
<tr>
<td>Tilikete, C.</td>
<td>73, 85, 106, 111</td>
</tr>
<tr>
<td>Tintore, M.</td>
<td>89, 103</td>
</tr>
<tr>
<td>Tizzano, E.</td>
<td>100</td>
</tr>
<tr>
<td>Toffa, D.H.</td>
<td>117</td>
</tr>
<tr>
<td>Tomson, T.</td>
<td>47</td>
</tr>
<tr>
<td>Topaloglu, H.</td>
<td>105, 125</td>
</tr>
<tr>
<td>Tracey, I.</td>
<td>83</td>
</tr>
<tr>
<td>Traylor, M.</td>
<td>113</td>
</tr>
<tr>
<td>Tremlett, H.</td>
<td>48, 94-95, 116</td>
</tr>
<tr>
<td>Trenkwalder, C.</td>
<td>63, 71</td>
</tr>
<tr>
<td>Trinka, E.</td>
<td>54, 72, 92</td>
</tr>
<tr>
<td>Truong, D.</td>
<td>65, 73, 83</td>
</tr>
<tr>
<td>Tsai, C.P.</td>
<td>39</td>
</tr>
<tr>
<td>Tseng, S.H.</td>
<td>67</td>
</tr>
<tr>
<td>Tsivgoulis, G.</td>
<td>127</td>
</tr>
<tr>
<td>Tsubota, M.</td>
<td>127</td>
</tr>
<tr>
<td>Tucker, L.</td>
<td>99</td>
</tr>
<tr>
<td>Tufo, T.</td>
<td>87</td>
</tr>
<tr>
<td>Udd, B.</td>
<td>75</td>
</tr>
<tr>
<td>Ugawa, Y.</td>
<td>43, 88</td>
</tr>
<tr>
<td>Upadhayya, H.</td>
<td>93</td>
</tr>
<tr>
<td>Uppala, V.</td>
<td>39</td>
</tr>
<tr>
<td>Vaccari, G.</td>
<td>129</td>
</tr>
<tr>
<td>Vadapalli, R.</td>
<td>117</td>
</tr>
<tr>
<td>Vadiyala, C.</td>
<td>113, 118</td>
</tr>
<tr>
<td>Valente, E.M.</td>
<td>33</td>
</tr>
<tr>
<td>Valente, K.</td>
<td>117</td>
</tr>
<tr>
<td>Van, B.</td>
<td>40, 47, 65</td>
</tr>
<tr>
<td>Van Dijkman, S.</td>
<td>94</td>
</tr>
<tr>
<td>Van, M.</td>
<td>63, 71, 105, 110</td>
</tr>
<tr>
<td>Vargas, S.</td>
<td>107</td>
</tr>
<tr>
<td>Varsha, P.</td>
<td>132</td>
</tr>
<tr>
<td>Vasenina, E.</td>
<td>51</td>
</tr>
<tr>
<td>Vasireddy, S.</td>
<td>108</td>
</tr>
<tr>
<td>Vedartham, V.</td>
<td>37</td>
</tr>
<tr>
<td>Vellinigiri, B.</td>
<td>93</td>
</tr>
<tr>
<td>Vemuri, R.</td>
<td>45</td>
</tr>
<tr>
<td>Vengalil, S.</td>
<td>75, 100</td>
</tr>
<tr>
<td>Vengurlekar, P.</td>
<td>131</td>
</tr>
<tr>
<td>Ventura, A.</td>
<td>107</td>
</tr>
<tr>
<td>Verena, R.C.</td>
<td>107</td>
</tr>
<tr>
<td>Verma, M.</td>
<td>88</td>
</tr>
<tr>
<td>Verma, R.</td>
<td>39, 45, 51, 67</td>
</tr>
<tr>
<td>Vermersch, P.</td>
<td>87</td>
</tr>
<tr>
<td>Vibha, D.</td>
<td>100</td>
</tr>
<tr>
<td>Vidal, T.</td>
<td>118</td>
</tr>
<tr>
<td>Videnovic, A.</td>
<td>48, 54, 63</td>
</tr>
<tr>
<td>Vikto, V.</td>
<td>67</td>
</tr>
<tr>
<td>Vila, J.F.</td>
<td>37</td>
</tr>
<tr>
<td>Villca, D.</td>
<td>107</td>
</tr>
<tr>
<td>Vinny, P.W.</td>
<td>127</td>
</tr>
<tr>
<td>Vinodhanand, G.</td>
<td>113, 118</td>
</tr>
<tr>
<td>Vishnu, V.</td>
<td>127</td>
</tr>
<tr>
<td>Viswanathan, L.G.</td>
<td>117</td>
</tr>
<tr>
<td>Voltattorni, C.B.</td>
<td>118</td>
</tr>
<tr>
<td>Von Oertzen, T.J.</td>
<td>117</td>
</tr>
<tr>
<td>Vooturi, S.</td>
<td>117</td>
</tr>
</tbody>
</table>
RECOGNITION
ACKNOWLEDGEMENTS
& INDUSTRY SUPPORT

WCN 2019
XXIV WORLD CONGRESS OF NEUROLOGY
DUBAI, UNITED ARAB EMIRATES, OCTOBER 27-31 2019
ACKNOWLEDGEMENTS

The Organizing Committee of WCN 2019 would like to express its gratitude and acknowledge the following companies and organizations for their generous support of the XXIV World Congress of Neurology.

PLATINUM

SILVER

GENERAL SUPPORTER
EXHIBITOR

EDUCATIONAL GRANT

In Support of an Educational Grant to the WCN 2019 Congress.
INDUSTRY SYMPOSIA

SUNDAY, OCTOBER 27 2019

NMOSD AND MS: TIME TO SHIFT OUR FOCUS

SYMPOSİUM IS ORGANIZED AND SUPPORTED BY

CHAIR: Bassem Yamout, Lebanon

SUNDAY, OCTOBER 27 | 13:00 - 14:30 | SHEIKH RASHID A

13:00-13:05 Welcome and Introduction
Bassem Yamout, Lebanon

13:05-13:35 NMOSD: A journey from pathogenesis to diagnosis
Brian Weinshenker, USA

13:35-13:55 Disease progression: Changing how we think about MS
Xavier Montalban, Canada

13:55-14:20 Ocrelizumab: Growing evidence from clinical trials on longer term outcomes
Bassem Yamout, Lebanon

14:20-14:30 Q&A and closing remarks
All faculty
SUNDAY, OCTOBER 27 2019

CHALLENGING OUR UNDERSTANDING OF THE MS SPECTRUM: AN EXPERT PANEL DISCUSSION

SYMPOSIUM IS ORGANIZED AND SUPPORTED BY

CHAIR: Jihad Inshasi, United Arab Emirates

SUNDAY, OCTOBER 27 | 13:00 - 14:30 | SHEIKH RASHID B

13:00-13:15 Chair’s opening and welcome
Jihad Inshasi, United Arab Emirates

13:15-13:35 A perspective change: reframing progression in MS
Raed Alroughani, Kuwait

13:35-13:55 Signal to noise: how do we better detect the transition to SPMS?
Magd Zakaria, Egypt

13:55-14:15 How we should slow down disease progression & to EXPAND possibilities
Sven Schippling, Switzerland

14:15-14:30 Q&A and closing remarks
All faculty
MONDAY, OCTOBER 28 2019

THE EVOLVING MANAGEMENT OF PATIENTS WITH EARLY AND LATER-ONSET SMA

SYMPOSIUM IS ORGANIZED AND SUPPORTED BY

Chair: Waseem Fathalah, UAE

MONDAY, OCTOBER 28 | 13:00 - 14:30 | SHEIKH RASHID A

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00–13:05</td>
<td>Welcome and introduction</td>
<td>Waseem Fathalah, UAE</td>
</tr>
<tr>
<td>13:05–13:20</td>
<td>Recognizing the patient with SMA</td>
<td>Eugenio Mercuri, Italy</td>
</tr>
<tr>
<td>13:20–13:40</td>
<td>Experience of managing patients with early and later-onset SMA with nusinersen</td>
<td>Francesco Muntoni, United Kingdom</td>
</tr>
<tr>
<td>13:40–14:00</td>
<td>Managing the adult patient with SMA: setting treatment expectations in the real world</td>
<td>Albert Ludolph, Germany</td>
</tr>
<tr>
<td>14:00–14:20</td>
<td>Real-world experience of managing SMA in the UAE: practical experience and challenges</td>
<td>Waseem Fathalah, UAE</td>
</tr>
<tr>
<td>14:20–14:30</td>
<td>Discussion and Q&amp;A</td>
<td>All faculty</td>
</tr>
</tbody>
</table>
TUESDAY, OCTOBER 29 2019

GENE THERAPY FOR SPINAL MUSCULAR ATROPHY: TRANSLATING RESEARCH INTO REALITY

SYMPOSIUM IS ORGANIZED AND SUPPORTED BY

CHAIR: Abdulaziz Saeid Al-Saman, Saudi Arabia

TUESDAY, OCTOBER 29 | 13:00-14:30 | SHEIKH RASHID A

13:00-13:10 Welcome and introduction
Abdulaziz Saeid Al-Saman, Saudi Arabia

13:10-13:25 Overview of spinal muscular atrophy (SMA) clinical course
Fouad Al-Ghamdi, Saudi Arabia

Samiah Al-Zaidy, USA

13:55-14:15 Practical aspects of gene therapy including biosafety
Daniel Gibbs, USA

14:15-14:25 Panel discussion
All Speakers

14:25-14:30 Symposium close
Abdulaziz Saeid Al-Saman, Saudi Arabia
WEDNESDAY, OCTOBER 30 2019

GETTING AHEAD OF MIGRAINE: A CASE BASED APPROACH

SYMPOSIUM IS ORGANIZED AND SUPPORTED BY Lilly

CHAIR: Uwe Reuter, Germany

WEDNESDAY, OCTOBER 30 | 13:00 - 14:30 | SHEIKH MAKTOUM D

13:00 – 13:05 Chairperson Welcome and Introductions
Uwe Reuter, Germany

Patricia Pozo-Rosich, Spain

Uwe Reuter, Germany

Rima Dafer, United States

14:15 – 14:30 Panel Discussion, Questions and Answers
All faculty
# LIST OF EXHIBITORS

<table>
<thead>
<tr>
<th>Exhibitor</th>
<th>Booth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allm</td>
<td>29</td>
</tr>
<tr>
<td>American Academy of Neurology</td>
<td>31B</td>
</tr>
<tr>
<td>AveXis, Inc.</td>
<td>02</td>
</tr>
<tr>
<td>BESA GmbH</td>
<td>37</td>
</tr>
<tr>
<td>Biologix FZco</td>
<td>13</td>
</tr>
<tr>
<td>Cadwell Industries, Inc.</td>
<td>27</td>
</tr>
<tr>
<td>DEYMED Diagnostic</td>
<td>33</td>
</tr>
<tr>
<td>Dubai Health Authority</td>
<td>31</td>
</tr>
<tr>
<td>EB NEURO S.p.A.</td>
<td>34</td>
</tr>
<tr>
<td>ELSEVIER</td>
<td>32</td>
</tr>
<tr>
<td>Emirates Neurology Society</td>
<td>12</td>
</tr>
<tr>
<td>EMS Handelsges.m.b.H.</td>
<td>36</td>
</tr>
<tr>
<td>GlaxoSmithKline</td>
<td>10A</td>
</tr>
<tr>
<td>IMPETO MEDICAL</td>
<td>40</td>
</tr>
<tr>
<td>Lilly</td>
<td>03</td>
</tr>
<tr>
<td>Mayo Clinic Laboratories</td>
<td>47</td>
</tr>
<tr>
<td>Micromed</td>
<td>38</td>
</tr>
<tr>
<td>Moleac Pte Ltd</td>
<td>10</td>
</tr>
<tr>
<td>Natus Medical Incorporated</td>
<td>48</td>
</tr>
<tr>
<td>Neurosoft</td>
<td>30</td>
</tr>
<tr>
<td>Nihon Kohden Corporation</td>
<td>26</td>
</tr>
<tr>
<td>Novartis Middle East FZE</td>
<td>06</td>
</tr>
<tr>
<td>PTC Therapeutics Gene Therapy, Inc</td>
<td>25</td>
</tr>
<tr>
<td>Ricoh Company, LTD.</td>
<td>31A</td>
</tr>
<tr>
<td>Roche Pharmaceuticals Middle East FZCO</td>
<td>17</td>
</tr>
<tr>
<td>Sanofi</td>
<td>24</td>
</tr>
<tr>
<td>The Searle Company Limited</td>
<td>28</td>
</tr>
<tr>
<td>WCNR 2020 jointly with SOFMER 2020 EHF 2020</td>
<td>10B</td>
</tr>
<tr>
<td>Wolters Kluwer</td>
<td>23</td>
</tr>
<tr>
<td>WORLD FEDERATION OF NEUROLOGY (WFN)</td>
<td>11</td>
</tr>
</tbody>
</table>
EXHIBITOR & SPONSOR COMPANY PROFILES

ALLM
Dhcc, Building 27, E003
Dubai
36444
United Arab Emirates
Booth #: 29
https://www.allm.net
Named after the phrase ‘all medical,’ Allm Inc. is dedicated to shaping healthcare. We seek to benefit society by launching next-generation technologies and medical communications platforms for the healthcare industry. Using cloud technologies and smart devices, we enable seamless communications among healthcare professionals anytime, anywhere.

AMERICAN ACADEMY OF NEUROLOGY
201 Chicago Avenue
Minneapolis
55415
USA
Booth #: 31B
http://www.aan.com
The American Academy of Neurology (AAN) is global! Visit booth 31B to discover what the AAN can do for you. Members around the world contribute significantly to the success of the AAN, including an impressive impact on Neurology® journal manuscript submissions, Annual Meeting attendance, and membership. You don’t have to live in the United States to experience the same top-quality education and science programming, clinical guidelines, publications, and more that our US members enjoy. The AAN is the world’s largest association of neurologists and neurology professionals with more than 36,000 members, including 21% of membership outside the US.

AVEXIS, INC.
2275 Half Day Road, Suite 200
Bannockburn
60015
USA
Booth #: 02
https://www.avexis.com
AveXis is a clinical-stage gene therapy company relentlessly focused on bringing gene therapy out of the lab and into the clinical setting for patients and families devastated by rare and life-threatening neurological genetic diseases.
BESA GMBH
Freihamer Str. 18
Graefelfing
82166
Germany
Booth #: 37
http://www.besa.de
BESA GmbH was founded in 1995 by Professor Michael Scherg. BESA Research is the leading commercial software package for EEG and MEG data analysis. Analysis options range from pre-processing to advanced source analysis, coherence, and statistical analysis. BESA Research is used in more than 1500 universities and hospitals world-wide.

BIOGEN INTERNATIONAL GMBH
Neuhofstrasse 30
Baar
6340
Switzerland
https://www.biogen.com/
At Biogen, we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 and today has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy and is focused on advancing neuroscience research programs in MS and neuroimmunology, Alzheimer’s disease and dementia, movement disorders, neuromuscular disorders, acute neurology, neurocognitive disorders, pain and ophthalmology. Biogen also commercializes biosimilars of advanced biologics.

BIOLOGIX FZCO
Dubai Airport Free Zone
WH C17
United Arab Emirates
Booth #: 13
Biologix FZco, a company organized and existing under the laws of the United Arab Emirates, was incorporated in the Dubai Airport Free Zone in September 2002 as a regional supplier and promoter of Biotechnology products. Biologix FZco is a service provider to Pharmaceutical and Biotech companies and performs Named Patient Supply, market access, promotion and sales, detailing, logistics, registration, medical and disease awareness activities including Pharmacovigilance and Risk Management Plan, on behalf of its partners in the Middle East and North Africa (MENA) markets.
CADWELL INDUSTRIES, INC.
909 N. Kellogg St
Kennewick
99336
USA
Booth #: 27
https://www.cadwell.com
Cadwell celebrates 40 years of delivering neurophysiology solutions. Family-owned in Washington State, USA, Cadwell combines customer input, employee expertise and USA-made components to serve our global customers. We develop Arc EEG for at-home ambulatory and clinical use, EMU, and LTM; the innovative Sierra Summit EMG/EP/NCS with optional integrated ultrasound; Cascade Surgical Studio IONM and CadX simulator; Easy III in-lab PSG and integrated ApneaTrak HSAT; CadLink Data Management; and neuro consumables. Our sales managers, support teams, and distributors serve physicians and medical centers worldwide. Cadwell: Helping you help others.

CELGENE
Route de Perreux 1
Boudry
2017
Switzerland
https://www.celgene.com/
Celgene International Sàrl, located in Boudry, in the Canton of Neuchâtel, Switzerland, is a wholly-owned subsidiary and International Headquarter of Celgene Corporation. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation.

DEYMED DIAGNOSTIC
Kudrnáčova 533
Hronov
54931
Czech Republic
Booth #: 33
http://www.deymed.com
The company was founded in 1997 and its first product was developing a 32 channel EEG device which was completed and sold in 1998. In the following years additional neurology products have been developed including EMG, PSG and TMS devices. The initial sales were to the Czech Republic but soon thereafter were offered in international markets. Due to the high level of innovation and modern design of the products, Deymed has become an established worldwide leader in neurology for both clinical and research applications.
EB NEURO S.P.A.
Via Pietro Fanfani 97/a
Florence
50127
Italy
Booth #: 34
http://ebneuro.com
EB Neuro is an historical worldwide player in design and manufacturing of Neurophysiology devices and it distributes its products all over the world. EB Neuro mission is to develop innovative ways to approach the traditional diagnostic methods which could allow the largest number of operators in this medical fields to achieve the most reliable results. EB Neuro Products Lines: - EEG/VideoEEG Systems, with Wi-Fi EEG/LTM, cEEG (Continuous EEG) and SLEEP Analysis - Holter EEG/PSG Systems - Neurodiagnosis Systems for ICU, aEEG (CFM) - EMG/NCS Systems, with EP/ERP functions - TMS and rTMS Systems (Repetitive Transcranial Magnetic Stimulation), also with Neuronavigation.

EHF 2020
14th European Headache Federation Congress
Date: 3–5 July 2020
Maritim Hotel Berlin
Stauffenbergstrasse 26
10785 Berlin
Germany
Booth #: 10B
www.ehf2020.com
New and exciting times are dawning, with a slew of new therapies underway: CGRP antibodies for migraine prophylaxis, lasmiditan as an alternative to triptans for acute therapy, atogepant, ubrogepant, possibly PACAP antibodies and more. That is why the motto “Head over Ache - Silver Lining Novel Treatments” was chosen. Physicians, psychologists, cost bearers, politicians, and those working in health care, must make sure that new as well as old treatments reach the right patients optimally. Therefore doctors and scientists from Europe and abroad, but also our partners EFIC, EAN, WONCA, EMA, and WHO are invited to take part.

ELSEVIER
The Boulevard Langford Lane - Kidlington
Oxford
OX51GB
UK
Booth #: 32
https://www.elsevier.com/
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge.
EMIRATES NEUROLOGY SOCIETY
907 Dusseldorf Business Point
Dubai
111704
United Arab Emirates
Booth #: 12
http://emins.ae/

Emirates Neurological Society (EMINS) is largest neurology organisation in United Arab Emirates. Founded in 2004, EMINS is dedicated to promoting the highest quality patient-centered care and improve the neurology management in the MENA region. EMINS regularly hosts regional and international conferences and in the coming year, we have the privilege to organise the WCN congress.

EMS HANDELSGES.M.B.H.
Jochingergasse 1
Korneuburg
2100
Austria
Booth #: 36
http://www.emsbiomed.com

EMS Biomed manufacture world leading solutions in the field of Neurophysiology: Routine EEG, LTM EEG, Ambulatory EEG, NCS/NCV, EMG, EP, ERP, PSG, IOM stand alone, network and cloud based technology. Based in Austria and with over 50 Distributors we are active in 116 countries worldwide with an installed base in over 90 countries. Our Sienna Ultimate EEG/PSG Amplifier offers world leading performance with LAN, WiFi and inbuilt storage providing 72hr+ ambulatory monitoring. Our Surpass range offers superb advanced NCV/EMG performance at exceptional value. Networked Amplifier,Portable (laptop) or cart/trolley All-in-one PC, wall mounted and roll stand based systems all available.

GLAXOSMITHKLINE
19th Floor Arenco Tower, Dubai Media City, Dubai
P.O.Box 50199
United Arab Emirates
Booth #: 10A
https://www.gsk.com/

GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. With a proven track record for providing medicines, vaccines and consumer products, the company has a long-standing innovation history of over 300 years and its presence in the Gulf Cooperation Council (GCC) has been expanding for the last 70 years – providing greater access and innovation to people in the region ever since. For further information please visit www.gsk.com
IMPETO MEDICAL
17 RUE CAMPAGNE PREMIERE
PARIS
75014
France
Booth #: 40
https://www.impeto-medical.com/
Impeto Medical is a French company created in 2005, which develops and markets in more than 35 countries SUDOSCAN, an innovative medical device allowing the detection and follow-up of autonomic peripheral neuropathy (small fiber neuropathy). SUDOSCAN is a rapid diagnostic test, only three minutes, simple, non-invasive and quantitative. This technology has been compared to reference techniques such as biopsy and tested in indications like amyloidosis, diabetes and neuropathy induced by chemotherapy. SUDOSCAN is also included in several international therapeutic guidelines.

LILLY
Lilly Corporate Center
Indianapolis
46285
USA
Booth #: 03
https://www.lilly.com/
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded in 1876 by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission. To learn more, visit www.lilly.com.

MAYO CLINIC LABORATORIES
3050 Superior Drive NW
Rochester
55901
USA
Booth #: 47
http://www.mayocliniclabs.com
Mayo Clinic Laboratories partners with health care organizations around the globe to help answer the most complex questions facing patients. With the most sophisticated test menu in the world, laboratory diagnostic testing and pathology services from Mayo Clinic span every medical subspecialty. We are committed to putting the needs of all patients first by focusing on providing clinically relevant answers, not just test results.

MERCK SERONO AUSTRALIA
Unit 3-4, 25 Frenchs Forest Road
Frenchs Forest
2086
Australia
https://www.merck.com.au
Merck, the vibrant science and technology company, operates across healthcare, life science and performance materials. Almost 53,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – Merck is everywhere.
MICROMED
via Giotto, 2
Mogliano Veneto
31021
Italy
Booth #: 38
http://www.micromed.eu
Founded in 1982, Micromed is a medical device company delivering solutions in Neurophysiology worldwide. Partnering with hospitals, sleep labs and research centers on a global scale, Micromed manufactures and markets high quality and clinically relevant neurodiagnostic solutions for use on adult and pediatric patients. The Micromed product portfolio ranges from Routine, Ambulatory and Video EEG to ECoG, SEEG, PSG, EP and EMG for clinical and research applications in addition to a full line of accessories.

MOLEAC PTE LTD
Helios #09-08, 11 Biopolis Way
Singapore
138667
Singapore
Booth #: 10
http://www.moleac.com/
Founded in 2003, Moleac is dedicated to developing innovative and high quality therapeutics in Neurology to supplement existing treatments for conditions where significant unmet needs remain. Its product NeuroAiD™ is a neurorestorative product that safely enhances recovery among patients who suffered a stroke or other brain injuries in the post-acute phase by amplifying the brain’s repair processes. NeuroAiD is a natural product made of several plant extracts selected for their pharmacological effects, clinical efficacy and safety. The product is distributed in over 30 countries today and aims to be available to the greatest number of people in need of solutions.

NATUS MEDICAL INCORPORATED
3150 Pleasant view road
Middleton
53562
USA
Booth #: 48
https://natus.com/
Natus Medical Incorporated Solutions that span the spectrum of neuro care. Natus is global market leader that provides diagnostic, therapeutic and surgical solutions in neurodiagnostics, neurocritical care and neurosurgery. Natus delivers clinician-led solutions that improve outcomes and enhance care for neuro patients through leading-edge equipment, service, education and supplies.
NEUROSOFT
5, Voronin str
Ivanovo
153032
Russia
Booth #: 30
https://neurosoft.com/en/
Development and manufacture of digital equipment for neurophysiological studies: neurophysiological systems for EEG and EP “Neuron-Spectrum”; neurophysiological systems for EMG and EP “Neuro-MEP”; series of transcranial magnetic stimulators for diagnostic, therapeutic and research purpose “Neuro-MS”; ABR, VEMP, MLR, LLR and OAE systems “Neuro-Audio”; systems for ERG and visual EP study “Neuro-ERG”. The manufacture’s quality management system is certified according to DIN EN ISO 9001:2008 and DIN EN ISO 13485:2007 International standard requirements. All the equipment has CE certificate and a two-year warranty. All the users gain a lifelong right to update the software which is always available on the Internet.

NIHON KOHDEN CORPORATION
1-31-4, Nishi Ochiai, Shinjuku-ku
Tokyo
161-8560
Japan
Booth #: 26
https://www.nihonkohden.com/
Since our foundation in 1951, our mission is to improve the quality of life with advanced technology. As a leading manufacturer of medical electronic equipment, Nihon Kohden provided a number of state of the art medical electronic equipment for clinical practice in the world. Our major product lines are patient monitors, electroencephalographs, evoked potential and electromyograph systems, electrocardiographs, defibrillators, and hematology analyzers. Nihon Kohden equipment is well known for its quality and ease of use. Our mission is to improve the quality of life by fighting disease and improving health with advanced medical technology.

NOVARTIS MIDDLE EAST FZE
Jumeirah Village Triangle, Limitless Building
Dubai
23510
United Arab Emirates
Booth #: 06
https://www.novartis.com
Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 105 000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com
PTC THERAPEUTICS GENE THERAPY, INC
100 Corporate Court
SOUTH PLAINFIELD
NJ 07080
USA
Booth #: 25
https://www.ptcbio.com/
PTC is a science-led, global biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. PTC’s ability to globally commercialize products is the foundation that drives investment in a robust pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need.

RICOH COMPANY, LTD.
3-2-3 Shin-yokohama, Kohoku-ku, Yokohama, Kanagawa, Japan
Yokohama
2228530
Japan
Booth #: 31A
https://www.ricoh.com/
Ricoh Company, Ltd. is a Japanese multinational company, producing electronic products, cameras and office equipment. In 2016, Ricoh acquired Yokogawa Inc. MEG, which launched Ricoh into the field of medical device industry. Ricoh is focusing on Epilepsy for clinical use and research as well, providing the MEG with its excellent axial gradiometers for deep brain explore and a user-friendly interface for lightening the diagnosis tasks. We always care for patients’ quality of life, doctors, nurses, and all for those who work for medical industry. Furthermore, Ricoh is researching a neuromagnetic field measurement system using the same operating principle as MEG.

ROCHE PHARMACEUTICALS MIDDLE EAST FZCO
PO BOX 27309 Galleries Building 4 Level 5
Dubai
27309
United Arab Emirates
Booth #: 17
https://www.roche.com/
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society.
SANOFI
Rep Office at JLT
Dubai
0000 United Arab Emirates
Booth #: 24
https://www.sanofigenzyme.com/

We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. At Sanofi, we are committed to being partner of the multiple sclerosis community and have been working for over a decade on the development of treatments for multiple sclerosis. We continue to focus our research efforts in areas such as early-stage research programs that focus on preventing and repairing the damage to the nervous system caused by multiple sclerosis.

TEVA PHARMACEUTICAL INDUSTRIES LTD.
5 Basel St.
Petach Tikva
49131 Israel
https://www.tevapharm.com

Teva Pharmaceutical Industries Ltd. has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products.

THE SEARLE COMPANY LIMITED
First Floor, NICL Building, Abbasi Shaheed Road, Karachi
Karachi
75530 Pakistan
Booth #: 28
https://www.searlecompany.com/

The SEARLE Company Ltd (TSCL) was incorporated in Pakistan as a Private Limited Company on October 5, 1965 as a subsidiary of G.D. Searle & Co., U.S.A. Today, Searle is one of the largest pharmaceutical companies in Pakistan having two state-of-the art manufacturing facilities in Lahore, and Karachi, Pakistan. SEARLE also has collaboration with several world recognized organizations like Grunenthal, RB, Nestle, CHR Hansen, etc. TSCL is manufacturing organization of branded generics and providing best research products in the services of mankind. Searle exports products in various parts of the world including South Asia, East Africa, South-East Asia, Europe, etc.
Neurorehabilitation as well as physical and rehabilitation medicine are fields both diverse and dynamic. Many different innovations have been established for the benefit of the patient. The WCNR together with the SOFMER keeps the important international dialogue between senior and junior physicians and therapists lively and flourishing. The congress supports continuous research as well as collaborative projects in order to avoid permanent damage and disabilities as consequences of inter alia cerebral, cardiovascular or cancer diseases, accidents and injuries, functional disorders, and improve the technical and the pharmaceutical treatments of persons with disabilities.

Wolters Kluwer Health is a leading global provider of medical information and point of care solutions for the healthcare industry. Our solutions are designed to help professionals build clinical competency and improve practice so that healthcare organizations can succeed in value-based care delivery models. We offer premier medical, nursing and allied health content; clinical decision support tools; drug information and patient surveillance; structured documentation and coding; healthcare terminology, data management and systems interoperability solutions; precision medical research tools; and continuing medical education solutions. Our leading product solutions include Lippincott®, Ovid®, UpToDate®, and others.

The World Federation of Neurology (WFN) is an association of national neurological societies representing 120 professional societies in all regions of the world. The mission of the WFN is to foster quality neurology and brain health worldwide, a goal we seek to achieve by promoting global neurological education and training, with the emphasis placed firmly on under-resourced parts of the world.
THE FIRST STEP IN PUSHING BACK ON PROGRESSION TO SPMS?

RECOGNIZING THE CHANGES
For some, the transition to SPMS happens sooner than expected.
Identifying the cognitive and physical signs early is crucial. 1,2

SPMS

There's a spectrum of different experiences in MS, but in patients with RRMS receiving DMTs, patients who did transition to SPMS were, on average, 38 YEARS OF AGE 3*

By helping patients identify the subtle cognitive and physical changes sooner, you can help keep them at their current stage of ability for longer. 2,4

Make a lasting difference for your patients with MS.


CHANGE THE CONVERSATION WITH A DISCUSSION GUIDE AT MSPRODUCTISCUS.COM
Getting Ahead of Migraine: A Case Based Approach

Wednesday, 30 October 2019
13:00 – 14:30
Sheikh Maktoum D
Dubai World Trade Center

LEARNING OBJECTIVES

• Increase knowledge around burden of migraine and spectrum of disability.
• Increase knowledge of what clinicians and patients can expect from preventive treatment with CGRP antibodies.
• Apply learnings from clinical case presentations to patient management in everyday practice.

AGENDA

13:00 – 13:05  Chairperson Welcome and Introductions
Uwe Reuter, MD, MBA (Germany)

Patricia Pozo-Rosich, MD, PhD (Spain)

Uwe Reuter, MD, MBA (Germany)

Rima Dafer, MD, MPH, FAHA (USA)

14:15 – 14:30  Panel Discussion, Questions and Answers
All faculty

A light lunch will be available from 12:45.

This session is not included in the main event CME/CPD credit.
GENE THERAPY FOR SPINAL MUSCULAR ATROPHY: TRANSLATING RESEARCH INTO REALITY

Tuesday 29 October 2019, 13:00 – 14:30
Sheikh Rashid Hall A, Dubai World Trade Centre
Dubai, United Arab Emirates

Faculty:
Dr. Abdulaziz Saeid Al-Saman (Chair)
Dr. Fouad Al-Ghamdi
Dr. Samiah Al-Zaidy
Dr. Daniel Gibbs

This AveXis-sponsored symposium at the World Congress of Neurology (WCN) will explore the latest advances of treatment for spinal muscular atrophy (SMA) and the potential application of gene therapy (GT) in treating this neuromuscular disease in clinical practice. The clinical practicalities and considerations of GT as a real-world treatment will also be explored.

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 – 13:10</td>
<td>Welcome and introduction</td>
<td>Dr. Abdulaziz Saeid Al-Saman (Chair)</td>
</tr>
<tr>
<td>13:10 – 13:25</td>
<td>Overview of SMA clinical course</td>
<td>Dr. Fouad Al-Ghamdi</td>
</tr>
<tr>
<td>13:25 – 13:55</td>
<td>Delivering cutting-edge gene therapy for SMA</td>
<td>Dr. Samiah Al-Zaidy</td>
</tr>
<tr>
<td>13:55 – 14:15</td>
<td>Practical aspects of GT including biosafety</td>
<td>Dr. Daniel Gibbs</td>
</tr>
</tbody>
</table>
| 14:15 – 14:25    | Panel discussion                                       | All Speakers
Facilitated by Chair |
| 14:25 – 14:30    | Closing remarks                                        | Dr. Abdulaziz Saeid Al-Saman (Chair)                         |
Everyone has a different definition of progress. PTC measures its progress in researching Duchenne muscular dystrophy. Now, we are committed to giving families living with other rare diseases more moments, whether it’s hours, days, months, or years. We use data and groundbreaking science in our search for progress in rare-disease treatments, of course, but also in the day-to-day lives of those affected.

PTC is a science-led, global biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. PTC’s ability to globally commercialize products is the foundation that drives investment in a robust pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need.

Based on our pioneering work that started over 20 years ago developing a treatment for Duchenne muscular dystrophy, PTC has developed several platform technologies in order to address multiple rare disorders most recently, adding 3 early and late stage programs for rare disorders, including:

- Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency
- Friedreich Ataxia
- Angelman Syndrome

To learn more about PTC, follow us on Facebook, on Twitter at @PTCBio, and on LinkedIn.

Come visit our booth to find out more.

There are no registered PTC products in UAE, if you would like to learn more please contact Medinfo at MedInfo@PTCbio.com

MAT-AADC-0303  |  August 2019

www.msgreymatters.com
© 2019 Celgene Corporation  All rights reserved.  NP-GII-OZD-0038  09/19
Everyone has a different definition of progress. PTC measures its progress in researching Duchenne muscular dystrophy. Now, we are committed to giving families living with other rare diseases more moments, whether its hours, days, months, or years. We use data and groundbreaking science in our search for progress in rare-disease treatments, of course, but also in the day-to-day lives of those affected.

PTC is a science-led, global biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. PTC’s ability to globally commercialize products is the foundation that drives investment in a robust pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need.

Based on our pioneering work that started over 20 years ago developing a treatment for Duchenne muscular dystrophy, PTC has developed several platform technologies in order to address multiple rare disorders most recently, adding 3 early and late stage programs for rare disorders, including:

• Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency
• Friedreich Ataxia
• Angelman Syndrome

To learn more about PTC, follow us on Facebook, on Twitter at @PTCBio, and on LinkedIn.

Come visit our booth to find out more.

There are no registered PTC products in UAE, if you would like to learn more please contact Medinfo at MedInfo@PTCbio.com
Committed to making a difference

Our mission is to leverage cannabinoid science. We recognize the needs of patients and their caregivers and use these insights to guide our research programs.

GW Pharmaceuticals is committed to evaluating new treatment options in neurology, oncology and psychiatric illness.

GW Pharmaceuticals is a biopharmaceutical company developing novel medicines in a broad range of disease states.
Do more, feel better, live longer.

We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.

http://jp.gsk.com
DOWNLOAD
THE OFFICIAL WCN APP

SEE FULL SCIENTIFIC PROGRAM
SEE FULL LIST OF SPEAKERS
CUSTOMIZE YOUR PERSONAL SCHEDULE

Search for 'WCN 2019'
WWW.2019.WCN-NEUROLOGY.COM
THE WCN 2019 MOBILE APP HAS BEEN SUPPORTED BY